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GENERAL AIM AND STRUCTURE 
GENERAL AIM OF THIS THESIS 
 
The last decade there is a booming development of therapeutic molecules 
with promising results to treat a wide variety of inherited and acquired diseases.  
pDNA, DNA, RNA, siRNA, peptides, proteins… are modern drug candidates, but 
often they lack stability once entered in the human body.  Most of these molecules 
are destabilized by enzymatic attack or they are cleared from the bloodstream by 
phagocytosis before they can carry out any therapeutic intervention.  As a result, 
there is a growing interest in drug carriers which can deliver therapeutic molecules 
intracellularly, intact and at the desired place and time.   
The general aim of this study is to develop nanometer sized hydrogel 
particles which are able to load therapeutic molecules, deliver them inside the cell 
in a time controlled manner, with high efficiency and without loss of the molecules’ 
integrity.  This process is schematically represented in Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic overview of intracellular uptake of PEGylated and pH sensitive lipid 
coated nanoparticles which release their coating upon acidification in the endosome.  As a 
result, the particles easily escape and release their therapeutic content in the cytosol.  (1) 
engulfment of the PEGylated lipid coated particle; (2) the particle is enclosed in an 
endosome; (3) degradation of the PEGylated lipid coating; (4) endosomal release of the 
particle into the cytosol; (5) delivery of the therapeutic content. 
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The first key aspect of this thesis includes the synthesis of nanoscopic 
dextran nanogels with and without a surrounding lipid-coating.  Our first aim is to 
achieve intracellular delivery, so the particles must be taken up by cells.  The 
second aim was to provide sustained delivery of therapeutic components, so the 
nanogels should contain some model molecules and release them in a time 
controlled manner.  As stability during blood circulation is a main feature in drug 
delivery, the particles must be provided with a PEGylated layer as it is well known 
that this creates a steric barrier to avoid macrophage uptake.  On the other hand, it 
is known that PEG hampers the endosomal escape of particles after cellular 
uptake.  Keeping this in mind, it would be convenient to dispose of nanogels that 
have a PEGylated lipid layer that comes off once entered in the endosome.  The  
intrinsic low pH of the endosomes will be the ideal trigger to achieve this.   
 
The second key aspect is the evaluation of poly(ethylene glycol) for the 
formation of drug delivery systems.  It is important to gain insight in the osmotic 
swelling behavior of PEG for the production of “self-exploding microparticles”, i.e. 
microscopic hydrogel particles surrounded by a lipid coating showing pre-
programmed pulsed drug delivery.  Different polymerizable PEG components, like 
PEG-HEMA, PEG-lactate-HEMA and star shaped PEG-HEMA were evaluated for 
microscopic as well as nanoscopic drug delivery device. 
vi 
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STRUCTURE OF THIS THESIS 
 
Chapter 1 represents a literature overview on “sustained release from 
nanosized matter”.  
Chapters 2-4 describe the production of biodegradable nanoparticles for the 
controlled release of therapeutic molecules with intracellular target.  In chapter 2 
the synthesis of nanogels using liposomes as a nanoscopic reaction container is 
described.  Liposomes were filled with a polymerizable dextran (hydroxyethyl 
methacrylated dextran, dex-HEMA) and subsequently irradiated with UV.  As a 
result, lipid-coated nanogels can be produced.  By adding a detergent, the lipid-
coating can be removed and naked nanogels are obtained.  As it is known that dex-
HEMA is biodegradable, it was checked whether nanosized dex-HEMA hydrogels 
with tunable degradation properties can be obtained.  We also wondered whether 
these particles are taken up by cells.   
 
Having established a good procedure to prepare biodegradable dextran 
nanogels in chapter 2, these nanogels were loaded with some model proteins in 
chapter 3.  The loading efficiency is determined and we also wondered whether the 
encapsulated proteins maintain their biological activity.  As our aim is to design 
nanogels showing sustained drug delivery profiles, we tried to govern the release 
profile of the included molecules in function of time by altering the degree of 
substitution of the nanogels.  The particles’ stability in serum was evaluated and 
also the possibility to freeze-dry them with an eye to long-time storage.   
 
The presence of the lipid-coating offers possibilities to change the surface 
properties of the nanogels.  In chapter 4 we inserted PEGylated lipids into this 
coating in order to increase their serum stability.  It was also checked whether the 
particles are still taken up by cells.  As PEGylation often hampers endosomal 
escape we also wanted to design nanoparticles with a PEGylated lipid-coating that 
comes of the particles at endosomal pH.  This was achieved by insertion of a 
synthetically derived diplasmenylcholine.   
 
In chapter 5 and 6 we took a close look at the properties and possibilities of 
poly(ethylene glycol) (PEG) in the field of drug delivery.  In chapter 5 the 
degradation behavior of hydroxyethyl methacrylated poly(ethylene glycol)  (PEG-
HEMA) was compared with dex-HEMA.  The osmotic swelling behavior of both 
polymers in the presence of unattached PEG and dextran chains was examined.  
This insight is of great importance in the design of self-rupturing microcapsules.   
 
Chapter 6 screens different polymerizable PEG as hydrogel forming 
polymers.  First, the degradation behavior of PEG-HEMA, PEG-lactate-HEMA and 
star shaped PEG end capped with HEMA (Â-PEG-HEMA) was evaluated on the 
macroscopic scale, showing that a time scale ranging from hours to months can be 
vii 
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achieved.  Second, lipid-coated and naked microgels were produced and the 
release profile of a fluorescent molecule was mapped.  In the last part of this 
chapter PEG-HEMA nanogels (with and without lipid-coating) were produced 
following the procedure described in chapter 2.  BSA was inserted and the release 
profile of this protein was followed in function of time.  
 
viii 
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Abstract 
The last decade a significant amount of active macromolecules like 
peptides, proteins and oligonucleotides is developed in the combat against a 
wide range of diseases.  However, at this moment some problems like 
stability, toxicity and poor biodistribution block the way to daily clinical use.  
Lots of efforts have been performed to obtain suitable carrier systems for 
these macromolecular drugs.  Nanoscopic particles show great promises to 
this end.  As they encapsulate the drug molecules in their interior, they keep 
them protected from enzymatic attack and they provide means for controlled 
and targeted delivery to specific organs or cells.  This first chapter outlines the 
concepts that have been proposed to release drugs in a sustained manner 
from nanoscopic delivery devices.   
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INTRODUCTION  
 
There is still a quest for an appropriate system for parenteral administration of 
macromolecular drugs, such as proteins, oligonucleotides or DNA.  Although these 
drugs have promising capacities, some non-ideal properties, such as poor solubility, 
rapid breakdown in vivo, rapid clearance by the reticuloendothelial system (RES), 
poor biodistribution and lack of selectivity for target tissues1 hinder their entrance in 
daily clinical use.  Nevertheless, a lot of these problems can be overcome by the use 
of an appropriate drug delivery system.  Pharmacokinetics can be modified in the first 
place by a change in molecular structure of the drug itself, e.g. attachment of PEG 
moieties to the therapeutic compound.  Another possibility that is more often used is 
by a change in drug formulation, more precisely by encapsulating the drugs in 
nanospheres or microspheres.  Due to their size micrometer sized particles cannot 
be used for systemic diseases -such as cancer-, as blood circulation of the delivery 
system is required.  Therefore, they are not discussed in this overview. 
In this first chapter an overview is given of the literature describing nanoscopic 
drug delivery systems showing sustained release for a prolonged period of time.  
Liposomal constructs, nanoscopic hydrogels, surface modified nanoscopic particles 
and core shell type nanoparticles showing sustained release for a prolonged time 
(i.e. more than 24 hours) were discussed.   
  
 
LIPOSOMES 
Introduction 
Liposomes are naturally occurring nanoscopic structures, consisting of one or 
more concentric lipid layers, enclosing an aqueous solution as represented in Figure 
1.  They can act as sustained release delivery system, as they can entrap thousands 
of (small) molecules2, offering possibilities for the encapsulation and sustained 
release of both lipophilic and hydrophilic components, as the molecules can be 
retained inside respectively the lipid layers or the central cavity of the liposome.  
Besides, due to their size they are passively targeted to the organs of the RES.  
Liposomes are relatively stable, biocompatible and biodegradable and 
prolonged drug release is achieved as a result of the diffusion of the drug through 
numerous phospholipid membranes3.  Since their first description in 19684, 
liposomes are described extensively as drug delivery system for therapeuticals 
against a wide range of diseases.   
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Liposomal constructs in the combat again
diseases 
Conventional liposomal formulations of anthra
approved for clinical use in AIDS-related Kaposi’s sarco
cancer (Myocet)6.  Other anti-cancer drugs, as mitoxan
better biodistribution patterns when they are administere
Also, liposomes are intensively studied in the c
infections, such as tuberculosis and leprosy.  As 
pathogens the drug has to be delivered inside the cell an
of time.  There are number of reports available that use
the treatment of Mycobacterium avium complex and M.
various drugs such as streptomycin10, amikacin11, ge
Due to the sustained release profile, the liposomal dru
limited number of injections, resulting in improved 
minimum toxicity and better patient compliance.   
Recently, Ishida et al.14 showed that fasudil, a
cerebral vasospasm that can cause severe side effe
free form, can be given to rats in the liposomal form
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dioxide pressure.  The release of fasudil from the lip
diffusion of fasudil molecules through the lipid membra
liposomes.  Animals treated with liposomal fasudil sh
neurological outcomes after 24h observation period com
Yang et al.15 used liposomal interferon-α-2b f
herpes.  Here the liposomes are filled with high encaps
they are administered intramuscularly.  The liposomes 
reservoir at the topical site of injection and provide stab
vivo transport and in blood circulation.  They are targeteLipophilic moleculAqueous interiorydrophilic 
olecule 
pid membrane 
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st a wide range of 
cyclines have already been 
ma (Daunoxome)5 and breast 
trone7 and vincristine8;9 show 
d in the liposomal form.   
ombat against mycobacterial 
mycobateria are intracellular 
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d conventional liposomes for 
 tuberculosis infections using 
ntamycin12 and kanamycin13.  
gs were administered with a 
pharmacokinetic properties, 
 cerebral vasodilator against 
cts when administered in the 
 and causes no significant 
heart rate or arterial carbon 
osomes was caused by the 
nes, not by the disruption of 
owed significantly improved 
pared to the control group.   
or the treatment of genital 
ulation efficiency (>80%) and 
(<100 nm) act as a sustained 
ilization of the drug during in 
d to RES organs such as the 
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liver and spleen.  In this way interferon-α-2b can keep a higher topical concentration 
for a prolonged period and interferon must be administered less frequently.   
Nanoscopic liposomes are not only suitable for parenteral injection, but also -
and especially- for eye treatment: small particles are necessary for delivery to the 
inner compartment of the eye.  Intravitreal injection in the eye should be applied as 
less as possible as severe risks for infection occur, so also here sustained release 
from liposomes could offer benefits.  Due to the sustained release liposomes 
encapsulating conventional small molecular weight drugs (usually anticancer) and 
larger genetic drugs (oligonucleotide and plasmid DNA) could be administered by 
intravitreal injection with significantly increased drug half-life and decreased 
intraocular side-effects and higher drug levels at the target site16.   
 
Disadvantages related to the use of liposomal constructs 
Although at the present time, liposomes are the premier particulate carrier 
systems over other drug delivery systems in terms of safety and usage in the clinic, 
liposomes may not be the best option for long term delivery of drugs, as liposomal 
particles are rapidly sequestered into the liver, spleen, kidneys and RES, it is more 
difficult to entrap macromolecular drugs with high efficiency17 and the included 
molecules are released quickly in comparison with polymeric delivery systems and 
controlling the release rate is not straightforward.  Besides, large scale manufacture 
of sterile liposomes is expensive and technically complicated18. 
 
NANOGELS 
Introduction 
Hydrogels are network structures formed by polymers that are mutually 
attached by cross-links, keeping large amounts of water in the formed matrix.  From a 
biomedical point of view, hydrogels have gained much attention last decades as they 
are considered to be attractive delivery systems for a wide range of therapeutic 
molecules due to some unique properties.  They can be loaded with high amounts of 
molecules (as the cross-links keep them entrapped in the formed matrix) and the 
release of the molecules can be controlled by varying the hydrogels’ characteristics. 
The following part of this first chapter handles on nanoscopic hydrogel 
particles in which therapeutic molecules are embedded in the hydrogel matrix (as 
represented in Figure 2), this in contrast to nanoparticles which arise through self-
assembling of DNA and degradable cationic polymers.  These so-called polyplexes 
are widely described in literature and are thus not the scope of this overview.   
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Hydrogel network 
Cross-link 
Hydrophilic molecule 
 
Figure 2. Schematic representation of a nanoscopic hydrogel containing therapeutic molecules 
 
To make a chance as drug delivery system, the nanogels should fulfill some 
basic requirements: (1) they should encapsulate the therapeutic molecule intact and 
with a high efficiency.  In the production process of nanogels harming activities, such 
as polymerization, sonificiation or contact with organic solvents, can damage the 
encapsulated drugs and must be evaluated carefully.  (2)  In vivo, the polymer matrix 
must protect the drugs against aggregation with serum components or enzymatic 
attack.  (3) The degradation of the matrix should not generate any hostile internal 
environment, for example a drop in pH.  (4) For toxicity reason, burst release should 
be avoided.   
Nanogels can be categorized in many possible ways.  (1) The way of cross-
linking used to form the hydrogel: in comparison with chemical cross-linking, physical 
cross-linking is in general less permanent and based on electrostatic or hydrophobic 
interaction or hydrogen bonding.  (2) The nanogels’ reaction on environmental 
changes can also be used as a classification criterium.  Non-responsive hydrogels, 
as the name already suggest do not react on environmental changes.  Stimuli 
responsive hydrogels can react on light, pH, temperature, ionic strength, electric field 
or the presence of biomolecules (like e.g. enzymes). (3) Another possible way of 
classification is the production method of the nanogels.  Commonly used methods 
are emulsification/solvent evaporation, emulsification/solvent diffusion, solvent 
displacement and interfacial deposition or salting-out19, but also more sophisticated 
techniques can be used, like using liposomes or reverse micellar droplets as 
nanoreactors to form the nanogels20;21.  (4) A last possible way of classification is 
following the method of loading the particles with the desired drug molecules.  This 
loading can be performed in two ways: the first is the loading during the preparation 
of the particles.  Mostly, the drugs are added during the formation process, but this 
has the main disadvantage that the therapeutic molecules are exposed to harming 
conditions like sonificiation, polymerization, contact with organic solvents…  Another 
possible way is the a posteriori method: the particles are uploaded after their 
formation.  Most often, electrostatic interaction is involved in this method: charged 
7 
SUSTAINED RELEASE FROM NANOSIZED MATTER 
particles are loaded with oppositely charged molecules.  The main disadvantage of 
this system is that the drug molecules are attached more likely at the outside of the 
particles and as a result, they are more susceptible to enzymatic attack in the body 
and they are also released more easily, often resulting in a burst release.   
In the following paragraph we will classify the nanogels according to their 
composing material.  This can range from synthetic polymers to naturally occurring 
polysaccharides.   
 
Synthetic polymers as nanogel forming material 
The first polymers that were used for the sustained release of therapeutic 
molecules were poly(acrylamide), poly(vinyl alcohol) and poly(hydroxyethyl 
methacrylate)22;23, but due to toxicity reasons, research was focused more on other 
synthetic polymers.   
Bharali et al.24 used poly(vinylpyrrolidone) (PVP, Figure 3), a hydrophilic, 
biocompatible and non-antigenic polymer to prepare injectable hydrogel 
nanoparticles with reverse micellar droplets as nanoreactors and N,N’-methylene bis-
acrylamide (MBA) as a cross-linking agent.  FITC-dextran was used as a model 
hydrophilic drug and its release profile could be controlled by changing the amount of 
cross-linker, the loading of the dye and the pH of the external medium.  That way, 
release times ranging form a few days to almost a month could be achieved.  As the 
degradation behavior of these PVP-MBA particles is almost zero, it is believed that 
the release is a diffusion controlled process from the highly swollen nanoparticles25.   
 
 
N
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Figure 3. Chemical structure of poly(vinylpyrrolidone) (PVP). 
 
These particles could also be used to entrap allergens of Aspergillus 
fumigatus, a complex mixture of more than 30 allergenic and antigenic proteins used 
for vaccination.  Aspergillus fumigatus is one of the most common Aspergillus 
species to cause diseases in immunocompromised individuals.  Release profiles of 
the allergens out of the nanoparticles ranging from two weeks up to 10 weeks could 
be achieved.  As a result, in mice subcutaneous injected nanogels with entrapped 
antigens show sustained levels of IgG antibodies, showing that the nanogels act as a 
repository for the antigens, protecting them from rapid degradation and allowing 
small antigenic mass to be delivered continuously and effectively.  The IgG levels 
achieved with three divided doses of entrapped antigen could also be achieved with 
same amount of entrapped antigens administered in a single dose26.   
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However the major disadvantage of these delivery systems is that they are not 
biodegradable.  As a result, the risk of chronic toxicity due to intracellular or tissue 
overloading of non-degradable polymers can be considered as a limitation for 
systemic administration. 
 
Nanoparticles based on biodegradable polymers such as poly(alkyl 
cyanoacrylate) (PACA, Figure 4), are being extensively investigated as delivery 
systems for small drug molecules27-33, proteins23;34-36 or nucleic acids37.  PACA 
nanoparticles can protect the active molecules and release is controlled by erosion of 
the particles.   
 
C
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PECA:  poly(ethyl cyanoacrylate)        
PBCA:  poly(n-butyl cyanoacrylate)
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R: CH3
R: CH2CH3
R: CH2CH2CH2CH3
R: CH2CH(CH3)2
R: CH2CH2CH2CH(CH3)2 
 
Figure 4. Chemical structure of different poly(alkyl cyanoacrylates) 
 
However, for sustained release, most of the poly(alkyl cyanoacrylate) 
nanoparticles release their content too quick, speaking in terms of a few hours.  Xun 
et al.38 tried to overcome the problem of fast release of 10-hydroxycamptothecin 
(HCPT) out of poly(butyl cyanoacrylate) (PBCA) nanogels by associating the particles 
with poly(butyl pyrrolidone) (PBP).  As a result, the release rate was significantly 
decreased: in vitro it was shown that 75% of the initially loaded HCPT was released 
after 48h.  In comparison, without the presence of PBP 70% of HCPT was released 
within 10h from the same PBCA particles.  Normally, HCPT as such is metabolized 
rapidly in vivo.  Nevertheless after injection of HCPT loaded PBCA nanoparticles 
associated with PBP, the HCPT plasma concentration decreased rapidly in the first 
2h and went up slightly afterwards and maintained the same level for 30h, suggesting 
a sustained release of HCPT from the PBP associated PBCA nanoparticles.  A 
possible reason was that the nanogels were taken up by the RES organs, which 
resulted first in a rapid decrease in blood concentration.  Afterwards HCPT was 
slowly released from the nanogels in the liver or spleen so that the blood 
concentration rose slightly.   
Zhang et al.39 used PBCA nanogels to deliver mitoxantrone, an anti-neoplastic 
agent.  The in vitro drug release data show that there are two phases in the drug 
release profile: first a burst release of more than 50% the first 24h followed by a 
slower release for 13 days.  The anti-tumor effect of an intravenous injection of 
mitoxantrone loaded in these particles turned out to be better when compared to an 
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injection of a mitoxantrone solution: the inhibition of orthotopically transplanted 
human hepatocellular carcinoma cells in rats was higher and the acute toxicity was 
lower.  The latter was due to the direct accumulation of the mitoxantrone to the liver 
when it was loaded into the PBCA particles.   
However, PACA’s did not seem to be completely harmless, as during 
degradation formaldehydes are formed.  It was observed from cell culture 
experiments that the viability of the cells was higher with a lower release of 
formaldehyde.  Alkyl homologues such as ethyl cyanoacrylate revealed a higher 
tissue toxicity than higher alkyl homologues40. 
 
Very recently, Devarajan et Sonavane41 formulated Eudragit (a co-polymer 
composed of acrylic acid and methacrylic acid) nanoparticles containing gliclazide, 
an oral hypoglycemic agent widely used for the treatment of non-insulin-dependent 
diabetes mellitus, to achieve a sustained drug delivery system suitable for per oral 
administration.  In vitro studies revealed that the release could be extended for over 
24h, depending on the pH of the release medium and the surfactant used during 
production.  In vivo, the encapsulated gliclazide showed a sustained activity in 
diabetic rat model as compared to plain gliclazide.  As a result, the dose frequency 
can be reduces, side effects are decreased and the patient compliance is improved.   
 
Poly(lactide) (PLA) and poly(lactide-co-glycolide) (PLGA, Figure 5) are 
probably the most studied biodegradable matrices for sustained drug delivery from 
nanoscopic materials.  It has been approved by the US Food an Drug Administration 
for application in drug delivery42, it is GMP grade, commercially available and it has a 
long history of safe use in both medical applications and drug delivery.  PLGA has 
been successful as a biodegradable polymer because it undergoes hydrolysis in the 
body to produce the composing monomers, being lactic acid and glycolic acid.  
These two monomers under normal physiological conditions, are by-products of 
various metabolic pathways in the body and as a result are completely non-toxic, 
they are eliminated from the body by the Kreb’s cycle.  Depending on their 
composition and molecular weight, PLGA provides degradation rates ranging from 
months to years43.   
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Figure 5. Chemical structure of poly(lactic-co-glycolic acid) (PLGA) 
 
PLGA nanoparticles can be used for the delivery of a wide range of 
therapeutic molecules to intracellular targets.  The intracellular destination of the 
particles depends mostly on the particles’ surface charge: nanoparticles which show 
transition in their surface charge from anionic (at pH 7) to cationic in the acidic 
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endosomal pH (pH 4-5) were found to escape the endosomal compartment whereas 
the nanoparticles which remain negatively charged at pH 4 were retained mostly in 
the endosomal compartment44.   
Already in 1999, Labhasetwar et al.45 were successful in encapsulating 
plasmid DNA (pDNA) into nanospheres and sustained release of the encapsulated 
pDNA in vitro under physiological conditions for over 17 days was demonstrated.  In 
cell culture, gene transfection with model genes like fire fly luciferase and heat stable 
human placental alkaline phosphatase using nanospheres was up to five orders of 
magnitude greater than the gene expression with the same amount of pDNA in 
solution.  Also in vivo, in a rat bone osteotomy model sustained gene expression was 
observed in tissue retrieved from the gap five weeks after the surgery.  This gene 
delivery strategy could be used to facilitate bone healing using therapeutic genes 
such as bone morphogenic protein.  Cohen et al.46 showed sustained marker gene 
expression with pDNA containing PLGA nanoparticles both in vitro and in vivo for up 
to 28 days.   
PLGA nanoparticles were also prepared for oral drug delivery to the inflamed 
gut tissue in inflammatory bowel disease.  Rolipram, an anti-inflammatory model 
drug, was incorporated within PLGA nanoparticles and showed a sustained release 
in vitro for over 1 week resulting from the diffusion of the drug through the polymer.  
These particles were administered to rats once a day orally for five consecutive days.  
During the next 5 days when animals were kept without drug treatment, the drug 
solution group displayed a strong relapse, whereas the nanoparticles groups 
continued to show reduced inflammation levels47.  Another oral drug delivery device 
composed of PLGA was proposed by Mittal et al48.  They studied the oral 
bioavailability and sustained release of estradiol, one of the most potent natural 
estrogens.  In vitro, drug release decreased with increase in molecular weight of the 
PLGA and the lactide content.  The in vivo performance of the nanoparticles was 
assessed in rats and showed that with all the PLGA nanoparticles the same dose 
produced detectable blood levels for 5-11 days, depending on the molecular weight, 
the polymer composition and the particles size.  This was a remarkable improvement, 
as the pure drug could only be detected in the blood for 1 day.  Derakhshandeh et 
al.49 used PLGA nanoparticles for oral delivery of 9-nitrocamptothecin.  The release 
of this anticancer agent in vitro could be maintained for up to one week. 
As already mentioned above, nanoscopic particles are particularly suited for 
delivery of drugs to the inner compartments of the eye.  Aukunuru et al.50 used PLGA 
nanoparticles for the sustained delivery of vascular endothelial growth factor (VEGF) 
antisense RNA to retinal cells.  Retinal neovascular diseases including diabetic 
retinopathy, retinopathy of prematurity and age-related macular degeneration, are 
typically associated by invitreal elevated VEGF levels.  Antisense oligonucleotides 
are single-stranded pieces of nucleic acids with a sequence specifically designed to 
bind a target sequence of intracellular RNA blocking the expression of a target 
protein, like in this case VEGF.  Thus, VEGF antisense RNA can inhibit VEGF 
production to treat retinal neovascular diseases.  VEGF antisense oligonucleotides 
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encapsulated into PLGA nanoparticles were released very slowly: the cumulative 
oligonucleotide release from the particles at the end of day 10 was only 39%.  The 
cellular uptake of oligonucleotides was significantly increased when entrapped in 
nanoparticles.  Moreover these nanoparticles significantly reduced VEGF mRNA 
levels and VEGF protein secretion from RPE cells, suggesting that the antisense 
oligonucleotides were able to reach intracellular compartments at VEGF inhibitory 
concentrations.  Kompella et al.51 successfully prepared PLA nanoparticles loaded 
with budesonide, a new agent capable of inhibiting VEGF expression in retinal 
pigment epithelial cells through its glucocorticoid receptor affinity.  Budesonide can 
be encapsulated with high efficiency and drug loading (resp. 65% and 16.25%) and 
in vitro sustained release at the end of two weeks was approximately 50%.  In vivo 7 
days after subconjunctival administration, sustained retinal budesonide levels were 
achieved when compared with a solution form in a rat model.   
 
The problem with PLGA is that it is often too hydrophobic, degradation rate is 
too slow, resulting in too slow drug release and often chemical emulsifiers like 
poly(vinyl acetate) (PVA) were used during synthesis.  The latter polymer has been 
found to show disadvantages including low emulsification efficiency, side effects and 
difficulties to wash away in the formulation process.  To cope with these problems, 
Zhang et al.52 incorporated D-α-tocopheryl poly(ethylene glycol)1000 succinate (TPGS) 
in PLA instead of glycolide.  The result is a copolymer, PLA-TPGS (Figure 6A) from 
which nanoparticles can be made (Figure 6B) with improved drug encapsulation 
efficiency and enhanced cellular uptake when compared with PLGA.  The study 
shows that PLA-TPGS nanoparticles can be loaded with paclitaxel and complete 
drug release takes much longer time than 30 days, depending on the molecular ratio 
PLA/TPGS used in the composing polymer: after 30 days, the accumulative drug 
release approaches 55-65%.  In comparison, the drug release from PLGA 
nanoparticles within one month is usually 30-40%, which is too slow to meet 
therapeutic needs.  The novel PLA-TPGS nanoparticle formulation of paclitaxel 
showed significant advantages in achieving larger cytotoxicity and smaller IC50, over 
the commercial formulation of paclitaxel (Taxol®, a formulation with Cremophor EL).  
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Figure 6. (A) Molecular structure of PLA–TPGS copolymer and (B) SEM image of paclitaxel-loaded 
PLA–TPGS nanogels (84:16 molar ratio)53 
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As already briefly mentioned above, PLGA shows some drawbacks to be used 
as a drug delivery system like hydrophobicity and slow degradation.  In addition, it is 
well shown that degradation of PLGA results in a decrease in pH in the particles due 
to the formation of lactic acid and as a result, acid sensitive molecules can be 
damaged during encapsulation, although basic additives such as Mg(OH)2 and 
Ca(OH)2 can avoid this54.  Also, it was demonstrated in vitro that the so called 
“bioinert” PLA can be cytotoxic to immune cells: cells that had phagocytosed PLA 
particles showed increased signs of cell damage and administration of “predegraded” 
PLA particles resulted in necrotic cells and cell debris after three or four days55.  
Besides, different factors influence the release rate out of PLGA nanoparticles: not 
only the chemical composition of the PLGA but also the molecular weight, particle 
size, morphology and processing condition influence the release.  For example, PVA 
is most commonly used as an emulsifier during the production process of PLGA 
nanoparticles.  It is shown that a fraction of PVA remains associated at the 
nanoparticle surface and affects the physical and cellular uptake properties of 
nanoparticles.  As a result, it is difficult to predict the in vivo release characteristics56.  
Bala et al.57 performed research on the influence of stabilizers used during 
processing, like PVA, didodecyldimethylammonium bromide (DMAB) and a 
combination of PVA and chitosan (PVA-CS) on the release characteristics of ellagic 
acid, a photochemical with antioxidant properties.  Release was depending on the 
hydrophobicity of the stabilizer following the order PVA > PVA-CS > DMAB releasing 
respectively 50%, 38% and 24% over 6 days57.    
 
Polysaccharides and derivatives as nanogel forming materials 
While synthetic polymers have the advantage of sustaining the release of the 
encapsulated therapeutic agent over a period of days to several weeks they are in 
general limited by the use of organic solvents and relatively harsher formulation 
conditions.  Natural polysaccharides constitute an important class of physiological 
materials, displaying well-documented biocompatibility and biodegradability, which 
are the basic characteristics for polymers used as a compound for drug delivery 
systems. 
Alginate is a naturally occurring polysaccharide composed of mannuronic acid 
and gluconic acid (Figure 7) and because of the negative charge of the carboxylic 
groups from the uronic acid, it can be cross-linked into nanoscopic structures by 
electrostatic interaction with oppositely charged counter ions58.  Is has been 
extensively investigated for drug delivery and tissue engineering applications59;60, but 
the use on the nanoscopic scale is rather rare.   
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Figure 7. Chemical structure of (A) Poly(mannuronic acid) and (B) poly(guluronic acid).  The negative 
charges of the carboxylic acids can interact with oppositely charged molecules to form nanoscopic 
hydrogels. 
 
However, Pandey et al.61 showed that it is possible to have a slow and 
controlled release of antifungal drugs, clotrimazole and econazole, by encapsulating 
them into alginate nanoparticles stabilized with Ca2+ and chitosan.  The formulations 
were orally administered to mice and pharmacokinetic data suggested that there was 
a controlled drug release for 5-6 days whereas unencapsulated drugs were cleared 
from the bloodstream within 3-4 hours.   
 
Chitosan and its derivatives are probably the most used modified sugars for 
sustained release.  It is a deacetylated product of chitin consisting of D-glucosamine 
and N-acetyl-D-glucosamine, comprising several benefits such as biocompatibility, 
biodegradability low immunogenicity and low cost62.  Moreover, due to its cationic 
nature this polymer is mucoadhesive offering possibilities for transmucosal drug 
delivery and transiently opening the tight junction between epithelial cells63.  It forms 
hydrogel nanoparticles by electrostatic interaction with polyanions like 
tripolyphosphate (TPP), simply by dropping chitosan droplets into a TPP solution.  
Calvo and co-workers64 succeeded in maintaining in vitro release of tetanus toxoid 
for 18 days and of BSA for 8 days.  Deng et al.65  also used TPP as a cross-linking 
agent to encapsulate lysozyme.  The release was in the range of days and could be 
controlled by the concentration of chitosan, TPP or initially added lysozyme or the 
molecular weight of the used chitosan.   
Kim et al.66 used a hydrophobically modified glycol chitosan.  This amphiphilic 
polymer self-assembles in water forming nanogels.  The particles can be loaded with 
paclitaxel, a hydrophobic antitumor drug, using a simple dialysis method.  Currently 
paclitaxel is formulated with Cremophor EL, which is not an inert vehicle as it exerts a 
series of biological and physiological effects as nephrotoxicity and anaphylactic 
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reactions67;68.  This newly developed chitosan based delivery system turned out to be 
less toxic.  In vitro sustained release can be achieved for over 8 days (assessed in 
PBS at 37°C pH 7.4) while in vivo tumor growth in tumor bearing mice can be 
prevented for the same period.  Cha et al.69 also used glycol modified chitosan: they 
used succinic anhydride as a pH sensitive linker to introduce cisplatin, an anticancer 
drug.  Nano-aggregates of 180-300 nm released cisplatin in a sustained manner: 
under physiological conditions, 40% of the incorporated cisplatin was released for 11 
days.   The pH sensitive linker cis-aconityl was also used to provide a pH sensitive 
bridge between glycol chitosan and doxorubicin70;71.  This polymer can be used to 
produce nanoscopic hydrogels which are mainly directed to the kidneys, tumor and 
liver after systemic administration.  Moreover, the drug content can be increased by 
an additional physical loading of free doxorubicin, resulting in a eight time higher 
loading capacity than the amount of chemically conjugated doxorubicin.  The release 
of doxorubicin out of these nanogels at pH 7 was negligible for almost ten days.  At 
endosomal pH however, a slow release was observed due to the pH sensitive linker.    
 
Very recently, Chen et al.72 developed novel composite nanoparticles based 
on glycidyl methacrylate derivatized dextrans (dex-GMA) combined with gelatin.  
The gelatin was added to load the particles with bone morphogenetic protein (BMP) 
as electrostatic interactions occurred between acidic BMP and basic gelatin 
segments.  The in vitro drug release studies showed that BMP released from the 
particles could maintain more than 12 days in the presence of dextranase.  This 
system could provide a proper local BMP delivery system for delivery of active drugs 
for periodontal healing enhancement.   
 
Wang et al.73 encapsulated cyclosporine A (CyA), a cyclic oligopeptide with 
potent immunosuppressive activity, with high yield and encapsulation efficiency into a 
cellulose derivative: hydroxypropyl methylcellulose phthalate (HPMP).  HPMP is an 
enteric dissolved polymer from which nanoscopic particles can be obtained by the 
solvent displacement technique.  It was shown that the concentration in the blood 
after oral administration of a single dose of CyA loaded HPMP nanoparticles was 
similar to that of Neoral, the current available CyA oral formulation with Cremophor 
EL.  However, the mean residence time and the decrease of elimination constant of 
the particles was increased compared to Neoral.  Sustained release of CyA from 
eroding HPMP nanoparticles was proved and as soon as the CyA molecules are 
released, they are absorbed by the lower segment of the small intestine.   
 
SURFACE MODIFIED NANOPARTICLES 
Introduction 
As shown above, there has been a considerable effort in developing 
(biodegradable) constructs for the sustained delivery of therapeutic molecules.  
Besides drug protection, stability and ability to control drug release, targeting is also 
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of major importance during drug delivery.  Targeting is the direct delivery of 
therapeutic molecules to the target cells, without damaging other tissues.  Several of 
the above mentioned drug delivery systems accumulate in non-target tissues, as they 
are not target-specific.  Surface properties of colloidal carrier systems play a pivotal 
role in their fate after intravenous injection.  This is the reason why research has 
been focused on the development of surface modified nanoparticles to target to 
specific cells or organs. 
Before describing the nanoscopic drug delivery systems with surface modified 
nanoparticles, we will first describe the types of targeting (more precisely active and 
passive targeting) as we feel it is important to have good insight in targeting 
strategies in order to understand the used techniques for development of the most 
appropriate targeted drug delivery systems.  Afterwards we discuss some surface 
modified particles for active and passive targeting and to conclude we will also give 
some examples of particles that were modified with other aims than targeting. 
 
Targeting 
Passive targeting  
In literature, “passive targeting” is used for two phenomena which are closely 
related, but not exactly the same.  Moreover, the result of these types of targeting is 
opposite: in the first type “passive targeting due to size”, target cells are phagocytes 
and the organs of the RES.  And in the second type “passive targeting due to surface 
modifications”, the aim is to avoid these cells.   
Passive targeting due to size.  After administration, small molecules and 
particles are removed from the blood system by renal filtration.  Particles that are too 
large to be cleared by renal filtration, more specific molecules with a molecular weight 
larger than 5 kDa or even 100 kDa for condensed particles, are being removed from 
the blood stream by opsonization and phagocytosis74.  Opsonization is the process in 
which body foreign materials are covered with opsonins, these are blood serum 
components that aid in the process of phagocytic recognition.  As a result, the 
particles are recognized by macrophages and after phagocytosis, they accumulate in 
organs of the RES like liver, spleen, lungs and bone marrow.  All the above 
mentioned nanoscale drug delivery systems were large enough to be taken up by 
phagocytosis and will end up in the RES organs.  As a result, due to this first passive 
targeting strategy, the utility of  these conventional colloidal carriers as vehicles for 
drug delivery to non-RES organs is inappropriate. 
Passive targeting due to surface modification.  A second passive targeting 
strategy is based on the typical vasculature of some pathological tissue.  Due to the 
rapid growth of the tissue, the vessels for blood supply are leaky, showing a 
disrupted endothelial cell layer75.  This leaky vasculature, typical for tumour tissue, 
inflammations and infarcted areas, offers targeting possibilities as larger particles can 
only penetrate in this type of tissue, leaving healthy tissue aside76.  The fact that 
larger particles or molecules tend to accumulate in tumour tissue much more than 
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they do in normal tissues is known as the enhanced permeability and retention (EPR) 
effect77 (Figure 8).   
 
 
 
 
Tumor cell
Tumor 
endothelium 
Long circulating 
particle with anti-
tumor drugs 
Healthy 
endothelium 
Blood
Figure 8.  Schematic representation of the passive targeting strategy: long circulation particles can 
escape from the bloodstream to the tumour by the leaky vasculature of the tumour. 
 
This passive targeting strategy can be achieved only by long time circulation, 
as conventional nanoparticles are cleared from the bloodstream within seconds by 
opsonization and phagocytosis78 as described above.  To avoid the binding of 
opsonins to the particles’ surface, and as a result avoid phagocytosis, several 
methods of camouflaging or masking nanoparticles have been developed.  Many 
systems make use of surface modifications that interfere with the binding of opsonin 
proteins.  Commonly used hydrophilic polymers are poly(ethylene glycol) (PEG), 
poloxamines, poloxamers and polysaccharides.  These coatings provide a dynamic 
‘cloud’ of hydrophilic and neutral chains at the particle surface, which repel opsonins.  
PEGylation is by far the most used strategy: the particles’ surface is covered with a 
PEG layer79.  The presence of this layer onto the particles’ surface causes not only 
an increase in size, but also attracts a hydrated shell around the liposome and steric 
hindrance is introduced80.  Removal from the bloodstream by renal clearance, 
opsonization, macrophage uptake and enzymatic degradation are decreased.  As a 
result pharmacokinetic -and hence pharmacodynamic- properties of the formulations 
are improved.  In addition, native drug delivery systems can evoke a severe 
immunogenic response, especially the once containing molecules of non-human 
nature.  PEGylated formulations often show reduced immunogenic response due to 
steric masking of the immunogenic sites.   
17 
SUSTAINED RELEASE FROM NANOSIZED MATTER 
Active targeting  
Given the potency (and toxicity) of modern pharmacological agents, tissue 
selectivity is a major issue.  In the delivery of chemotherapeutic agents to solid 
cancers this is particularly critical, since the therapeutic window for these agents is 
often small and the dose-response curve is steep.  Drug delivery systems may 
function through their ability to recognize certain types of target tissue, termed as 
active targeting.  Active targeting of a therapeutic agent is achieved by modifying the 
carrier system’s surface by conjugation of a tissue or a cell-specific ligand. 
 
Now we have gained insight in the necessary features to provide targeted drug 
delivery systems we will discuss several nanoscopic drug delivery systems described 
in literature that provide sustained drug delivery targeted to specific organs. 
 
Surface modification to obtain passive targeting to non-RES 
organs 
Doxil was the first commercially available PEGylated liposomal sustained 
delivery system, releasing the anti-cancer drug doxorubicin in a retarded manner 
within the tumor81.  Encapsulation in liposomes containing surface-bound PEG 
significantly limits the distribution and elimination of doxorubicin, results in greater 
accumulation of the drug in Kaposi sarcoma (KS) lesions 72 hours after dosing than 
does standard doxorubicin, and improves drug efficacy and therapeutic index in the 
treatment of AIDS-KS.  PEGylated liposomes containing rifampicin and isoniazid 
provide a drug carrier system exhibiting a sustained release in plasma and organs.  
The PEGylated liposomal form of these antitubercular drugs given at 1/3rd of the 
recommended dose was more effective than their corresponding free form, showing 
increased affinity to the lung tissue and uptake in RES was reduced as compared to 
conventional liposomes82-84. 
Perez et al.85 tried to prepare PLGA-PEG nanoparticles loaded with pDNA for 
vaccination after intranasal administration.  The low surface charge of PLGA-PEG 
nanoparticles as compared to that of PLA nanoparticles showed the presence of a 
PEG layer on the nanoparticles surface.  They selected the appropriate conditions for 
the nanoencapsulation of pDNA in order to achieve a significant pDNA loading and 
sustained release.  Encapsulation efficiencies for up to 90% could be achieved and 
release could be sustained for 28 days.  Nevertheless, it turned out that despite the 
use of PVP or PVA as co-encapsulating agent, the supercoiled plasmid –the most 
active form of pDNA- was converted into open circular and linear forms, which are 
less active.  This conversion to open circular and linear forms has been attributed to 
the sonication step in the nanoparticle formation process, even for very short periods 
of time (5 s).   
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Figure 9. TEM micrograph of a plasmid DNA-loaded PLGA-PEG nanoparticle prepared by a water–
oil–water solvent evaporation technique86. 
 
Zweers et al.87 used PLGA-PEG for the controlled delivery of dexamethasone 
and rapamycin, two drugs used in the combat against restenosis after percutaneous 
transluminal coronary angioplasty.  When PLGA-PEG particles were used, 100% of 
the drugs was released within 5h under physiological conditions.  This was attributed 
to the presence of the drugs at the surface of the particles and the presence of pores 
in the interior of the particles.  To extend the release, drug loaded nanoparticles were 
redispersed in an aqueous gelatin or albumin solution.  As a result, sustained release 
could be achieved: dexamethasone for 17 days and rapamycin for 50 days.  A likely 
explanation for the effect of protein treatment on the drug release is that the protein 
molecules penetrate and/or block the pores of the particles, thereby decreasing 
diffusion of drug through the pores.  In addition, the proteins increase the viscosity of 
the aqueous phase in the pores resulting in a decrease of diffusion of the drug 
through the pores.   
Very recently, Zhang et al.88 were able to prepare poly(caprolactone-co-
lactide)-b-PEG-b-poly(caprolactone-co-lactide) (PCLLA-PEG-PCLLA) nanoparticles, 
resulting in particles consisting of PCLLA with PEG molecules stretching out from it.  
24h after injection of HCPT loaded nanogels, the HCPT concentration in plasma was 
almost the same as that at 8h post administration, indicating that HCPT level in blood 
could be maintained for an extended time.  When HCPT in solution was injected, 24h 
post administration the HCPT concentration in the plasma could not be detected 
anymore.  Nonetheless the presence of an outer PEG layer, the particles were 
accumulated in the organs of the RES, like liver and spleen, even at 24h after 
administration a certain level of HCPT was still maintained in all the tested RES 
organs.  Unfortunately, the particles could not reach the tumor tissue as efficiently as 
the RES organs.   
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Zhang and Zhuo89 used ε-caprolactone in a block copolymer with PEG to 
prepare nanoparticles with prolonged blood-circulation time.  The poorly water-
soluble anticancer drug 4’dimethyl-epipodohyllotoxin (DMEP) could be encapsulated 
with high efficiency in the hydrophobic PCL structure of these nanoparticles.  It was 
shown that the release time of DMEP out of the particles was influenced by the chain 
length of the PEG block.  When PEG with a molecular weight of 4000 g/mol was 
used, 90% drug was released from the polymeric nanoparticles in 50h. 
Missirlis et al.90 described the preparation of nanoparticles composed of PEG 
and poloxamer 407.  Micellar structure are present in the bulk of these hydrogel 
nanoparticles and they are surrounded by a hydrophilic PEG-rich matrix.  This 
nanoarchitecture not only allows for protection against opsonization and 
phagocytosis, but also sustained delivery of small hydrophobic drugs like doxorubicin 
can be achieved: encapsulation provided sustained release for up to one week in 
vitro.  Doxorubicin was encapsulated following an a posteriori drug loading protocol, 
which avoids the exposure of the drug to the harsh conditions of radical 
polymerization.  Nevertheless, degradation studies of doxorubicin revealed that this 
procedure does not fully protect the drug, most likely because of the presence of 
some water in the hydrophobic domains.   
Owens et al.91 have given a very good overview of studies on opsonization of 
polymeric nanoparticles with surface adsorbed and covalently bound PEG and PEG 
containing polymer layers like for example poloxamer and poloxamines.   
 
Instead of using PEGylation to produce long circulating particles, the Couvreur 
group succeeded in producing a series of comb-like amphiphilic copolymers in which 
poly(ε-caprolactone) were covalently grafted onto a dextran backbone (Dex-PCL).  
These amphiphilic co-polymers have the ability to self assemble into PCL 
nanoparticles surrounded by a dextran layer by a technique derived from emulsion-
solvent evaporation92.  They were examined for the sustained delivery of tamoxifen, a 
poorly water soluble drug for oral breast cancer treatment.  The PCL of the Dex-PCL 
nanoparticles was degraded by the Pseudomonas lipase. In vitro release studies of 
tamoxifen performed in phosphate buffer containing 0.5% (w/v) sodium lauryl sulfate 
showed a sustained release over more than 72h93.  
 
Surface modification to obtain active targeting 
A possible way to actively target to cells is by coupling transferrin to the 
particles’ surface.  When a transferrin protein loaded with iron encounters a 
transferrin receptor on the surface of a cell, it binds to it and is consequently 
transported into the cell by endocytosis.  Li et al.94 used transferrin conjugated 
PEGylated polycyanoacrylate nanoparticles for the controlled delivery of pDNA to 
target cells.  The in vitro release experiments showed that the cumulated pDNA 
release over 7 days ranged from 86% to 74.4%, depending on the concentration of 
the polymer in the nanogels.  It was also shown in vitro that due to the presence of 
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transferrin on the nanogels’ surface, the particles were directed towards target cells, 
as the presence of free transferrin decreased significantly the degree of cell binding 
of the nanogels.  Besides, efforts were made to reduce the damage of pDNA during 
the encapsulation process by use of PVP or PVA as a stabilizer during the emulsion 
forming: 0.1M NaHCO3 with 3% PVA (w/v) could reduce the damage of pDNA during 
encapsulation.   
 
Core shell type particles with other aims than targeting 
Sometimes the surface of nanoscopic particles is modified with other aims 
than targeting.  For example, particles can be foreseen with an extra layer as an 
extra feature to control drug release.  Most often, the core consists of a 
(biodegradable) polymer that can contain high amounts of drugs and that can provide 
a first barrier for drug release.  The shell that surrounds the core can form a second 
barrier for (diffusional) drug release, as burst release of a certain drug might result in 
toxic concentrations.   
Very recently Chavanpatil et al.95 reported on Aerosol OT™ (AOT)-alginate 
nanoparticles for the sustained intracellular delivery of doxorubicin.  The particles 
were formulated by emulsification-cross-linking technology and polymerization was 
performed by Ca2+.  As AOT (dioctyl sodium sulfosuccinate) has a polar 
sulfosuccinate head group with a large and branching hydrocarbon tail, alginate was 
captured inside liposome-like structures formed by AOT during the multiple 
emulsion/cross-linking process used.  Upon cross-linking, core-shell like 
nanoparticles were formed with the ability to enclose small hydrophilic molecules 
inside the alginate core (Figure 10).  Ca-alginate hydrogels get converted into soluble 
alginate in the presence of sodium ions.  As a result, in vitro release studies in PBS 
demonstrated near zero order drug release over a 15 day period.  Drug release was 
even slower in cell culture medium, probably due to the presence of divalent metal 
salts slowing down the sodium-calcium exchange.  Doxorubicin in nanoparticles 
demonstrated significantly higher cytotoxicity against two breast cancer cell lines 
when compared to doxorubicin in solution.   
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Figure 10. Proposed structure of AOT-alginate nanoparticles.  The 
cross-linked with calcium, surrounded by one or more bilayers of AOT.  
 
Hitzman et al.96-98 presented an elaborated study on 
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tripalmitin, tristearin, cetyl alcohol and stearyl alcohol.  The p
be used as a respirable sustained delivery system to tr
fluoroacil (5-FU).  Depending on the composition of the she
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cores excipients are observed to undergo relatively rapid d
5-FU, suggesting that the lipid shell is the rate limiting step
The nanoparticles were successfully aerosolized using a
system.  In vivo assays of the release characteristics were
following intratracheal instillation and aerosol inhalation.  
lipid coated nanoparticles effectively reached the lower res
release profiles in vivo and in vitro were observed.   
 
Another possibility is that the surrounding shell provid
in order to make particles that interact with environmental
light, pH, enzymes or temperature.  Jeong et al.99 rep
nanoparticles composed of PLGA-grafted dextran for use
PLGA formed the inner-core and acted as a incorporating do
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As a result, most of the drugs will be released before reachin
 
 
22 Alginate Core 
dioctyl 
inner c
Figure 
lipid c
ed of 
variou
article
eat lu
ll and 
d from
d of 5
issolu
 for t
n ultr
 carr
By the
pirato
es a 
 chan
orted 
 as a 
main
 the c
itable
ce a
 prese
g theDoxorubicinsodium sulfosuccinate 
ore consist of alginate 
not drawn to scale. 
oated nanoparticles 
poly(glutamic acid), 
s combinations of 
s were prepared to 
ng cancer with 5-
especially the core, 
 these lipid coated 
-FU with polymeric 
tion and release of 
he release of 5-FU.  
asonic nebulization 
ied out in hamsters 
 two methods, the 
ry tract and similar 
responsive reaction 
ges: it can react to 
on core-shell type 
colon drug carrier.  
 for doxorubicin and 
olon as dextranase 
 for colon-targeting, 
s the presence of 
nce of the enzyme.  
 colon.   
CHAPTER 1 
 
 
Figure 11. TEM photographs of core-shell type nanoparticles composed of PLGA-grafted dextran100 
 
Recently, our group proposed dextran and PEG nanoparticles provided with a 
lipid coating for the sustained delivery of therapeutic molecules.  The particles were 
obtained by using liposomes as a nanoscopic reactor: the liposomes were filled with 
a polymerizable dextran or PEG solution and these polymers were subsequently 
cross-linked by means of UV in the interior of the liposomes.  The cores of the 
particles were composed of hydroxyethylmethacrylated dextran or PEG (respectively 
dex-HEMA and PEG-HEMA) which are degradable under physiological conditions.  
The degradation time of these particles could range from some hours to several 
weeks.  Moreover, the particles could be uploaded with some model proteins and 
sustained release could be achieved.  
The use of this preparation technique offers several advantages over other 
well established techniques like for example emulsion polymerization or controlled 
precipitation.  (1) The size of the nanogels can be controlled by using membranes 
with the appropriate pore size in the preparation of the liposomes. (2) organic 
solvents are not used to avoid drug inactivation.   (3) We also showed that it was 
possible to use PEGylated and pH sensitive lipid coatings in order to provide long 
circulating nanoparticles that can be taken up by cells and loose their protecting lipid 
coating in the acidic environment of the endosomes.   
 
 
CONCLUDING REMARKS 
 
This literature overview shows that, especially within the last decade, different 
concepts and systems have been developed for sustained drug delivery from 
nanoscopic particles.  By use of nanoscopic materials, different targets can be 
reached: specific cells, like tumor cells or phagocytes, but also specific organs, like 
the RES organs (liver, spleen, bone marrow), the lungs, the gastrointestinal tract or 
even the eye.  The altered body biodistribution combined with a prolonged retention 
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time of the therapeutic molecules in various tissues and protection against many 
possible “attacks” in the human body may be responsible for the better therapeutic 
effect of drug loaded nanogels. 
Nevertheless, a long way of research is still open for exploration: the complex 
processes of gradual nanosphere degradation and erosion within the vasculature and 
the kinetics of drug release into the blood have been poorly addressed.  Not only the 
clearance kinetics of the nanoparticle from the blood should be considered, but also 
the in vivo process of gradual nanosphere matrix degradation and the extent of drug 
release must be worked out in relation to a pharmacologically desired free drug 
profile.  Other critical considerations are the biocompatibility of the pharmaceutical 
ingredients, the shelf life and the ease and cost of large scale manufacturing.  
Especially the latter two are important considerations which are often ignored in the 
first steps of scientific research. 
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Abstract 
Hydrogels are widely investigated as carriers in drug delivery. 
To be suitable carriers for intracellular drug delivery the hydrogels 
should be small enough to be able to enter cells. This second chapter 
reports on the synthesis and characterization of both lipid-coated and 
‘naked’ biodegradable hydroxyethyl methacrylated dextran (dex-
HEMA) nanogels. Dynamic Light Scattering (DLS), atomic force 
microscopy and transmission electron microscopy showed that lipid-
coated nanogels could be obtained by polymerization of an aqueous 
dex-HEMA solution entrapped in SOPC:DOTAP liposomes (SOPC 
and DOTAP respectively being 1-stearoyl-2-oleoyl-sn-glycero-3-
phosphocholine and 1,2-dioleoyl-3-trimethylammonium propane 
chloride).  Naked dex-HEMA nanogels were prepared by removing 
the lipid coating by Triton X 100.  DLS measurements on dex-HEMA 
nanogels stored in buffer at 37°C revealed that the degradation time 
depended on the cross-link density of the nanogels: dex-HEMA 
nanogel prepared from dextran lowly substituted with HEMA 
degraded fast while it took days to weeks for nanogels prepared from 
highly substituted dextran. Furthermore, confocal laser scanning 
microscopy showed that SOPC:DOTAP coated dex-HEMA nanogels 
can be taken up by VERO cells.  
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INTRODUCTION 
 
Many molecules which are under development as therapeutic agents have 
targets located intracellularly.  Examples are certain proteins, oligonucleotides, 
plasmid DNA and interference RNA.  However, most of these molecules show a 
poor cellular uptake and become easily degraded in extra- and intracellular media.  
Appropriate nanosized delivery systems which protect and deliver the drug 
molecules intracellularly are therefore required1.  While intracellular drug release 
has been shown to occur from many types of nanoparticles, it remains however 
rather unknown which parameters govern the drug release process once the 
nanoparticles enter the cell.  This is partly due to difficulties in characterizing 
quantitatively the biophysical behavior of nanoparticulate matter in living cells.  As a 
consequence it remains also very challenging to design drug loaded nanoparticles 
with optimized intracellular release properties.  Indeed, while micron sized particles 
(which remain extracellularly after injection) with tunable release properties have 
been well studied2-8, however, little attention has been paid so far to nanoparticles 
which could slowly release the drug in the cell after uptake by the cells.   
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Figure 1. (A) Chemical structure of the monomer in dex-HEMA, i.e. glucopyranose 
substituted with HEMA.  (B) Schematic representation of the dex-HEMA polymer network 
before (left) and after (right) degradation.  The HEMA cross-links degrade through 
hydrolysis of the carbonate esters, resulting in dextran chains and poly(HEMA) 
 
In previous work the physicochemical and release properties of 
biodegradable hydroxyethyl methacrylate dextran (dex-HEMA, Figure 1A) 
hydrogels and microgels was investigated3,9-13.  Dex-HEMA gels are 
biocompatible14 and degrade spontaneously under physiological conditions12.  Drug 
molecules can be entrapped in a dex-HEMA network and controlled degradation of 
the network can result in sustained drug release during several days.  The 
degradation rate of dex-HEMA hydrogels and dex-HEMA microgels is dependent 
on their cross-link density, which can be varied by altering the degree of substitution 
of the dextran (DS, i.e. the numbers of HEMA groups per 100 glucose units) and 
the dex-HEMA concentration.  Recently, we became interested in dex-HEMA 
nanogels for sustained intracellular drug delivery.  This chapter deals with the first 
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step in this research: it describes the preparation of dex-HEMA nanogels and tuning 
of their degradation rate by changing their composition.  
Several methods have been reported to obtain nanoscopic hydrogel 
particles.  A commonly used method is emulsion polymerization15-17: a stable 
emulsion is formed and next the droplets of the aqueous polymer solution are 
polymerized to form the nanogels while the surrounding organic solvent is removed 
by evaporation15 or extraction and dialysis17.  Major drawbacks of this method are 
the use of organic solvents and the need of energy (e.g. sonication) to form the 
emulsion, which may inactivate the entrapped therapeutic molecules.  Also, 
nanogels obtained by emulsion polymerization are often strongly polydisperse in 
size.  An interesting approach, without the use of organic solvents, has been 
recently described by the Levon group18,19: nanogels were made by UV 
polymerization of a solution of acrylamide and N, N’-methylenebis(acrylamide) 
entrapped in liposomes.  After the formation of these nanogels, the surrounding 
lipid layer was removed by adding a detergent.  Besides the absence of organic 
solvents, another advantage of this method is that the size and polydispersity of the 
nanogels can be easily controlled since the liposomes, which act as a container in 
which the nanogels are composed, are formed by multiple extrusion through a 
membrane with a well defined pore size.  Another benefit of this method is that both 
non-coated (naked) nanogels and lipid-coated nanogels can be made, which may 
be attractive for certain drug delivery applications.  Recently, Patton et al.20 also 
made use of liposomes as nanoreactors for making artificial oxygen carriers as 
blood substitutes20: bovine hemoglobin was entrapped in poly(acrylamide)/poly(N-
isopropylamide) nanogels prepared in liposomes.  Another recent study reported on 
actin nanogels prepared by polymerizing actin monomers to filamentous structures 
in phosphatidyl choline based liposomes21,22.  These lipid-coated actin nanogels 
were aimed at revealing how the cytoskeleton, coupled to the surrounding cell 
membrane, determines the cell shape during dynamic processes.   
The aim of this chapter is threefold.  First, we wonder whether both lipid-
coated and naked dex-HEMA nanogels could be obtained by using liposomes as a 
nanoreactor.  Second, we investigate whether in this way dex-HEMA nanogels 
could be obtained which differ in degradation properties.  Third, we are interested to 
know whether the obtained dex-HEMA nanogels could be taken up by cells. 
 
 
EXPERIMENTAL SECTION 
Dex-HEMA preparation and characterization 
Dex-HEMA batches were prepared and characterized according to a method 
described elsewhere20.  Dextran (Fluka, from Leuconostoc ssp.) with a molecular 
weight Mn of 19 000 g/mol was used.  The degree of substitution (DS, the number of 
HEMA groups per 100 glucopyranose residues of dextran) was determined by proton 
nuclear magnetic resonance spectroscopy (H-NMR) in D2O with a Gemini 300 
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spectrometer (Varian).  The DS of the samples used in the present study were 2.9, 
5.0, 7.5 and 18 respectively.   
 
Preparation of dex-HEMA nanogels 
As outlined in the introduction, dex-HEMA nanogels were prepared using 
liposomes as a nanoscaled reactor.  The procedure is schematically depicted in 
Figure 2. 
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Figure 2. Schematic representation of lipid coated and naked nanogels formation 
A conventional procedure to prepare the liposomes was used.  A 5 mg lipid 
film of SOPC:DOTAP (9:1) (SOPC and DOTAP respectively being 1-stearoyl-2-
oleoyl-sn-glycero-3-phosphocholine and 1,2-dioleoyl-3-trimethylammonium propane 
chloride, Avanti Polar Lipids) was made by dissolving the lipids in chloroform and 
drying this solution under a nitrogen flow while gently spinning the vial.  This 
resulted in a thin lipid film on the bottom of the vial (Figure 2A).  The vial was placed 
under vacuum for at least 4 hours to remove all remaining chloroform.  
Subsequently, this dry lipid film was hydrated with 1 mL of a dex-HEMA solution 
(i.e. 20% (w/w) dex-HEMA in 50 mM phosphate buffer (PB) at pH 7.0) which 
contained 0.05% (w/w) Irgacure 2959 (Ciba Specialty Chemicals) as a photo 
38 
CHAPTER 2 
initiator.  The resulting dispersion was placed at 25°C for 30 minutes while 
vortexing every 5 minutes.  This dispersion of large vesicles was aged overnight.  
Next, the dispersion was extruded with a hand-held syringe fitted with a standard 
filter holder (Avanti Polar Lipids) provided with a 450 nm polycarbonate membrane 
(Schleicher & Schuell) (Figure 2B).  After 11 back-and-forth passages of the 
dispersion through the extrusion membrane, the liposome dispersion was diluted, 
10 times with PB.  This dilution was necessary as not all the dex-HEMA was 
entrapped in the liposomes.  If not diluted this “free” dex-HEMA would form a gel in 
the polymerization step, thereby enclosing the liposomes in a polymer matrix.  The 
dispersion was subsequently exposed to UV light (365 nm from a Bluepoint 2.1 UV 
source, Honle UV Technology) at 25°C for 450 s which cross-linked the dex-HEMA 
solution in the liposomes with the formation of “lipid-coated dex-HEMA nanogels” 
(Figure 2C).  To obtain “naked dex-HEMA nanogels” the lipid layer was removed by 
adding 20 µL of a 100 mM solution of the detergent Triton X 100 (TX 100, Merck) to 
1 mL of the liposome dispersion (Figure 2D).   
 
Dynamic light scattering (DLS) analysis on dex-HEMA nanogels 
Dynamic light scattering measurements were done with a Malvern Autosizer 
4700 at a fixed angle of 90°.  A He-Ne laser (633 nm, 25 mW) was used as a light 
source.  PB, used to dilute the dispersions of the nanogels for DLS measurements, 
was filtered through a 0.1 µm Millipore Durapore® filter.  Polystyrene nanospheres 
(220 ± 6 nm; Duke Scientific Corporation) were used to check the performance of 
the DLS instrument.  The mean hydrodynamic diameter of the particles (dh) was 
computed from the intensity-intensity correlation function using the Malvern 
software package based on the theory of Brownian motion and the Stokes-Einstein 
equation  
 
 
hd
kTD πη3=   eq. 1 
 
where D is the diffusion coefficient (the primary parameter obtained from 
DLS measurements), k the Boltzmann constant, T the temperature (298 K) and η 
the viscosity of the solvent (0.96 cP).   
To study the degradation of the nanogels in function of (degradation) time, a 
cuvette was filled with 1.2 mL of the nanogel dispersions and sealed with 
Parafilm™ to avoid contamination with dust particles.  The cuvette was placed at 
37°C and DLS measurements on the degrading nanogels were performed at 
regular times.   
 
Atomic force microscopy (AFM) on dex-HEMA nanogels 
Atomic force microscopy images of the nanogels were recorded in air at 
ambient temperature with an Autoprobe CP (Thermomicroscopes) using a 5 µm 
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scanner.  The images were recorded in the intermittent-contact (tapping) mode.  
Pointprobe "Low Frequency Non-Contact" Sensors (Nanosensors) were used.  
These cantilevers have a resonance frequency around 150-170 kHz, a typical 
spring constant of about 50 N/m and an integrated Si tip with a radius of curvature 
at the apex around 10 nm.  To minimize particle deformation due to tip indentation, 
all the images were acquired in the so-called "soft-tapping" conditions with a ratio 
between the set-point amplitude and the free amplitude of vibration larger than 0.9. 
The nanogels made for AFM measurements were prepared from dex-HEMA 
and photo initiator in destilled water (instead of PB).  After polymerization, the free 
dex-HEMA, initiator and mixed micelles in the water surrounding the lipid-coated 
dex-HEMA nanogels were removed by dialysis using SpectraPore 50 kDa 
membrane tubes (dialysis during one week, against destilled water, changing the 
water once a day) at 4°C (to avoid degradation of the dex-HEMA nanogels12).  
Using water to dissolve the dex-HEMA (in stead of PB) and intensive dialysis of the 
nanogel dispersion was necessary to avoid the deposition of salts and micelles on 
the mica surface, which would complicate the AFM imaging of the nanogel. 
 
Negative stain transmission electron microscopy (TEM) on dex-
HEMA nanogels 
Lipid-coated and naked dex-HEMA nanogels were adsorbed on glow 
discharged Formvar-carbon-coated copper grids, subsequently washed twice in 
hepes buffered saline solution and negatively stained with 2% (w/v) uranyl acetate.  
The ultrastructure was analyzed with a Tecnai 10 electron microscope (FEI 
Company, Eindhoven, The Netherlands) at 100 kV acceleration voltage. 
 
Cellular uptake of dex-HEMA nanogels  
African green monkey kidney (VERO) cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM, Gibco) containing 2 mM glutamine, 10% heat-
inactivated fetal bovine serum and 1% penicilline-streptomycine.  Cells were 
prophylactically treated against mycoplasma with Plasmocin (Invivogen).  The cells 
were seeded onto sterile glassbottomed culture disks (MatTek Corporation), 
allowed to grow and to adhere for 1 day (at 37°C in a humidified atmosphere 
containing 5% CO2) before applying the nanogel dispersions.  
For evaluation of the cellular uptake of the dex-HEMA nanogels, the 
nanogels were fluorescently labeled with Texas Red labeled dextran (70 kDa, 
Molecular Probes).  Therefore 60 µL of a Texas Red dextran solution (25 mg/mL) 
was added to the 1 mL dex-HEMA/photo initiator solution used to hydrate the lipid 
film.  To remove the Texas Red dextran which was not entrapped in the liposomes 
we used Microcon™ centrifugal filter devices (molecular weight cut off 100 kDa, 
Millipore Corporation).  After centrifugation (at 14000×g for 24 minutes), the 
fluorescent dex-HEMA filled nanogels were recovered by inverted spin and diluted 
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ten times with DMEM before UV polymerization.  DLS measurements showed no 
remarkable change in size after centrifugational filtration (data not shown). 
200 µL of lipid-coated nanogels (containing Texas Red labeled dextran) were 
added to the cells in one well and incubated for 1 h at 37°C.  The cells were 
washed three times with PB before imaging by confocal laser scanning microscopy 
(CLSM, Bio-Rad MRC 1024) using a 60 × water immersion objective and a 
krypton/argon laser (568 nm) for the excitation of the Texas Red labeled nanogels.   
 
 
RESULTS AND DISCUSSION 
Loading liposomes with dex-HEMA 
The first step in the preparation of dex-HEMA nanogels was the loading of 
the liposomes with dex-HEMA.  It is well known that liposomes can be formed upon 
hydration of a thin lipid film: the hydrated lipid film detaches during agitation and 
self-closes to form large multilamellar liposomes23.  Figure 3 shows DLS 
measurements on the dispersions obtained by hydrating a SOPC:DOTAP lipid film 
with a dex-HEMA/photo initiator solution respectively before and after extruding the 
dispersion through a 450 nm polycarbonate membrane.  It is clear that before 
extrusion strongly polydisperse, micron sized, badly defined aggregates exist.  
Upon extrusion through the polycarbonate membrane, the aggregates turn into 
(less polydisperse) vesicles of about 400 nm in diameter, approximately being the 
pore size of the used polycarbonate membrane.  
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Figure 3. DLS measurements on liposomes (SOPC:DOTAP (9:1)) loaded with dex-HEMA 
before polymerization by UV light.  The lipid film was hydrated with a 20% (w/w) dex-HEMA 
(DS 5.4) solution.  The x-axis indicates how many times the liposome dispersion was 
extruded through the polycarbonate membrane.  The polydispersity of the particles before 
extrusion and after one extrusion was >0.7.  After that polydispersity did never exceed 0.3.  
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Overall the DLS data in Figure 3 show that liposomes are indeed formed 
after hydrating the SOPC:DOTAP film with (the rather viscous) dex-HEMA/photo 
initiator solution followed by extrusion through a 450 nm membrane.  Extrusion of 
the liposome dispersion through 100 nm membranes was not feasible, probably 
due to the high viscosity of the dispersion.   
We also tried to reduce the size of the liposomes obtained after hydrating the 
lipid film with dex-HEMA/photo initiator solution by sonication (using a tipsonicator), 
according to the method described by Kazakov et al.18.  However, small metal 
particles were coming of the tip sonicator and interfered strongly with the DLS 
measurements which made it impossible to accurately characterize the obtained 
liposomes by DLS. 
 
Evidence for dex-HEMA nanogels from DLS measurements 
In the next step, the liposomes, as characterized in Figure 3, were exposed 
to UV light to polymerize the dex-HEMA in the liposomes.  Figure 4A shows that the 
average size of the nanoparticles did not change upon polymerization.   
Subsequently TX 100 was added to the dispersion to solubilize the lipid 
coating.  Particles of about 400 nm in size could still be detected (Figure 4A), a first 
evidence that polymerization of the dex-HEMA in the liposomes occurred.  
However, also much smaller particles (~12 nm) were detected (Figure 5).  These 
were probably mixed micelles formed by TX 100, SOPC and DOTAP.  They 
indicated that TX 100 was able to remove the lipid layer from the particles resulting 
in a mixture of “naked” dex-HEMA nanogels and micelles.   
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Figure 4. (A) Bar 1 shows the hydrodynamic diameter of the dex-HEMA containing 
liposomes described in Figure 3 before UV polymerization.  Bar 2 represents the 
hydrodynamic diameter of the corresponding particles after UV treatment.  Bar 3 shows the 
hydrodynamic diameter of the particles after addition of TX 100.  (B) Bar 4: DLS on naked 
dex-HEMA nanogels treated with dextranase revealed that the nanogels were not present 
anymore.  Bar 5 shows the DLS data obtained after adding dextranase to lipid-coated dex-
HEMA particles. 
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Another indication for the removal of the lipid layer was the significant drop of 
the intensity of the light scattered by the dispersion after adding TX 100 (data not 
shown).  The removal of the lipid layer lowers the difference in refractive index 
between the nanogels and the dispersion solvent, which explains the lower intensity 
of the scattered light. 
Although the DLS measurements described above indicated the formation of 
naked dex-HEMA nanogels we tried to confirm that the 400 nm particles in Figure 
4A and Figure 5 were indeed naked dex-HEMA nanogels.  Therefore 20 µL of a 
dextranase solution (10U/mL) was added to 1 mL of a dex-HEMA nanogel 
dispersion.  Figure 4B shows that no nanoparticles were detected anymore after 
addition of dextranase.  Clearly, this was attributed to the degradation of the 
nanogels.  However, when dextranase was added to the (still) lipid-coated dex-
HEMA nanogels, nanoparticles remained present (Figure 4B).  This was explained 
by the fact that the enzyme could not pass through the lipid coating.  These 
observations all together indicate that naked dex-HEMA nanogels were indeed 
obtained after UV polymerization of dex-HEMA filled liposomes followed by TX 100 
treatment. 
 
 
 
Figure 5. Typical outcome of a DLS experiment on lipid-coated dex-HEMA nanogels 
treated with TX 100.  The x-axis shows the hydrodynamic diameter of the observed 
particles.  The SOPC:DOTAP (9:1) lipid film was hydrated with a 20% (w/w) dex-HEMA 
(DS 5.4) solution.  The peak with an average size of 12 nm is attributed to micelles, the one 
with an average size of 450 nm comes from naked dex-HEMA nanogels. 
 
Microscopic characterization of the dex-HEMA nanogels 
Confocal (fluorescence) microscopy is limited in imaging of particles of a few 
hundred nanometers.  Therefore we preferred to further characterize the nanogels 
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by AFM and negative stain EM.  Figure 6A shows an AFM image of SOPC:DOTAP 
coated dex-HEMA nanogels: the lipid coating is clearly visible at the surface of the 
dex-HEMA nanogels as a rough ring around the particle.  The size of the lipid-
coated nanogels is some hundreds of nanometers, which is in well agreement with 
the size data obtained by DLS, although little bit smaller.  This is maybe due to the 
drying of the particles, which is necessary for AFM analysis.  Figure 6B is an AFM 
image of nanogels treated with TX 100: compared to Figure 6A a more smooth line 
confines the nanoparticles suggesting that the lipid coating has indeed been 
removed.   
EM on the nanogels further confirmed the AFM and DLS data: the surface of 
the lipid-coated dex-HEMA nanogel seems different from that obtained after 
addition of TX 100.  The lipid surface of the coated nanogels was clearly visible on 
EM images (Figure 7A) while it disappeared upon treating the lipid-coated nanogels 
with TX 100 (Figure 7B).  
 
A B 
   
Figure 6. (A) AFM image of SOPC:DOTAP coated dex-HEMA nanogels.  The 
SOPC:DOTAP (9:1) lipid film was hydrated with a 20% (w/w) dex-HEMA (DS 18) solution.  
(B) AFM image of naked dex-HEMA nanogels obtained by adding TX 100 to the dispersion 
imaged in (A). 
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Figure 7. (A) Negative stain EM image of SOPC:DOTAP coated dex-HEMA nanogels.  The 
SOPC:DOTAP (9:1) lipid film was hydrated with a 20% (w/w) dex-HEMA (DS 18) solution.  
(B) Negative stain EM image of naked dex-HEMA nanogels obtained by adding TX 100 to 
the dispersion imaged in (A). 
Monitoring the degradation of dex-HEMA nanogels 
As schematically shown in Figure 1B dex-HEMA hydrogels consist of dextran 
chains which are mutually cross-linked by hydroxyethyl methacrylates.  Our group, 
as well as the Hennink group, have well documented3,12,24,25 that the HEMA cross-
links in dex-HEMA hydrogels spontaneously degrade by hydrolysis of the carbonate 
ester links formed between the hydroxyethyl methacrylate groups and the dextran 
chains (Figure 1A).  Especially the cross-link density (determined by both the dex-
HEMA concentration in the gel and the DS of the dex-HEMA) determines the 
degradation rate of dex-HEMA hydrogels.  It was shown experimentally that, the 
higher the cross-link density, the longer it takes for dex-HEMA gel slabs3,12,25 and 
dex-HEMA microgels3,24 to degrade.  We wondered whether also dex-HEMA 
nanogels could be obtained which show different degradation times.  Tunable 
degradation properties could be of interest to regulate the drug release from the 
nanogels after uptake by cells. 
Lipid-coated and naked dex-HEMA nanogels were dispersed in PB (pH 7.0) 
at 37°C and their size was measured by DLS at different times.  The behavior of 
lipid-coated nanogels in PB is depicted in Figure 8 while Figure 9 shows the 
behavior of the naked nanogels.  Figure 8A shows that the size of “empty” 
SOPC:DOTAP liposomes (i.e. without dex-HEMA) in PB (at 37°C) does not change 
drastically in 2 weeks time.  Figure 8B, C and D reveal that nanoparticles remain to 
exist for at least 2 weeks when lipid-coated dex-HEMA nanogels are dispersed at 
37°C in PB (independent on the DS of the dex-HEMA).   
At a first sight one could conclude that the dex-HEMA nanogels in the 
liposomes do not degrade.  However, another explanation could be that hydrolysis 
of the dex-HEMA nanogels in the liposomes does occur but that the degradation 
products of the nanogels (being dextran chains and poly(HEMA)12, Figure 1B) 
remain in the liposomes as these are stable for weeks (see Figure 8A).  The latter 
hypothesis was confirmed by the following experiments: lipid-coated nanogels (DS 
2.5; 5.4 and 8.9) were allowed to degrade for respectively 5, 14 and 18 days.  After 
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that period TX 100 was added.  In this way only particles of about 12 nm were still 
detected.  This proved that the nanogels in the liposomes were indeed completely 
degraded into a dextran and poly(HEMA) solution.   
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Figure 8. DLS measurements on SOPC:DOTAP (9:1) liposomes (A) and SOPC:DOTAP 
(9:1) coated nanogels (B,C,D) stored in PB at 37°C.  To prepare the dex-HEMA nanogels 
the SOPC:DOTAP (9:1) lipid film was hydrated with a 20% (w/w) dex-HEMA solution.  The 
DS of the dex-HEMA was respectively 2.5 (B), 5.4 (C) and 8.9 (D).  At this moment it is not 
clear why the DS 5.4 nanogels were larger than the DS 2.5 and 8.9 nanogels.  Data shown 
are the result of one set of experiments. Repeated experiments revealed the same results.   
 
Theoretically one could argue that the turnover from the gels into the solution 
of degradation products would increase the osmotic pressure inside the liposomes 
which should rupture this lipid layer, especially as the lipid membranes are not 
permeable for the large dextran chains (19000 g/mol) used to synthesize the dex-
HEMA in this study.  Indeed, we showed previously that the osmotic pressure of a 
dex-HEMA gel increases upon degradation, which also explains the swelling of 
degrading dex-HEMA gels25,26.  However, the following considerations point out that 
the increase in osmotic pressure is probably too low to osmotically destroy the 
liposomes.  Following the method of Mui et al.27 the rupture strength (τ) of a 
SOPC:DOTAP (9:1) film was determined and turned out to be 0.075 N/m.  From 
Laplace's law (eq. 1)  
46 
CHAPTER 2 
 
 2
rP ×∆=τ
 eq. 2 
 
in which ∆P (in N/m²) stands for the pressure difference over the lipid membrane, τ 
(in N/m) being the tensile strength and r (in m) the radius of the liposome, one can 
calculate that for a 450 nm SOPC:DOTAP (9:1) liposome the pressure increase 
needed to overcome the tensile strength, i.e. to rupture the membrane, should 
exceed 666 kPa.  We measured previously the osmotic pressure of completely 
degraded dex-HEMA hydrogels25,26 and could estimate that the osmotic pressure of 
the solutions obtained by degradation of the dex-HEMA nanogels used in Figure 
8B, C and D (assuming the dex-HEMA concentration of these gels is 20% (w/w)) is 
only 120 kPa and thus insufficient to rupture the liposomal membrane.  This 
supports the idea that the SOPC:DOTAP lipid-coated dex-HEMA nanogels do 
degrade yielding SOPC:DOTAP liposomes filled with a dextran/poly(HEMA) 
solution and that the degradation products remain in the liposomal vesicles.   
Figure 9 (B, C and D) shows DLS data obtained on naked dex-HEMA 
nanogels stored in PB at 37°C.  As Figure 5 already illustrated, DLS measurements 
on naked dex-HEMA nanogels indicated the presences of both small micelles and 
larger nanogels.  The y-axis in Figure 9 plots the average size of the nanogels.  
Clearly, the average size of the nanogels in the dispersions decreases (rather 
slowly) in time, indicating that they indeed degrade.  Especially, as seen earlier for 
dex-HEMA hydrogel slabs and dex-HEMA microgels3,12,24,25, the degree of cross-
linking influences the degradation rate of the dex-HEMA nanogels: the higher the 
DS of the dex-HEMA (i.e. the higher the cross-link density of the dex-HEMA 
nanogels) the longer nanogels can be detected in the dispersions (compare Figure 
9B, C and D).  Note that before degradation starts (i.e. at t=0 in Figure 9) dex-
HEMA nanogels DS 2.5 are smaller than the nanogels DS 5.4 and 8.9.  This is 
possibly due to the fact that the dex-HEMA nanogels DS 2.5 were already partially 
degraded at the time of the first DLS measurement (as dex-HEMA nanogels DS 2.5 
degrade very fast due to the low cross-link density).   
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Figure 9. DLS measurements on SOPC:DOTAP (9:1) liposomes exposed to TX 100  (A) 
and naked dex-HEMA nanogels (B,C,D) stored in PB at 37°C.  To prepare the naked dex-
HEMA nanogels the SOPC:DOTAP (9:1) lipid film was hydrated with a 20% (w/w) dex-
HEMA solution.  The DS of the dex-HEMA was respectively 2.5 (B), 5.4 (C) and 8.9 (D).  
Subsequently the lipid coating was removed by adding TX 100.  Repeated experiments 
revealed the same results.   
 
Uptake of dex-HEMA nanogels by VERO cells 
We studied the cellular uptake of the lipid-coated dex-HEMA nanogels.  As 
explained in the Experimental section, for monitoring the cellular uptake the 
nanogels were fluorescently labeled with Texas Red dextran.  To remove free 
Texas Red dextran (i.e. Texas Red dextran not encapsulated in the nanogels), the 
nanogel dispersions were filtrated by centrifugational filtration.  Separate 
fluorescence measurements showed that the 70 kDa Texas Red dextran chains 
could freely pass through the used membrane (molecular weight cut off 100 kDa) 
while the nanogels (a few hundred nanometer in size) were prevented from passing 
the membrane, as expected. 
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Figure 10. CLSM images of VERO cells incubated with lipid-coated dex-HEMA nanogels 
(containing Texas Red labelled dextran).  To prepare the dex-HEMA nanogels the 
SOPC:DOTAP (9:1) lipid film was hydrated with a 20% (w/w) dex-HEMA solution (DS 5.4).   
 
Figure 10 shows confocal microscopy images of VERO cells one hour after 
incubating them with lipid-coated dex-HEMA nanogels: internalization (most likely 
by endocytosis) of the nanogels clearly occurred as highly fluorescent punctuations 
were observed in the cytoplasm.  Also, the dex-HEMA nanogels seemed to be 
excluded from the nucleus.  This can be expected considering that the pores in the 
nuclear membrane are by far too small to allow the passage of the 
(intact/degrading) nanogels28. 
 
 
CONCLUSIONS 
 
In this second chapter it is shown that lipid-coated dex-HEMA nanogels can 
be prepared by UV polymerization of dex-HEMA containing liposomes which were 
obtained by hydrating a SOPC:DOTAP lipid film with a dex-HEMA solution.  DLS 
measurements indicated that the lipid-coated dex-HEMA nanogels thus obtained 
were around 350 nm in size, as could be expected considering the 450 nm pores of 
the membranes used to extrude the liposome dispersions.  DLS measurements 
also clearly showed that TX 100 efficiently removed the lipid coating as the intensity 
of the light scattered by the dispersions significantly dropped upon adding TX 100.  
On its turn this was attributed to a lowering of the difference in refractive index 
between the nanogels and the solvent upon removing the lipid coating.  AFM en EM 
imaging confirmed the existence of the particles and showed that both lipid-coated 
and naked dex-HEMA nanogels could be obtained.   
Compared to e.g. the emulsion polymerization method the use of liposomes 
to prepare nanogels comprehends several advantages.  The size of the nanogels 
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can be controlled by using membranes with the appropriate pore size in the 
preparation of the liposomes.  Also, organic solvents are not used which is a clear 
benefit when the nanogels are considered for pharmaceutical purposes (e.g. drug 
inactivation may occur upon contact with organic solvents).  Moreover, and 
especially, the liposome based method allows the design of both naked nanogels 
as well as lipid-coated nanogels.  The lipid coating may offer additional interesting 
features to the nanogels.  E.g. in the next chapter, we will verify whether the 
presence of a lipid coating may prevent the ‘burst release’ of some model drug 
molecules which will be encapsulated in the hydrogel core.  In a following chapter, 
we will make use of pH sensitive29-31 and PEGylated lipids to surround the 
nanogels, as this may improve the escape of the nanogels from endosomes (which 
is attractive if the nanogels have to be delivered in the cytosol) and improve the 
particles stability and prolong blood circulation times after parenteral administration.  
Also, in analogy with immunoliposomes, being liposomes bearing antibodies at their 
surface, “immunogels” may be easily designed by grafting the antibodies at the lipid 
surface of the lipid-coated nanogels, making use of well known chemistry. 
A major question in this work was whether nanogels could be obtained which 
degrade over different times.  DLS measurements on naked dex-HEMA nanogels 
stored in PB at 37°C revealed that slowly degrading dex-HEMA nanogels could 
indeed be realized by increasing the cross-link density of the dex-HEMA nanogels 
(through the use of dextran densely substituted with HEMA): nanogels prepared 
with dex-HEMA DS 2.5 were completely degraded in a few days while nanogels 
synthesized from dex-HEMA DS 8.9 remained to exist, roughly spoken, during two 
weeks.  Our experiments showed that in lipid-coated dex-HEMA nanogels stored 
over days in buffer at 37°C the dex-HEMA gel also degraded.     
As this work showed that the dex-HEMA nanogels could be taken up by 
endocytosis in VERO cells further research will explore the potentials of the dex-
HEMA nanogels for intracellular delivery of antisense therapeutics, plasmid DNA 
and proteins.  In the next chapter, drug loading and release will be in focus as well 
as the behavior of the nanogels in biological media like serum which may induce 
aggregation of the nanogels through e.g. the adsorption of proteins at their surface.  
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Abstract  
The use of drugs with intracellular targets will strongly depend on 
the availability of delivery systems that are able to deliver them to 
specific intracellular sites at an optimal rate. In the previous chapter 
biodegradable dextran nanogels were prepared using liposomes as a 
nanoscaled reactor.  In this chapter we will encapsulate some model 
proteins (bovine serum albumin (BSA) and lysozyme) in these 
nanogels.  We found that the encapsulation efficiency of BSA and 
lysozyme in the dextran nanogels was about 50%.  Specifically, the 
release of BSA and lysozyme from the dextran nanogels was clearly 
governed by the cross-link density of the tiny gels.  Depending on the 
size of the encapsulated protein, the cross-link density of the dextran 
network and the presence or absence of a lipid coating, proteins were 
released from the nanogels over days to weeks.  Interestingly, when 
sufficiently diluted, dextran nanogels did not aggregate in human 
serum, being of major importance when one considers intravenous 
administration of such nanogels.  Also, reconstitution of lyophilized 
dextran nanogels seemed perfectly possible, being also an important 
finding since dextran nanogels will have to be stored in dry form.   
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INTRODUCTION 
 
The successful use of therapeutic molecules with intracellular targets will 
certainly depend on the availability of delivery systems that deliver an optimal dose of 
the pharmacologically active agents to specific intracellular sites at an optimal rate.  
There is an emerging need for intracellular delivery vehicles for nucleic acids to be 
used in gene therapy.  Also systems which deliver therapeutic antibodies, peptides 
and proteins into cells (like for example β-galactosidase, to treat lysozomal storage 
disease, or apoptosis inducing proteases like caspase 3, caspase 8 and granzyme B) 
will become of major importance1.  Liposomes have attracted much attention during 
the last decade for intracellular delivery of proteins and nucleic acids since they may 
allow a better targeting of specific cells and may protect the encapsulated drugs from 
degradation in the blood and the extracellular matrices2.  Also, liposomes can be 
made responsive to different stimuli, for example light and pH3,4, which may hold 
promise for triggered release of the encapsulated drugs.  Generally speaking, 
liposomes have a low encapsulation efficiency for nucleic acids and protein drugs 
and they are easily destroyed after injection into the body.  Especially, controlling the 
rate of protein or nucleic acid release from liposomes is not straightforward.  Though, 
in this context we would like to refer to Dalkara et al.5 who reported on a lipid 
formulation consisting of in situ dimerized CholSpermine (cholesterol linked to 
carboxy-spermine by a cysteine) and DOPE (1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine) able to enter adherent cells and to release the protein over a 
prolonged period of time.   
In the last few years there has been a significant interest in (biodegradable) 
polymeric nanoparticles as, compared to liposomes, they are more robust and thus 
more stable in the body.  Some of them show higher encapsulation efficiencies for 
certain drugs and they can be tailored for time controlled release of drugs.  Different 
types of polymers have been used to design biodegradable polymeric nanoparticles.  
Poly(lactic-co-glycolic acid) (PLGA) nanoparticles have been extensively 
investigated6,7 due to their biocompatibility and biodegradability.  GMP grade PLGA is 
commercially available and it has a long history of safe use in both medical 
applications (like implants, internal sutures) and drug delivery (like peptide and 
protein delivery), all features that make PLGA attractive to so many researchers.  It is 
well known, however, that the hydrolysis of PLGA may substantially decrease the pH 
in PLGA micro- and nanoparticles, which may destroy encapsulated proteins and 
peptides.  But, basic additives like Mg(OH)2 and Ca(OH)2 encapsulated in the  PLGA 
matrix may overcome this8.  Another disadvantage of PLGA nanoparticles is that the 
rate of degradation in the body, and thus drug release, is too slow in many cases.  
Additionally, there is only a limited possibility of modifying the release from PLGA 
matrices.  Besides PLGA, many other types of biodegradable polymers are being 
investigated to design drug containing nanoparticles, like e.g. poly(cyanoacrylates) 
(PCA)9, chitosan10, gelatin11, sodium alginate12,13.   
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In chapter 2 we reported on the synthesis of biodegradable dextran nanogels 
of about 400 nm in size14.  We showed that lipid-coated dextran nanogels -
sometimes referred to as “lipobeads”15- can be prepared by UV polymerization of 
hydroxyethyl methacrylated dextran (dex-HEMA; Figure 1A) containing liposomes 
which were obtained by hydrating a lipid film with a dex-HEMA solution.  “Naked” 
dextran nanogels (i.e. without lipid coating) were prepared by removing the lipid 
coating with Triton X 100.  Dex-HEMA nanogels spontaneously hydrolyze under 
physiological conditions into free dextran chains and some poly(HEMA) fragments16.  
DLS measurements on dex-HEMA nanogels stored in buffer at 37°C revealed that 
the degradation time depended on the cross-link density of the nanogels; dex-HEMA 
nanogels prepared from dextran sparsely substituted with HEMA degraded quickly 
while it took days to weeks for nanogels prepared from densely substituted dextran.  
Furthermore, confocal laser scanning microscopy showed that dex-HEMA nanogels 
could be taken up by cells.  
.  
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Figure 1. (A) Chemical structure of the monomer in dex-HEMA, i.e. glucopyranose 
substituted with HEMA and (B) schematic representation of a dex-HEMA network before and 
after degradation. 
 
In this chapter we investigated whether dextran nanogels can be efficiently 
uploaded with proteins.  Since we know from chapter 2 that the degradation time of 
the dextran nanogels depends on the cross-link density14, we evaluated whether we 
can govern the protein release from such tiny gels by varying their cross-link density.  
Initially we investigated whether the lipid coating surrounding the dextran nanogels 
influences the protein release.  Finally we studied whether or not dextran nanogels 
(a) aggregate in serum and (b) keep their physicochemical properties after 
lyophilization, because dextran nanogels will have to be stored in dry form as 
moisture degrades them. 
 
 
EXPERIMENTAL SECTION 
Synthesis of dex-HEMA 
Dex-HEMA was prepared and characterized as described elsewhere17.  
Dextran with a molecular weight of 19000 g/mol was used in the synthesis of dex-
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HEMA.  The degree of substitution (DS, i.e. the number of HEMA groups per 100 
glucopyranose residues of dextran) was determined by proton nuclear magnetic 
resonance spectroscopy (1H NMR) in D2O with a Gemini 300 spectrometer (Varian).  
The different DS of the dex-HEMA used in this study were respectively 2.5, 5.4 and 
8.9.   
 
Preparation of (protein loaded) dextran nanogels 
Dextran nanogels were prepared using liposomes as a nanoscaled reactor, as 
described in the previous chapter14.  A conventional procedure to prepare the 
liposomes was used.  A 5 mg lipid film of SOPC (1-stearoyl-2-oleoyl-sn-glycero-3-
phosphocholine, Avanti Polar Lipids) was made by dissolving the lipid in chloroform 
in a test-tube.  This solution was dried under a nitrogen flow while gently spinning the 
vial.  This resulted in a thin lipid film on the bottom of the vial.  The vial was placed 
under vacuum for at least 4 hours to remove all remaining chloroform.  Subsequently, 
this dry lipid film was hydrated with 1 mL of a dex-HEMA solution (i.e. 20% (w/w) dex-
HEMA in 50 mM phosphate buffer (PB) at pH 7.0) which contained 0.05% (w/w) 
Irgacure 2959 (Ciba Specialty Chemicals) as a photo initiator.  The resulting 
dispersion was placed at 25°C for 30 minutes while vortexing every 5 minutes.  This 
dispersion of large vesicles was aged overnight.  Next, the dispersion was extruded 
with a LiposoFast Pneumatic-Actuator (Avestin) provided with a 400 nm 
polycarbonate membrane (Whatman International).  After 11 back-and-forth 
passages of the dispersion through the extrusion membrane, the liposome dispersion 
was diluted 10 times with PB.  This dilution was necessary as not all the dex-HEMA 
was entrapped in the liposomes.  If not diluted, this “free” dex-HEMA would form a 
gel in the polymerization step, thereby enclosing the liposomes in a polymer matrix.  
The dispersion was subsequently exposed to UV light (365 nm from a Bluepoint 2.1 
UV source, Honle UV Technology) at 25°C for 450 s, which cross-linked the dex-
HEMA solution in the liposomes with the formation of “lipid-coated dex-HEMA 
nanogels”.   
To obtain “naked dex-HEMA nanogels” the lipid layer was removed by adding 
20.0 µL of a 100 mM solution of the detergent Triton X 100 (TX 100, Merck) to 1 mL 
of the lipid-coated nanogel dispersion.   
To prepare protein loaded dextran nanogels, the protein (bovine serum 
albumine; BSA; Sigma – lysozyme; Fédération International Pharmaceutique) was 
added to the dex-HEMA solution used to hydrate the dry lipid film.  The protein 
concentration in the dex-HEMA solution was 50 mg/mL.  
 
Protein encapsulation efficiency in dextran nanogels 
To determine the protein encapsulation efficiency the lipid coated dextran 
nanogels were intensively washed using a stirring cell (Amicon; provided with a 100 
nm membrane from Whatman) to remove the non-encapsulated proteins.  The 
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protein content of the waste water after each washing step was measured by a 
micro-assay procedure18.  Washing of the nanogels was stopped once the protein 
content of the waste water came to a minimum. 
To determine the protein encapsulation efficiency all the waste fractions were 
collected and the protein content was measured by HPLC (see details below).  
Subsequently the lipid coating of the nanogels was removed by adding TX 100 (20 µL 
of a 100 mM TX 100 solution to 1 mL of nanogels dispersion) and the nanogels were 
degraded by adding 20.0 µL dextranase (10U/mL) to 1 mL nanogel dispersion.  The 
dextranase was from Sigma (D-1508; diluted to 10 U/ml in 10 mM PB at pH 7.0; one 
unit delivers 1 µmol of isomaltose per min at pH of 6.0 at 37°C).  The protein content 
of the thus obtained degraded nanogel dispersion was determined by HPLC (see 
details below).  We made sure that dextranase and the degradation products of the 
dex-HEMA nanogels (being dextran and poly(HEMA) fragments19 (see Figure 1B)) 
did not interfere with the detection of BSA and lysozyme by HPLC.   
 
Dynamic light scattering (DLS) analysis on dextran nanogels 
Dynamic light scattering measurements were done with a Malvern Autosizer 
4700 at a fixed angle of 90°.  A He-Ne laser (633 nm, 25 mW) was used as a light 
source.  The phosphate buffer used to dilute the dispersions of the nanogels for DLS 
measurements was filtered through a 0.1 µm Millipore Durapore® filter.  Polystyrene 
nanospheres (220 ± 6 nm; Duke Scientific Corporation) were used to check the 
performance of the DLS instrument.  The mean hydrodynamic diameter of the 
particles (dh) was computed from the intensity-intensity correlation function using the 
Malvern software package based on the theory of Brownian motion and the Stokes-
Einstein equation  
 
D
kTdh πη3=   eq. 1 
where D is the diffusion coefficient (the primary parameter obtained from DLS 
measurements), k the Boltzmann constant, T the temperature (298 K) and η the 
viscosity of the solvent (0.96 mPa.s).   
To study the degradation of the nanogels in function of (degradation) time, a 
cuvette was filled with 1.2 mL of the nanogel dispersions and sealed with Parafilm™ 
to avoid contamination by dust particles.  The cuvette was placed at 37°C and DLS 
measurements on the degrading nanogels were performed at regular intervals.   
 
Protein release from degrading dextran nanogels 
The amount of protein released from the degrading dextran nanogels was 
measured as schematically presented in Figure 2.  A Vivaspin centrifugation filtration 
device (having a membrane with a 300 kDa MWCO, Vivascience) was filled with a 
known weight (at least 2,5 g) of a dispersion of protein loaded dextran nanogels in 
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PB (Figure 2A).  Before the nanogels began to degrade and at different times during 
their degradation (which occurred at 37°C), the amount of released protein was 
determined by centrifugation of the dispersion for 3 minutes (at 100×g, Figure 2B).  
The filtrate was stored for protein analysis till the end of the experiment (at 4°C, it 
was then verified  that no degradation of the protein had occurred).  PB was added to 
the nanogel dispersion (remaining in the Vivaspin device) until reaching the original 
weight of the dispersion (Figure 2C and D).  The protein release was measured until 
the nanogels were completely degraded, as could be detected by DLS 
measurements.   
 
 
 
A B
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic representation of protein separation process from degrading nanogels. 
 
Determination of the protein concentration  
The protein concentration was measured by Reversed Phase HPLC (RP-
HPLC, LaChrom Elite).  An aliquot (2 µl) of the samples was automatically injected 
into an RP-HPLC system (Hitachi LaChrom Elite, L-2100 SMASH pump, L-2200 
autosampler, L-2300 column oven and L-2450 Diode Array Detector).  An RP C4 
column (Alltech, 300Å, 5 µm, 25 cm) was used.  A water/acetonitrile mixture (the 
solvent’s composition and the concentration gradient in function of time are given in 
Table 1A and B), adjusted to pH 2.0 with trifluoroacetic acid (TFA, Sigma) was used 
as the mobile phase at a constant flow rate of 0.75 mL/min.  A calibration curve was 
obtained by injecting various volumes of a 5 mg/mL protein solution in PB.  The 
Sample in Vivaspin weighing filtrate 
Let sample degrade at 
37°C 
C D 
Fill 
supernatant 
untill original 
weight 
Cap and store 
filtrate until 
HPLC analysis 
3’ centrifugation 
at 1000 rpm 
300 kDa 
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protein concentration in the samples was calculated from the area under the protein 
peak, using the calibration curve. 
 
Table 1. Eluents’ (A) composition and (B) concentration gradient used in the mobile phase 
measuring the protein concentration with HPLC.   
  
 A 
component solvent A  solvent B  
Water  95 % (v/v) 5% (v/v) 
Acetonitrile 5% (v/v) 95% (v/v) 
TFA 1 mL/L 1 mL/L 
 
 B 
time (min) % solvent A % solvent B 
0 80 20 
15 50 50 
20 0 100 
21 80 20 
40 80 20 
 
Enzymatic activity of released lysozyme 
The enzymatic activity of lysozyme released from the nanogels was measured 
by monitoring the clearance of a Micrococcus luteus suspension (lysozyme degrades 
the outer cell wall of these bacteria).  For comparison, the same M. luteus 
suspension was treated with a lysozyme standard with well known activity20.  To 3.00 
mL of a buffered M. luteus suspension, 10.0 µL of sample was added and mixed at 
25°C.  The absorbance at 450 nm was read with a spectrophotometer (Pharmacia 
Biochrom 4060 UV-Visible spectrophotometer) every 15 s for 3 min.  The activity of 
the sample was calculated as follows: 
 
 
cS
acSa
st
stst
×
××=  eq. 2 
Where a is the activity of the sample, S is the absorbance decrease per 
minute (as calculated from the initial linear part of the absorbance ~ time curve) and c 
is the concentration of the sample.  Sst, cst and ast refer to the lysozyme standard, S, 
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c and a  refer to the unknown sample which contains lysozyme released from the 
nanogels.  For kinetic reasons the unknown lysozyme sample was diluted to give an 
absorbance decrease per minute of the same order of magnitude as the lysozyme 
standard.   
 
Behavior of dextran nanogels in serum 
A Venosafe Serum-Gel tube with cloth activator (6 mL) was filled with human 
blood.  Serum was obtained after blood clotting for 30 min at room temperature, 
followed by centrifugation at 3000 rpm for 8 min.  Subsequently the serum was 
filtered through a 2 µm filter (Whatman International).   
A lipid-coated dextran nanogel dispersion (prepared with dex-HEMA DS 5.4) 
was added to prewarmed serum (37°C) and further incubated at 37°C.  At regular 
time intervals DLS measurements were performed. 
 
Lyophilization of dextran nanogels 
Dextran nanogels with and without SOPC coating were prepared as described 
above, however, instead of PB, the same amount of distilled water was used.  The  
dextran dispersions were dialyzed at 4°C (to retard/avoid degradation of the 
nanogels) for one week in a 100 fold volume of water.  Subsequently the dispersions 
were weighed and sucrose was added (final sucrose concentration was 10% (w/w)).  
Then the dispersions were freeze-dried (Amsco-Finn Aqua GT4 freeze –dryer) as 
follows: The dispersions were frozen to 228 K within 175 min at 1000 mbar.  Primary 
drying was performed at 258 K and at a pressure varying between 0.8 and 1 mbar for 
13 h, followed by secondary drying at an elevated temperature (283 K) and reduced 
pressure (0.1-0.2 mbar) for 7 h.  
 
 
RESULTS AND DISCUSSION  
Synthesis of protein loaded dextran nanogels using liposomes as 
reactor  
In chapter 2 we reported that both lipid-coated and ‘naked’ dex-HEMA 
nanogels can be prepared by UV polymerization of dex-HEMA containing liposomes 
which were obtained by hydrating a lipid film with a dex-HEMA solution14.  We 
wondered whether protein filled dextran nanogels could also be obtained in this 
manner.  Figure 3A shows the typical outcome of DLS measurements on a liposome 
dispersion obtained by hydrating a SOPC lipid film with a dex-HEMA/lysozyme 
solution.  The size of the liposomes is around 400 nm, well in agreement with the 
pore size of the extrusion membrane used.  Figure 3B shows DLS measurements on 
the same liposomes but after UV treatment that cross-links the dex-HEMA in the 
interior of the liposomes.  One can see no aggregates are formed.  It therefore 
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seems possible to prepare (rather sparsely dispersed) dextran nanogels using 
liposomal vesicles as reactor when proteins are present in the dex-HEMA solution 
which hydrates the lipid film.  In the process of their formation liposomes passively 
entrap water and these dissolved molecules being dex-HEMA and proteins in this 
study.   
As described in the Experimental section, the non-encapsulated proteins and 
non-encapsulated dex-HEMA were washed away from the nanogels by the use of a 
stirring cell.  Figure 3C shows DLS measurements on “washed” dextran nanogels; 
clearly, after washing, intact dextran nanogels, approximately 400 nm in size, remain 
present.  In the filtrate we could not detect any nanogels by DLS, as expected, 
proving that the nanogels could not pass the filter of the stirring cell.    
 
 A B C 
 
Figure 3. Size distribution, as measured by DLS, of SOPC coated dex-HEMA nanogels 
loaded with lysozyme.  A 20% (w/w) dex-HEMA (DS 5.4) solution was used to hydrate the 
SOPC lipid film.  (A) shows the SOPC liposomes before polymerization of the dex-HEMA, (B) 
and (C) show the SOPC coated dex-HEMA nanogels respectively before and after 3 washing 
steps. 
 
Figure 4 shows the outcome of protein measurements on the filtrate.  As one 
can see, most of the non-encapsulated proteins were removed from the nanogels 
after two washing steps, since the absorbance by the filtrate after two washing steps 
is not higher than the absorbance by the blank (PB 50 mM pH 7.0).  In all further 
experiments, the dextran nanogel dispersions were washed three times. 
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Figure 4. Protein absorbance of the filtrate after washing a dex-HEMA nanogel dispersion 
several times (DS 5.4; SOPC coated, BSA loaded nanogels).  As blank PB (50 mM, pH 7.0) 
was used. 
 
Encapsulation of proteins in dextran nanogels 
To determine the loading efficiency of dextran nanogels with proteins we 
determined both the amount of protein encapsulated in the nanogels as well as the 
amount of non-encapsulated protein (i.e. the amount of protein in the washing water).  
The former was determined after removal of the lipid coating of the dextran nanogels 
and digestion of the nanogels with dextranase.  The removal of the lipid is necessary 
since we observed in the previous chapter that dextranase could not penetrate 
through the lipid layer14.  Table 2 shows that about half of the proteins are entrapped 
in the nanogels.  As expected, the protein loading was not dependent on the cross-
link density of the nanogels since the loading occurs before the cross-linking of the 
dex-HEMA solution in the liposomes.  Note that the “total amount of protein”, being 
the sum of the encapsulated and non-encapsulated amount, is somewhat lower than 
expected (i.e. 50 mg per sample) which is, highly likely, due to some protein loss 
during the experiment.  Because the non-coated nanogels were made from the lipid-
coated ones, we assume that the protein loading of the naked dextran nanogels 
equals the loading of the corresponding lipid-coated nanogels.   
 
Table 2. Protein encapsulation in SOPC coated nanogels.  
Protein 
DS 
dex-
HEMA 
Removed with 
washing water 
(mg) 
Encapsulated in 
the nanogels 
(mg) 
Encapsulated in 
the nanogels 
(%) 
BSA 2.5 24 22 48 
 5.4 21 23 52 
 8.9 20 22 51 
     
lyso 2.5 26 22 45 
 5.4 25 22 46 
 8.9 24 21 46 
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Protein release from (hydrogel free) liposomes 
A major objective of this study was to evaluate whether the dextran network in 
the nanogels allows controlling the release of encapsulated proteins.  For this 
purpose we first studied what the release of proteins from (hydrogel free, i.e. without 
dex-HEMA) liposomes looks like.  Figure 5 clearly shows that about 20% of the 
encapsulated BSA was initially released from SOPC liposomes.  No further release 
occurred during the next 18 days; showing that BSA remains encapsulated in the 
SOPC liposomes.  Note that a 100% release in Figure 5 corresponds to the amount 
of BSA measured after treatment of the liposomes with TX 100.  In contrast to BSA, 
lysozyme is released almost immediately (Figure 5).  While the reason is unclear, the 
fact that lysozyme is much smaller than BSA, may play a role.  The molecular weight 
and hydrodynamic diameter of BSA are 67000 g/mol and 7.2 nm while they are 
12000 g/mol and 4.1 nm for lysozyme21.   
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Figure 5. Relative cumulative release of BSA () and lysozyme (●) from (hydrogel free) 
SOPC liposomes in function of time.  100% release corresponds to the amount of protein 
measured after adding TX 100 to the liposomes. 
 
Protein release from dextran nanogels 
DLS measurements on dex-HEMA nanogels stored in buffer at 37°C 
described in chapter 2 revealed that the degradation time depends on the cross-link 
density of the nanogels: dex-HEMA nanogels prepared from dextran sparsely 
substituted with HEMA degrade quickly while it takes days to weeks for nanogels 
prepared from densely substituted dextran14.  We now wondered whether varying the 
cross-link density of the dextran nanogels influences the release of the encapsulated 
proteins.  
Measuring drug release in vitro from nanoparticles is always a challenge 
because the nanoparticles must be separated from the release medium22.  For that 
purpose ultra-centrifugation is often used23-25.  This is a rather time consuming 
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process which occurs at high centrifugal forces, which may destroy the nanoparticles, 
especially since nanogels become softer and softer as degradation proceeds.  We 
separated the dextran nanogels from the released proteins by centrifugational 
filtration as described in the Methods and Materials section.  The separation process 
was optimized to make sure the nanogels remained quantitatively on the filter and 
that the protein concentration on top of the filter equaled the concentration in the 
filtrate. 
Figure 6 represents the release of BSA from sparsely (DS 2.5; A), moderately 
(DS 5.4; B) and densely (DS 8.9; C) cross-linked dextran nanogels, respectively with 
and without SOPC lipid coating.  As we know from chapter 2, the “life-time” of the 
naked dextran nanogels (i.e. the time to become completely degraded under the 
conditions of the release experiment and as measured by DLS) is around 
respectively 5 days for DS 2.5, 12 days for DS 5.4 and 18 days for DS 8.914.   
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Figure 6.  Cumulative release of BSA from degrading SOPC coated () and naked (●) dex-
HEMA nanogels.  In all experiments a 20% (w/w) dex-HEMA solution was used to hydrate 
the lipid film.  The DS of the dex-HEMA was 2.5 (A), 5.4 (B) and 8.9 (C).  100% release 
corresponds to the amount of BSA released when the nanogels were completely degraded 
(i.e. when nanogels could no longer be detected by DLS).  
 
Let us first consider the BSA release from the naked nanogels.  Clearly, the 
cross-link density of the dextran nanogels has an important influence on the release 
of the proteins.  The insets in Figure 6 tabulate the time it takes to release 
approximately 50% of the proteins (t1/2).  For the sparsely cross-linked nanogels 
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(Figure 6A) t1/2 is shorter than 1 day while t1/2 is 2 to 3 days for the DS 5.4 and 8.9 
dextran nanogels (Figure 6B and C, respectively).  This suggests that BSA molecules 
are initially physically entrapped in the dex-HEMA network of the nanogels.  The 
higher the cross-link density, the more cross-links have to be hydrolyzed to 
sufficiently enlarge the pores of the network thereafter allowing the proteins to be 
released.  
 
Compared to the naked nanogels, the lipid-coated dextran nanogels release 
BSA more slowly (Figure 6).  An effect of the lipid coating on the BSA release could 
be somehow expected, as BSA remains encapsulated in SOPC liposomes for longer 
times (see Figure 5).  The question arises as to why BSA is rather continuously 
released from the lipid-coated dextran nanogels.  To explain this, the following 
considerations may be important.  First, we showed in chapter 2 that dex-HEMA 
nanogels in the liposomes degrade, just like the naked dex-HEMA nanogels do14.  
Indeed, after keeping lipid-coated dextran nanogels for a sufficiently long time in PB 
(to allow degradation) and after removing the remaining lipid coating (by TX 100), 
nanogels were no longer detected.  Second, as was also observed for dex-HEMA gel 
slabs and dex-HEMA microgels26,27, dex-HEMA nanogels very likely swell during 
degradation.  Third, our research group observed previously that the turnover from 
dextran gels into a solution of the degradation products increases their osmotic 
pressure; provided the gels are surrounded by a semi-permeable membrane, which 
allows water transport, but keeps the free dextran chains in the degrading 
matrix26,28,29.  Considering these three observations we hypothesize that the 
degrading (swelling) dextran nanogel cores deform their surrounding lipid coatings 
thereby making them leaky to proteins.  As a result, BSA may be continuously 
delivered from the lipid-coated nanogels, rather than remaining in the vesicles.  On 
the other hand, another possibility could be that the particles completely loose their 
lipid coating before they can release the included proteins.  However, this is highly 
unlikely because it is shown in chapter 2 that the lipid coat stays around the particles 
during degradation.14  
Figure 7 shows the release of lysozyme from degrading dextran nanogels.  
The following observations can be made.  First, in contrast to the release of BSA, the 
release of lysozyme from lipid-coated and naked dextran nanogels occurs similarly.  
In other words, the lipid coating does not retard the release of lysozyme.  This could 
be expected as Figure 5 showed that lysozyme does not stay within SOPC 
liposomes suggesting that the SOPC lipid membrane is fully permeable to lysozyme.  
Second, lysozyme is released faster from dextran nanogels than BSA, and this 
occurs in the sparsely, moderately as well as the densely cross-linked nanogels.  
This could be explained by the fact that lysozyme is a smaller protein than BSA (the 
calculated hydrodynamic diameters are respectively 4.1 nm and 7.2 nm30).  Third, as 
was also seen for the release of BSA, there is an influence of the network structure. 
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Figure 7. Cumulative release of lysozyme from degrading SOPC coated () and naked (●) 
dex-HEMA nanogels.  In all experiments a 20% (w/w) dex-HEMA solution was used to 
hydrate the lipid film.  The DS of the dex-HEMA is 2.5 (A), 5.4 (B) and 8.9 (C). 100% release 
corresponds to the amount of lysozyme released when the nanogels were completely 
degraded (i.e. when nanogels could no longer be detected by DLS). 
 
Comparing Figure 7A to C, one can see that the lysozyme release from a 
more densely cross-linked dextran network is slower than from a sparsely cross-
linked dextran network.  This shows that lysozyme is physically entrapped in the 
polymer network of the nanogels; cross-links have to be degraded before the 
entrapped lysozyme can escape.   
 
Enzymatic activity of released lysozyme 
It is of great importance that proteins do not loose their biological activity due 
to the encapsulation process, thus keeping their tertiary and quaternary structure. 
Indeed, the main disadvantage of photopolymerization comes from the necessary 
production of highly reactive free radicals that initiate the cross-linking.  These free 
radicals may induce side reactions between the encapsulated drug molecules and 
polymer chains. As an example, Quick et al.31-33 used photopolymerized hydrogels 
for DNA encapsulation and delivery.  They showed that without the presence of 
monomer, free radicals attack and damage the DNA molecules.  Chun et al.34 came 
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to similar conclusions; DNA entrapped in Pluronic™ hydrogels made by UV 
polymerization was gradually damaged with increasing UV exposure time.  Leach et 
al.35 included BSA into glycidyl methacrylate-hyaluronic acid hydrogels by 
photopolymerization and showed that protein aggregates were formed. 
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Figure 8. Enzymatic activity of lysozyme after different treatments.  The activity of a non-
irradiated lysozyme solution was set to 100.  The enzymatic activity of each sample was 
normalized against the lysozyme concentration of the sample. 
 
Enzymes are ideal model proteins to test whether encapsulated proteins do 
not become destroyed during the photopolymerization step as even minimal 
structural changes may lower their catalytic activity.  For this purpose we tested 
whether lysozyme encapsulated in dextran nanogels keeps its enzymatic activity.  
The activity of lysozyme was monitored by absorbance measurements on a M. luteus 
suspension, as described in the Experimental Section.  The results are shown in 
Figure 8.  The activity of a non-UV irradiated lysozyme solution was set as 100%.  
The activity of non-encapsulated lysozyme, as separated from the dextran nanogels 
by the use of the stirring cell, was measured as well.  The activity of the lysozyme 
released from the dextran nanogels (kept at 37°C for several days until they were 
completely degraded, and checked by DLS) was also measured.  The enzymatic 
activity of each lysozyme sample was normalized to the lysozyme concentration in 
the sample.  As Figure 8 shows, the activity of the released lysozyme was 75% of the 
activity of the non-UV irradiated reference solution.  We also measured the 
enzymatic activity of the reference lysozyme solution after irradiation in the presence 
of the photo initiator to determine the effect of UV-induced radicals on the activity of 
lysozyme.  Two things can be seen in Figure 8; the UV irradiation significantly 
lowered the activity, and that the activity of non-encapsulated lysozyme is somewhat 
lower than the activity of released lysozyme.  This could possibly be explained by the 
fact that radicals in the liposome container are primarily used for activation of the 
double bonds on dex-HEMA which would keep the lysozyme molecules more 
protected.  Although the results on lysozyme are promising, one should realize that 
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other peptides or proteins may undergo structural changes during the 
photopolymerization step.   
 
Dextran nanogels in human serum 
Clearly, after intravenous administration dextran nanogels should never be 
allowed to aggregate since micron sized particles cannot pass through narrow (lung) 
capillaries.  We evaluated in vitro how lipid-coated dextran nanogels behave in 
human serum.  DLS measurements on nanoparticles in human serum are not 
evident, because serum components (like proteins) strongly scatter the light.  
Aggregated structures were indeed detected by DLS in serum (i.e. before the dextran 
nanogels were added; data not shown) and therefore the serum was filtered through 
a 2.0 µm filter before adding the nanogels.  The outcome of DLS measurements on 
the filtered serum is represented in Figure 9A while Figure 9B shows the outcome of 
DLS measurements on nanogels in PB.  Subsequently we mixed human serum and 
a nanogel dispersion in respectively 5:5 and 9:1 volume ratios.  In case of the 5:5 
ratio (part) of the nanogels aggregated immediately as micron sized particles were 
detected (Figure 9C).  After 5h the 400 nm-sized particles could even no longer be 
detected, only particles in the µm range were seen (Figure 9E).  When much more 
serum was used in the dilution, (volume ratio 9:1) the nanogels did not seem to 
aggregate (Figure 9D); not even after being in serum for 5h (Figure 9F).  The results 
in Figure 9 suggest that, very likely, dextran nanogels will not aggregate after 
intravenous injection since the injected nanogel dispersion will become very diluted in 
the bloodstream. 
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 A Serum (filtered) B  nanogels in PB 
  
 
 C 5:5 (0h) D 9:1 (0h) 
  
  
 E 5:5 (5h) F 9:1 (5h) 
   
  
Figure 9. Size distribution, as measured by DLS, of (A) human serum after filtration through 
a 2.0 µm filter; (B) SOPC coated dex-HEMA nanogels (DS 5.4) in PB pH 7.0.  SOPC coated 
dex-HEMA nanogels in (filtered) human serum (in a 5:5 volume ratio) immediately (C) and 5 
h (E) after mixing.  SOPC coated dex-HEMA nanogels in (filtered) human serum (in a 9:1 
volume ratio) immediately (D) and 5 h (F) after mixing.  
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Lyophilization of dextran nanogels 
We next evaluated (a) whether it is possible to freeze dry lipid-coated and 
naked dextran nanogels and (b) whether reconstituted lyophilized nanogels still show 
the same degradation behavior as the original, non-lyophilized samples.  Particles 
were lyophilized in the presence of 10% (w/w) sucrose as a cryoprotectant.  After 
lyophilization, the dry dextran nanogels were reconstituted in PB reaching the original 
weight (i.e. the weight of the sample before lyophilization).  The reconstituted 
nanogels were incubated at 37°C and measured by DLS at regular time intervals  
Figure 10A and B show the results for respectively the naked and lipid-coated 
nanogels.  The following observations were made.  First, after reconstitution dextran 
nanogels were still detected.  Second, the lyophilized naked dextran nanogels 
degraded similarly to the non-lyophilized ones, which is an important finding.  It 
suggests that the lyophilization process does not change the physicochemical 
properties of the naked dextran nanogels.  Third, Figure 10B indicates that both the 
lyophilized and the non lyophilized lipid-coated nanogels show the same behavior: it 
seems that the lipid-coated nanogels do not disappear as a function of time.   
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Figure 10. DLS measurements on freeze-dried () and non freeze-dried (●) nanogels 
without (A) or with (B) SOPC coating.  In between measurements, the nanogels were stored 
in PB at 37°C.  To prepare the dex-HEMA nanogels, the SOPC lipid film was hydrated with a 
20% (w/w) dex-HEMA solution.  The DS of the dex-HEMA was 5.4.  Data shown are the 
mean of five size measurements on one same sample. 
 
At first sight one could conclude that the dex-HEMA nanogels in the liposomes 
do not degrade.  However, we showed in the previous chapter that the hydrolysis of 
the dex-HEMA nanogels in the liposomes does occur.  When TX 100 was added to a 
dispersion of lipid-coated dextran nanogels that were allowed to degrade for 12 days, 
nanogels were no longer detected14.  This proved that the nanogels in the liposomes, 
the non-lyophilized as well as the lyophilized ones were indeed completely degraded 
into a dextran and poly(HEMA) solution.  
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CONCLUSIONS  
 
In this third chapter it is shown that dextran nanogels, which are prepared by 
UV polymerization of dex-HEMA containing liposomes, are promising carriers for the 
encapsulation and controlled delivery of proteins.  We found the encapsulation 
efficiency of BSA and lysozyme in the dextran nanogels to be about 50%.  
Especially, the release of BSA and lysozyme from the dextran nanogels was clearly 
governed by the cross-link density of the tiny gels.  Depending on the size of the 
encapsulated protein, the cross-link density of the dextran network and the presence 
or absence of a lipid coating, proteins were released from the nanogels over days to 
weeks.  Interestingly, when sufficiently diluted, dextran nanogels did not aggregate in 
human serum, being of major importance considering the intravenous administration 
of such nanogels.  Also, reconstitution of lyophilized dextran nanogels seemed 
perfectly possible, being also an important finding since dextran nanogels will have to 
be stored in dry form.  
We would like to stress that compared to the emulsion polymerization method, 
the use of liposomes to prepare nanogels has several advantages.  The size of the 
nanogels can be controlled by using membranes with the appropriate pore size in the 
preparation of the liposomes.  Also, organic solvents are not used which is a clear 
benefit when the nanogels are considered for the encapsulation of proteins that may 
inactivate upon contact with organic solvents.  Moreover, and especially, the 
liposome-based method allows the design of both naked nanogels as well as lipid-
coated nanogels.  The lipid coating may offer at least three additional interesting 
features to the nanogels.  One, the use of pH sensitive lipids36-38 may improve the 
escape of the nanogels from endosomes which is attractive if the nanogels have to 
be delivered in the cytosol.  Two, in analogy with immunoliposomes, being liposomes 
bearing antibodies at their surface, “immunogels” may be easily designed by grafting 
the antibodies at the lipid surface of the lipid-coated nanogels, making use of well 
known chemistry.  And three, by using PEGylated lipid coatings, the circulation time 
of the nanogels may be prolonged39-41.   
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Abstract 
The aim of this chapter was to design PEGylated lipid coated dextran 
nanogels as an intracellular drug delivery system.  Additionally, when the particles 
are in an acidic environment, for example in the endosome, the particles must loose 
their coating 
DOTAP:DOPE liposomes containing DSPE-PEG2000 (1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000) were used 
as a nanoscopic mould to cross-link dex-HEMA.  To obtain particles with a pH 
sensitive lipid layer, an acid sensitive lipid, diplasmenylcholine, was formulated into 
the liposome.  The size and charge of the particles and the interaction with serum 
was evaluated by DLS and zèta potential measurements.  The interactions with cells 
were visualized by confocal microscopy. 
It was shown that lipid coated dextran nanogels with a PEG modified surface 
are about 450 nm in size and bear almost no charge.  Although the cellular binding is 
lower than non-PEGylated particles, cellular uptake both by VERO and retinal 
pigment epithelial cells was equally efficient.  When the particles were mixed with 
human serum in equal amounts, aggregation is observed, however at higher 
dilutions, the particle suspension was stable for at least 7 hours.   
As it is well known that PEGylated particles often do not escape from the 
endosomal compartment and end up in the lysosomes were they are degraded.  We 
wanted to make nanogels that lose their PEGylated coating in the endosome, after 
which they can escape to the cytosol.  It was shown that the incorporation of an acid 
sensitive lipid into the lipid coating, resulted in the removal of the PEGylated coating 
at lower pH.   
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INTRODUCTION 
 
Appropriately designed materials should improve the intracellular delivery of 
large molecules such as peptides, oligonucleotides and plasmids.  PEGylation of 
nanoscopic drug carriers is a widely used technique since it improves their stability 
and prolongs the blood circulation time1-3.  Biological entities such as serum consist 
of numerous components including lipids and proteins, causing non-specific 
adsorption on the nanosphere surface4.  To improve the non-fouling characteristics of 
the particles, PEGylation is often used as PEG creates a steric barrier against 
interactions with molecular and cellular components in the biological environment5,6.  
Besides stability, PEGylation also prolongs the blood circulation time of drug carriers 
by inhibition of opsonin proteins binding to the particles’ surface.  These proteins 
allow macrophages of the mononuclear phagocytic system (MPS) to easily recognize 
and remove drug delivery devices before they can perform their desired therapeutic 
function7.  A sufficient blood circulation time is of great importance for drug delivery 
because the required therapeutic level of pharmaceuticals can be achieved only 
when the carriers stay in the blood stream for an appropriate time.  If this is achieved, 
the nanoparticles will accumulate in pathological sites with affected and leaky 
vasculature (such as tumours, inflammations and infarcted areas) due to the 
enhanced permeability and retention (EPR) effect8.  PEGylated liposomes have been 
extensively investigated for delivery of many therapeutic molecules, for example 
doxorubicin, docetaxel, paclitaxel, vasoactive intestinal peptide and different 
cytokines9-13. Although promising, liposomes may not be the best candidates for 
sustained drug delivery because of their relatively limited drug loading capacity and 
short release duration of entrapped drugs14.   
Hydrogels are more stable and higher loading efficiencies can eventually be 
achieved.  For that reason, in this chapter we wanted to develop nanoscopic dextran 
hydrogel particles surrounded by a PEG-modified lipid surface as a long-circulating 
intracellular delivery system. In chapter 2 we showed that it is possible to produce 
nanogels using liposomes as a nanoscopic mould, following a procedure described 
by Kazakov et al.15  A solution of a polymerizable dextran -i.e. dextran-
hydroxyethylmethacrylate (dex-HEMA, Figure 1A)- was captured inside the cavity of 
a liposome and polymerized by UV irradiation, resulting in a dextran nanogel 
surrounded by a lipid layer16. Dex-HEMA is composed of a dextran backbone 
substituted with polymerizable HEMA groups and the corresponding hydrogel 
degrades spontaneously under physiological conditions into dextran and some 
poly(HEMA) fragments (Figure 1B).  The degradation time depends on the polymer 
concentration and the degree of substitution (DS, i.e. the number of HEMA groups 
per 100 glycopyranose residues)17,18.  
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Figure 1. (A) Chemical structure of the monomer in dex-HEMA, i.e. glucopyranose 
substituted with HEMA.  (B) Schematic representation of the dex-HEMA polymer network 
before (left) and after (right) degradation.  The HEMA cross links degrade through hydrolysis 
of the carbonate esters, resulting in dextran chains and poly(HEMA). 
 
It was shown that the degradation time of these nanogels could be altered 
from a few days to some weeks and depends on the DS.  In chapter 319, we showed 
that nanogels can be loaded with proteins simply through the addition of the desired 
protein to the starting polymer solution.  Depending on the size of the encapsulated 
protein, the cross-link density of the dextran network and the presence or absence of 
a lipid coating, proteins were released from the nanogels over days to weeks.  The 
loading efficiency is about 50% and -in spite of the UV treatment of the nanogels in 
the presence of proteins- lysozyme kept about 75% of its activity.  Moreover, the 
nanogels can be freeze-dried without change in degradation profile, offering 
possibilities for long-term storage 19. 
As described above, the nanogels are made using liposomes as nanoscopic 
“reaction containers”.  To produce PEGylated nanogels, we will use PEGylated 
liposomes as a mould for polymerization and fill them with a dex-HEMA solution.  
After polymerization, lipid covered nanogels are produced, surrounded by a PEG 
“halo” and filled with a dex-HEMA hydrogel holding drug molecules, as schematically 
represented in Figure 2. 
 
 
 
Figure 2. Schematic representation of nanogels filled with a therapeutic molecule and 
surrounded by a PEGylated lipid layer.   
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A major problem with PEGylated particles is their retention in the endosome 
followed by lysosomal degradation.  As a result, the bioavailability and efficacy of 
included drugs is often minimal20.  Particles that lose their PEGylated lipid coating 
upon arrival in the endosome would be a solution to this issue.  The intrinsic low pH 
within endosomal environments offers an appropriate trigger to detach the lipid layer 
from the nanogel.  The acid labile lipid coating falls apart at the acidic environment of 
the endosome, leaving naked (non-PEGylated) nanogels that can escape easily into 
the cytoplasm.  One of the first studies concerning the inclusion of PEG lipids in pH 
sensitive liposomes was performed by Slepushkin et al.21 and contained 
DOPE:CHEMS:PE-PEG (DOPE being 1,2-dioleoyl-sn-glycero-3-
phosphatidylethanolamine, CHEMS is cholesteryl hemisuccinate and PE-PEG is a 
PEG coupled lipid).  These polymer modified liposomes show fusion properties at 
acidic conditions and transfer their content into the cytoplasm by fusing with the 
endosomal membrane.  Although the development of sterically stabilized pH-
sensitive liposomes has been associated frequently with the incorporation of DOPE 
in the liposome formulation22-28, other strategies have been examined29-32. 
Nanoscopic particles surrounded by a lipid coating -also referred to as 
lipobeads15- are already produced for diverging purposes such as drug delivery33-37, 
biosensors38-41 or artificial blood substitutes42,43.  Lipid coated nanogels with a pH 
sensitive core were developed by Kazakov et al.15; the poly(N-isopropylacrylate-vinyl 
imidazole) core was surrounded by an egg phosphatidylcholine (EPC) coating, but 
the pH sensitivity was demonstrated only on naked nanogels -i.e. without the 
surrounding lipid layer.  To the best of our knowledge, no lipid coated hydrogel 
particles have been produced with both a PEGylated and pH sensitive coat. 
Rui et al.44 reported on the acid-catalyzed hydrolysis of synthetic 
diplasmenylcholine: 1,2-di-O-(Z-1’-hexadecenyl)-sn-glycero-3-phosphocholine 
(DPPlsC, Figure 3).  The electron-rich vinyl ether linkage in this lipid is susceptible to 
acid catalyzed hydrolysis, resulting in glycerophosphocholine and single-chain 
surfactant products.   
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Figure 3. 1,2-di-O-(Z-1’-hexadecenyl)-sn-glycero-3-phosphocholine (DPPlsC), a pH sensitive 
lipid for the synthesis of a pH sensitive lipid membrane.  At low pH degradation occurs into 
glycerophosphocholine and hexadecanoal. 
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As a result, liposomes containing DPPlsC are stable at physiological pH (pH 
7.4) but undergo degradation at endosomal pHs45.  We wanted to investigate 
whether it is possible to create lipid coated dextran nanogels using both pH sensitive 
and PEGylated liposomes as a mould for the polymerization reaction. This would 
result in PEGylated lipid coated nanogel that loses its surrounding lipid layer at low 
pH values (Figure 4).   
 
     
[H+] 
Figure 4. Schematic representation of a dex-HEMA nanogel, containing therapeutic 
molecules and surrounded by a pH sensitive (PEGylated) lipid-coating.  At pH 4.0, the lipid-
coating comes of, resulting in a naked nanogel and micelles. 
 
So briefly, in this chapter we will examine whether it is possible to prepare 
dextran nanogels with a PEGylated lipid coating, we will examine their serum stability 
and their cellular binding and uptake properties.  We will also try to produce dextran 
nanogels with a pH sensitive and PEGylated lipid coating, being detached from the 
nanogels at endosomal pH.   
 
 
EXPERIMENTAL SECTION 
Dex-HEMA Preparation and Characterization.  
Dex-HEMA batches were prepared and characterized according to a method 
described elsewhere46.  Dextran (Fluka, from Leuconostoc ssp.) with a number 
average molecular mass of 19000 g/mol was used.  The degree of substitution was 
determined by proton nuclear magnetic resonance spectroscopy (1H NMR) in D2O 
with a Gemini 300 spectrometer (Varian). The DS of the dex-HEMA used in this 
study was 5.4. 
 
Preparation of dextran nanogels 
Dextran nanogels were prepared using liposomes as a nanoscaled reactor, as 
described in the second chapter16.  We prepared the liposomes using a standard 
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procedure.  A 5 mg lipid film of DOTAP:DOPE (1:1 molecular ratio, resp 1,2-Dioleoyl-
3-Trimethylammonium-Propane and 1,2-dioleoyl-sn-Glycero-3-
Phosphoethanolamine, Avanti Polar Lipids) was made by dissolving the lipid in 
chloroform in a test-tube.  This solution was dried under a nitrogen flow while gently 
spinning the vial.  This resulted in a thin lipid film which was placed under vacuum for 
at least 4 hours to remove all remaining chloroform.  Subsequently, this dry lipid film 
was rehydrated with 1 mL of a dex-HEMA solution (i.e. 20% (w/w) dex-HEMA in 50 
mM phosphate buffer (PB) at pH 7.0) containing 0.05% (w/w) Irgacure 2959 (Ciba 
Specialty Chemicals) as a photo initiator.  The resulting dispersion was placed at 
25°C for 30 minutes while vortexing every 5 minutes.  This dispersion of large 
vesicles was aged overnight and was extruded with a LiposoFast Pneumatic-
Actuator (Avestin) provided with a 400 nm polycarbonate membrane (Whatman 
International).  After 11 back-and-forth passages of the dispersion through the 
extrusion membrane, the liposome dispersion was diluted 10 times with PB.  This 
dilution was necessary because not all the dex-HEMA was entrapped in the 
liposomes.  If not diluted, this “free” dex-HEMA would form a gel in the polymerization 
step, thereby enclosing the liposomes in a polymer matrix.  The dispersion was 
subsequently exposed to UV light (365 nm from a Bluepoint 2.1 UV source, Honle 
UV Technology) at 25°C for 450 s which cross-linked the dex-HEMA solution in the 
liposomes with the formation of “lipid coated dex-HEMA nanogels”.  To obtain “naked 
dex-HEMA nanogels” the lipid layer was removed by adding 20.0 µL of a 100 mM 
solution of the detergent Triton X 100 (TX 100, Merck) to 1 mL of the lipid coated 
nanogel dispersion.   
To obtain PEGylated nanogels, 5 mol% of DSPE-PEG2000 (1,2-Distearoyl-sn-
Glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-2000] 
(Ammonium Salt), Avanti Polar Lipids) was added to the starting lipid/chloroform 
solution.  
For the preparation of nanogels with a PEGylated pH sensitive lipid coat, the 
starting lipid film was composed of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC, Avanti Polar Lipids) and 1,2-di-O-(Z-1’-hexadcenyl)-sn-glycero-3-
phosphocholine (DPPlsC) in a 8:2 molar ratio with 5 mol% DPSE-PEG2000.  This pH 
sensitive lipid is presented in Figure 3 and was synthesized as described by Van den 
Bossche et al.47  The liposome dispersion was obtained by hydrating the lipid film 
with 1 mL PB at a temperature at least 10°C above the phase transition temperature 
(i.e. at 45°C) during 30 min and vortexing every 5 min.  Extrusion was performed at 
the same temperature.   
 
Dynamic light scattering (DLS) and zèta potential analysis on 
dextran nanogels 
Phosphate buffer, filtered through a 0.1 µm Millipore Durapore® filter, was 
used to dilute the dispersions of the nanogels to study the hydrodynamic diameter 
(dh) and zèta potential (ζ) of the nanogels.  A cuvette was filled with 1.2 mL of the 
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nanogel dispersions and sealed with Parafilm™ to avoid contamination with dust 
particles.  Polystyrene nanospheres (220 ± 6 nm; Duke Scientific Corporation) were 
used to check the performance of the DLS instrument.  The size distribution and the 
zèta potential of the degrading particles were determined by use of a Zetasizer Nano 
ZS (Malvern Instruments).   
 
Cell lines and cellular uptake of nanogels 
African green monkey kidney (VERO-1) cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) at 37°C containing 2 mM glutamine, 10% heat-
inactivated fetal bovine serum and 1% penicilline-streptomycine.  Cells were 
prophylactically treated against mycoplasma with Plasmocin (Invivogen).  The retinal 
pigment epithelial cell line (D407) 48 was a kind gift from Dr. Richard Hunt (University 
of South Carolina, Medical School, Columbia, USA).  The cells were cultured in 
DMEM with phenol red.  The cells were seeded onto sterile glass bottomed culture 
disks (MatTek Corporation), allowed to grow and to adhere for 1 day (at 37°C in a 
humidified atmosphere containing 5% CO2) before applying the nanogel dispersions. 
 
Cell binding experiments 
For evaluation of the cellular binding and uptake of the dex-HEMA nanogels 
(DS 5.4), the nanogels were fluorescently labeled with Texas Red labeled dextran 
(70 kDa, Molecular Probes). 60 µL of a Texas Red dextran solution (25 mg/mL) was 
added to 1 mL of dex-HEMA/photo initiator solution used to hydrate the lipid film.  
Removal of free Texas Red dextran (i.e. not entrapped in the liposomes) was 
achieved with Microcon™ centrifugal filter devices (molecular weight cut off 100 kDa, 
Millipore Corporation).  After centrifugation (at 14000×g for 24 minutes), the 
fluorescent dex-HEMA filled liposomes were recovered by inverted spin and diluted 
ten times with DMEM before UV polymerization.  DLS measurements showed no 
remarkable change in size after centrifugational filtration (data not shown). 
For cell binding experiments, the cells were incubated for 15 minutes at 4°C 
with the labelled nanogels.  The culture medium was removed and replaced by 200 
µL cold (4°C) DMEM, containing lipid coated nanogels labeled with Texas Red 
Dextran.  The cells were incubated for another 15 minutes at 4°C before microscopy 
experiments were performed.   
 
Cell internalization experiments 
For cell internalization experiments, the nanogels were labelled with Texas 
Red dextran as described above.  200 µL of lipid coated nanogels (containing Texas 
Red labeled dextran and prewarmed to 37°C) were added to the cells and incubated 
for 1 h at 37°C.  The cells were washed three times with PB before imaging by 
confocal laser scanning microscopy.  Confocal Laser Scanning Microscopy (CLSM, 
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Nikon C1si) images were taken using a Nikon 60× oil immersion objective and a 561 
nm DPSS laser for the excitation of the Texas Red labeled nanogels. 
 
Behavior of dextran nanogels in (human) serum 
A Venosafe Serum-Gel tube with cloth activator (6 mL) was filled with human 
blood.  Serum was obtained after blood clotting for 30 min at room temperature, 
followed by centrifugation at 3000 rpm for 8 min.  Subsequently the serum was 
filtrated trough a 2.0 µm filter (Whatman International).  The lipid coated dextran 
nanogel dispersion (prepared with dex-HEMA DS 5.4) was separated from the 
surrounding buffer using Microcon™ centrifugal filter devices.  Prewarmed serum 
(37°C) was added and further incubated at 37°C.  At regular time intervals DLS and 
zèta potential measurements were performed. 
 
 
RESULTS 
Synthesis of PEGylated nanogels 
To produce PEGylated nanogel using liposomes as a nanoscaled mould, the 
starting lipid film was composed of DOTAP:DOPE with 5 mol% of a PEGylated lipid, 
i.e. DSPE-PEG2000.  The lipid film was hydrated with a 20% (w/w) dex-HEMA (DS 
5.4) solution and the size distribution was measured by DLS.  As shown in Figure 5A 
there is hardly any difference in size between the PEGylated and non-PEGylated 
liposomes filled with a dex-HEMA solution.  Also the cross-linking of this polymer 
solution inside the liposomes has no effect on the size distribution of both type of 
particles (Figure 5B).  The zèta potential on the other hand differs significantly 
(Figure 5C): non-PEGylated nanogels have a zèta potential of about 50 mV while the 
PEGylated nanogels have an almost neutral zèta potential (i.e. 8 mV).  
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Figure 5. Size distribution, as measured by DLS, of (⎯) DOTAP:DOPE and 
DOTAP:DOPE:DSPE-PEG2000 (⎯) coated dex-HEMA nanogels.  A 20% (w/w) dex-HEMA 
(DS 5.4) solution was used to hydrate the lipid film.  (A) and (B) show the nanogels before 
respectively after polymerization of the dex-HEMA; (C) shows the zèta potential of both types 
of nanogels. 
 
Cellular uptake of PEGylated nanoparticles 
Cellular binding and uptake of the particles was monitored using confocal laser 
scanning microscopy.  The nanogels were fluorescently labeled with Texas Red 
dextran.  The free Texas Red dextran (i.e. Texas Red dextran not encapsulated in 
the nanogels) was removed by centrifugational filtration.  Separate fluorescent 
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measurements showed that the 70 kDa Texas Red dextran chains could freely pass 
through the membrane (molecular weight cut off 100 kDa) while the nanogels (a few 
hundred nanometer in size) were prevented from passing through the membrane 
(data not shown).   
 
Cell binding experiments.  The cells were incubated with nanogels at 4°C, 
which avoids cellular internalization.  Figure 6A and C show that PEGylated particles 
exhibit little membrane association to respectively RPE and VERO cells. Non-
PEGylated particles on the other hand bind very well to the cells’ surface (Figure 6B 
for RPE cells and Figure 6D for VERO cells).   
 
A1 A2  B1 B2
    
C1 C2  D1 D2
     
 
Figure 6. Microscopy images of an RPE cell incubated at 4°C for 15 minutes with (A) 
PEGylated and (B) non-PEGylated DOTAP:DOPE coated dex-HEMA nanogels.  (C) and (D) 
show a VERO cell incubated at 4°C for 15 minutes with PEGylated and non-PEGylated 
DOTAP:DOPE coated dex-HEMA nanogels respectively.  Subscript 1 and 2 refer 
respectively to the CLSM image and the transmission image.  To prepare the dex-HEMA 
nanogels the lipid films were hydrated with a 20% (w/w) dex-HEMA solution (DS 5.4) 
containing Texas Red labelled dextran.  Scale bars represent 5µm. 
 
Cell internalization experiments.  Figure 7A and C show confocal images of 
respectively RPE and VERO cells after incubation of dextran nanogels with a 
PEGylated lipid coating during 1 hour at 37°C.  Fluorescent punctuations in the 
cytoplasm, equally distributed throughout the cytoplasm, in both types of cells are 
observed. However, they are excluded from the nucleus.  As a control experiment, 
we administered  non-PEGylated particles to RPE and VERO cells and as expected 
from former studies16 they are taken up as well (Figure 7B and D respectively).   
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C1 C2  D1 D2
     
Figure 7. Microscopy images of an RPE cell incubated at 37°C for one hour with (A) 
PEGylated and (B) non-PEGylated DOTAP:DOPE coated dex-HEMA nanogels.  (C) and (D) 
show a VERO cell incubated at 37°C for one hour with PEGylated and non-PEGylated 
DOTAP:DOPE coated dex-HEMA nanogels respectively. Subscript 1 and 2 refer respectively 
to the CLSM image and the transmission image.  To prepare the dex-HEMA nanogels the 
lipid films were hydrated with a 20% (w/w) dex-HEMA solution (DS 5.4) containing Texas 
Red labelled dextran.  Scale bars represent 5µm. 
 
Stability of PEGylated nanoparticles in human serum 
The outcome of DLS measurements on the filtered serum is represented in 
Figure 8A.  Figure 8B and C show 100 µL of nanogel suspension mixed with 900 µL 
of human serum, kept at 37°C and measured 7h after mixing.  It is clearly shown that 
both the PEGylated as the non-PEGylated particles are stable during this period, 
because 300nm sized particles - coming from the nanogels- can be separately 
distinguished from the particles present in the serum (particles < 100 nm, see Figure 
8A).  When the nanogel suspension and serum were mixed in equal amounts, 
aggregation occurs, as micron sized particles can be detected (Figure 8D and E).   
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Figure 8. Size distribution, as measured by DLS, of (A) human serum after filtration through 
a 2.0 µm filter; DOTAP:DOPE:DSPE-PEG2000 (B) and DOTAP:DOPE (C) coated dex-HEMA 
nanogels in (filtrated) human serum (in a 1:9 volume ratio); DOTAP:DOPE:DSPE-PEG2000 (D) 
and DOTAP:DOPE (E) coated dex-HEMA nanogels in (filtrated) human serum (in a 1:1 
volume ratio).  Measurements were performed 7 h after mixing. 
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Synthesis of pH sensitive nanogels 
Figure 9A and B show that pH sensitive and pH insensitive nanogels do not 
differ in size at pH 7.4, before or after polymerization: in both cases particles of about 
350 nm in size could be detected.  At pH 4,0 the pH sensitive nanogels show not only 
a peak at 350 nm, but also much smaller particles (~12 nm) were detected (Figure 
9C).  12 nm is the typical size of micelles, in this case formed by DPPC, DSPE-
PEG2000 and degradation products of DPPlsC (see 1D). The control nanogels, i.e. 
nanogels with a DPPC coating containing 5 mol% DSPE-PEG2000, do not show the 
appearance of such a peak.  To make sure that the 12 nm peak is coming from the 
remainder of the lipid layer, TX 100 was added to both dispersions to solubilize the 
lipid coating.  A peak of 12 nm could be detected for the pH sensitive as well as the 
pH insensitive nanogels, coming from micelles composed of TX 100 and lipid 
molecules.   
Another indication for the removal of the lipid layer was the significant drop of 
the intensity of the light scattered by the dispersion which could even be seen 
visually.  Figure 10 shows a picture of nanogel dispersions at different conditions.  At 
pH 7.4 both types of dispersions are opaque because the surrounding lipid layer 
scatters the incident light (Figure 10 cuvette 1 and 2).  At pH 4.0, the lipid coating of 
the pH sensitive nanogels is removed.  As a result, the scattering of the light is 
lowered due to the refractive index difference between the (aqueous) nanogels and 
the surrounding aqueous medium is almost zero, resulting in a transparent 
suspension of nanogels (Figure 10 cuvette 3).  The pH insensitive nanogel dispersion 
is still opaque because the lipid layer stays around the nanogels (Figure 10 cuvette 
4).  When the lipid layer is removed by use of a detergent, all nanogel dispersions 
are transparent (Figure 10 cuvette 5 and 6). 
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Figure 9. Size distribution, as measured by DLS, of (⎯) DPPC:DPPlsC (8:2 molar ratio) 
containing 5 mol% DSPE-PEG2000 and DPPC:DSPE-PEG2000 (⎯) coated dex-HEMA 
nanogels.  A 20% (w/w) dex-HEMA (DS 5.4) solution was used to hydrate the lipid film.  (A) 
and (B) show the nanogels before respectively after polymerization of the dex-HEMA, (C) 
shows the nanogels at pH 4.0 and (D) shows the nanogels after addition of TX 100 to 
remove the lipid-coating. 
96 
CHAPTER 4 
 
 
 
Figure 10. Picture of lipid-coated dex-HEMA (DS 5.4) nanogels.  Cuvette 1 and 2 are filled 
with respectively DPPC:DPPlsC:DSPE-PEG2000 and DPPC:DSPE-PEG2000 coated dex-
HEMA nanogels at pH 7.4.  Cuvette 3 and 4 are filled with respectively 
DPPC:DPPlsC:DSPE-PEG2000 and DPPC:DSPE-PEG2000 coated dex-HEMA nanogels at pH 
4.0.  Cuvette 5 and 6 are filled with respectively DPPC:DPPlsC:DSPE-PEG2000 and 
DPPC:DSPE-PEG2000coated dex-HEMA nanogels at pH 7.4 after addition of TX 100.  All lipid 
films were hydrated with a 20% (w/w) dex-HEMA (DS 5.4) solution. 
 
DISCUSSION 
The first objective was to determine the possibility to produce PEGylated lipid 
coated dextran nanogel particles, by use of liposomes as a nanoscopic mould.  
DOTAP:DOPE liposomes with and without 5 mol% DSPE-PEG were filled with a 
polymerizable dex-HEMA solution.  The nanogels with a PEGylated lipid coating are 
similar in size when compared to nanogels with a non-PEGylated lipid coating 
(Figure 5A and B) before and after polymerization. This follows previous data 
showing that the presence of PEG on the surface of liposomes has no influence on 
their size49.  On the other hand, the surface charge of the DOTAP:DOPE:DSPE-
PEG2000 coated particles is almost neutral, while the DOTAP:DOPE coated particles 
are positively charged due to the positive charge of DOTAP.  The positive charge of 
DOTAP in the PEGylated nanogels was shielded by the long PEG tales stretching 
out from the particles’ surface.   
We know from chapter 2 that it is possible to administer lipid coated nanogels 
to VERO cells16, cells with a very good endocytotic capacity.  As PEGylation changes 
the physicochemical properties of the particles’ surface, we wanted to investigate the 
cellular uptake of PEGylated dextran nanogels.  Nanoscopic particles showing 
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sustained release of a therapeutic molecule are possible candidates for treatment of 
ocular disorders, because repeated intravitreal injections can be avoided.  Liposomes 
as drug delivery vehicles after intravitreal injections have been studied for two 
decades; they show significantly increased drug half-life and they minimize 
intraocular side-effects50.  Hence we examined the intracellular behavior of the 
PEGylated lipid coated nanogels in retinal pigment epithelial (RPE) cells.   
The first step in the (endosomal) uptake of these particles is binding to the 
cellular membrane.  It is shown that the PEGylated particles bind to a lower extent to 
the cellular surface when compared to the non-PEGylated ones, both for the RPE as 
for the VERO cells.  This arises from the negative charge of the cellular membrane, 
whereas PEGylation significantly lowers the (positive) surface charge of the dextran 
nanogels (as shown in Figure 5C).  It is shown that the two types of nanogels are 
taken up by cells at 37°C (conditions under which endocytosis is performed) as 
fluorescent punctuations are observed in the cytosol of both types of cells, but no 
fluorescence was seen in the nucleus.  This is probably due to the fact that the 
nucleopores are much smaller than these nanosized particles, thereby forming a 
barrier for the nanogels to enter the nucleus51.  These results indicate that the 
presence of a PEG coated surface has no influence on the uptake and endosomal 
release of dextran nanogels by RPE and VERO cells, although the cellular binding of 
the PEGylated particles is somewhat lower.   These results are in agreement with the 
findings of Vertut-Doï et al.52,  which show that the binding of EPC liposomes to the 
macrophage cell line J774 is higher than the same liposomes containing 5 mol% 
PEG2200-CHOL.  Surprisingly, the PEGylated liposomes do not differ so much from 
control liposomes with regard to endocytotic uptake.   
As it is of great importance that the nanoparticles do not aggregate upon 
parenteral injection, since particles of several micrometers in diameter are able to 
clog in the lung capillaries53 and submicron particles are rapidly cleared by the 
MPS54.  For that purpose it is of great importance that the PEGylated nanogels are 
stable in human serum.  It is however not evident to perform DLS measurements in 
serum, due to the abundance of small particles capable of light scattering.  
Therefore, the serum was first filtrated through a 2.0 µm filter.  The nanogels did not 
show aggregation at ten-fold dilution with serum, however at 1:1 dilutions, 
aggregation was observed for both types of nanogel.  So, despite the presence of a 
“protecting” PEGylated lipid layer, concentrated nanogel suspensions in serum 
aggregate after 7 hours.  Nevertheless, these results are promising, since the 
injected nanogel dispersion would become very diluted in the bloodstream.   
A critical issue in the in vitro and in vivo use of pH sensitive particles relates to 
the possibility that properties like stability, pH sensitivity and cell affinity may be 
changed as a consequence of their interactions with components of biological fluids 
or with cells.  For that purpose PEG can be foreseen on the surface of particles 
showing pH dependent stability, forming a steric barrier around the nanogels.  
Particles entering the bloodstream are covered with opsonines very fast and as a 
result they are recognized by phagocytes and are removed within minutes.  It is the 
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flexible nature of PEG which ensures that the particles are protected.  When 
opsonins approach, the chains are compressed, resulting in opposing repulsive 
forces.  To be effective, the PEG layer must be, however, thick enough.  This 
generally implies that PEG chains have to be 2000 g/mol or more.  Also the surface 
chain density and the conformation of the PEG molecules on the particles is very 
important.  When the chain density is too low the PEG molecules take the typical 
mushroom configuration: the PEG chains are close at the surface and opsonins can 
freely bind to the particles’ surface.  At too dense occupancy the PEG chains lose 
their flexibility and exhibit the brush configuration.  The optimal surface coverage is 
located somewhere in between the brush and mushroom configuration7. 
It has been reported that the acid catalyzed hydrolysis of the plasmalogen 
vinyl ether linkage in DPPlsC (Figure 3) triggers the calceine release from liposomes 
containing DPPlsC32.  Also the use of lipids with high transition temperatures, like 
DPPC, have led to a significant decrease of leakage of the encapsulated drugs 
during circulation or in the extracellular milieu55.  For that reason a DPPC:DPPlsC 
lipid coating in a 8:2 molar ratio containing 5 mol% DSPE-PEG2000 was hydrated with 
a 20% (w/w) dex-HEMA solution.  It was shown both by DLS and visually that the pH 
sensitive lipid coating around the particle stays intact at physiological pH, but comes 
off at lower pH.  This result is of great importance, since PEG often hampers 
endosomal escape. 
 
 
CONCLUSION 
The most common approach for enhancing the delivery of parenteral agents is 
through attachment of PEG moieties, referred to as PEGylation.  By use of 
PEGylation the immunological, pharmacokinetic and hence pharmacodynamic 
properties of the drug delivery vehicle are often improved56.   
In this chapter we report on PEGylated lipid coated dextran nanogels.  These 
are obtained by using PEGylated liposomes as a reaction mould for the 
polymerization of dex-HEMA. We reported on the easy and efficient production of 
PEGylated lipid coated nanogels.  The particles have a lower surface charge 
resulting in lower binding properties to both VERO and RPE cells.  Nevertheless, this 
is no obstacle for cellular uptake: PEGylated as well as non-PEGylated particles are 
taken up by these cells equally efficient.  Both PEGylated and non PEGylated 
nanogels show serum stability, at sufficient dilution, Finally we have obtained pH 
responsive PEGylated particles where the lipid coating can be removed at lower pH 
values. This was achieved by the inclusion of a pH sensitive lipid, DPPlsC.  This 
might offer possibilities as a dePEGylation strategy in endosomal compartments.   
These particles show great promise for the intracellular delivery of therapeutic 
molecules with a cytosolic or nuclear target 
99 
DEXTRAN NANOGELS WITH FUNCTIONAL COATINGS 
REFERENCE LIST 
 
 (1) Allen, T. M.; Hansen, C.; Martin, F.; Redemann, C.; Yau-Young, A. Liposomes 
containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged 
circulation half-lives in vivo. Biochimica et Biophysica Acta 1991, 1066, 29-36. 
 (2) Woodle, M. C. Surface-modified liposomes: assessment and characterization 
for increased stability and prolonged blood circulation. Chemistry and Physics 
of lipids 1993, 64, 249-262. 
 (3) Torchilin, V. P.; Trubetskoy, V. S. Which Polymers Can Make Nanoparticulate 
Drug Carriers Long-Circulating. Advanced Drug Delivery Reviews 1995, 16, 
141-155. 
 (4) Hayashi, H.; Iijima, M.; Kataoka, K.; Nagasaki, Y. pH-sensitive nanogel 
possessing reactive PEG tethered chains on the surface. Macromolecules 
2004, 37, 5389-5396. 
 (5) Storm, G.; Belliot, S. O.; Daemen, T.; Lasic, D. D. Surface Modification of 
Nanoparticles to Oppose Uptake by the Mononuclear Phagocyte System. 
Advanced Drug Delivery Reviews 1995, 17, 31-48. 
 (6) Klibanov, A. L.; Maruyama, K.; Beckerleg, A. M.; Torchilin, V. P.; Huang, L. 
Activity of Amphipathic Poly(Ethylene Glycol)-5000 to Prolong the Circulation 
Time of Liposomes Depends on the Liposome Size and Is Unfavorable for 
Immunoliposome Binding to Target. Biochimica et Biophysica Acta 1991, 
1062, 142-148. 
 (7) Owens, D. E.; Peppas, N. A. Opsonization, biodistribution, and 
pharmacokinetics of polymeric nanoparticles. International Journal of 
Pharmaceutics 2006, 307, 93-102. 
 (8) Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular 
permeability and the EPR effect in macromolecular therapeutics: a review. 
Journal of Controlled Release 2000, 65, 271-284. 
 (9) Immordino, M. L.; Brusa, P.; Arpicco, S.; Stella, B.; Dosio, F.; Cattel, L. 
Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes 
containing docetaxel. Journal of Controlled Release 2003, 91, 417-429. 
 (10) Sethi, V.; Onyuksel, H.; Rubinstein, I. Liposomal vasoactive intestinal peptide. 
Methods in enzymology 2005, 391, 377-395. 
 (11) Ten Hagen, T. L. M. Liposomal cytokines in the treatment of infectious 
diseases and cancer. Methods in enzymology 2005, 391, 125-145. 
 (12) Van Slooten, M. L.; Boerman, O.; Romoren, K.; Kedar, E.; Crommelin, D. J. 
A.; Storm, G. Liposomes as sustained release system for human interferon-
gamma: biopharmaceutical aspects. Biochimica et Biophysica Acta-Molecular 
and Cell Biology of Lipids 2001, 1530, 134-145. 
100 
CHAPTER 4 
 (13) Yang, T.; Cui, F. D.; Choi, P. K.; Cho, J. W.; Chung, S. J.; Shim, C. K.; Kim, D. 
D. Enhanced solutbility and stability of PEGylated liposomal paclitaxel: in vitro 
and in vivo evaluation. International Journal of Pharmaceutics 2007, in press,  
 (14) Gregoriadis, G.,  in: Anonymous (eds.), Liposome technology,  Boca 
Raton1994. 
 (15) Kazakov, S.; Kaholek, M.; Teraoka, I.; Levon, K. UV-induced gelation on 
nanometer scale using liposome reactor. Macromolecules 2002, 35, 1911-
1920. 
 (16) Van Thienen, T. G.; Lucas, B.; Flesch, F. M.; van Nostrum, C. F.; Demeester, 
J.; de Smedt, S. C. On the synthesis and characterization of biodegradable 
dextran nanogels with tunable degradation properties. Macromolecules 2005, 
38, 8503-8511. 
 (17) Stubbe, B. G.; Braeckmans, K.; Horkay, F.; Hennink, W. E.; De Smedt, S. C.; 
Demeester, J. Swelling pressure observations on degrading dex-HEMA 
hydrogels. Macromolecules 2002, 35, 2501-2505. 
 (18) van Dijk Wolthuis, W. N. E.; Hoogeboom, J. A. M.; Van Steenbergen, M. J.; 
Tsang, S. K. Y.; Hennink, W. E. Degradation and release behavior of dextran-
based hydrogels. Macromolecules 2003, 30, 4639-4645. 
 (19) Van Thienen, T. G.; Raemdonck, K.; Demeester, J.; de Smedt, S. C. Protein 
release from biodegradable dextran nanogels. Langmuir 2007, submitted,  
 (20) Boomer, J. A.; Inerowicz, H. D.; Zhang, Z. Y.; Bergstrand, N.; Edwards, K.; 
Kim, J. M.; Thompson, D. H. Acid-triggered release from sterically stabilized 
fusogenic liposomes via a hydrolytic DePEGylation strategy. Langmuir 2003, 
19, 6408-6415. 
 (21) Slepushkin, V. A.; Simoes, S.; Dazin, P.; Newman, M. S.; Guo, L. S.; Pedroso 
de Lima, M. C.; Duzgunes, N. Sterically stabilized pH-sensitive liposomes. 
Intracellular delivery of aqueous contents and prolonged circulation in vivo. 
Journal of Bioconjugate Chemistry 1997, 272, 2382-2388. 
 (22) Boomer, J. A.; Inerowicz, H. D.; Zhang, Z. Y.; Bergstrand, N.; Edwards, K.; 
Kim, J. M.; Thompson, D. H. Acid-triggered release from sterically stabilized 
fusogenic liposomes via a hydrolytic DePEGylation strategy. Langmuir 2003, 
19, 6408-6415. 
 (23) Bergstrand, N.; Arfvidsson, M. C.; Kim, J. M.; Thompson, D. H.; Edwards, K. 
Interactions between pH-sensitive liposomes and model membranes. 
Biophysical Chemistry 2003, 104, 361-379. 
 (24) De Oliveira, M. C.; Fattal, E.; Couvreur, P.; Lesieur, P.; Bourgaux, C.; Ollivon, 
M.; Dubernet, C. pH-sensitive liposomes as a carrier for oligonucleotides: a 
physico-chemical study of the interaction between DOPE and a 15-mer 
oligonucleotide in quasi-anhydrous samples. Biochimica et Biophysica Acta 
1998, 1372, 301-310. 
101 
DEXTRAN NANOGELS WITH FUNCTIONAL COATINGS 
 (25) Ropert, C.; Lavignon, M.; Dubernet, C.; Couvreur, P.; Malvy, C. 
Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward 
Friend retrovirus. Biochimica et Biophysica Acta-Research Communiciations 
1992, 183, 879-885. 
 (26) Ropert, C.; Malvy, C.; Couvreur, P. Inhibition of the Friend retrovirus by 
antisense oligonucleotides encapsulated in liposomes: mechanism of action. 
Pharmaceutical Research 1993, 10, 1427-1433. 
 (27) Ishida, T.; Kirchmeier, M. J.; Moase, E. H.; Zalipsky, S.; Allen, T. M. Targeted 
delivery and triggered release of liposomal doxorubicin enhances cytotoxicity 
against human B lymphoma cells. Biochimica et Biophysica Acta 2001, 1515, 
144-158. 
 (28) Hong, M. S.; Lim, S. J.; Oh, Y. K.; Kim, C. K. pH-sensitive, serum-stable and 
long-circulating liposomes as a new drug delivery system. Journal of 
Pharmacy and Pharmacology 2002, 54, 51-58. 
 (29) Sudimack, J. J.; Guo, W.; Tjarks, W.; Lee, R. J. A novel pH-sensitive liposome 
formulation containing oleyl alcohol. Biochimica et Biophysica Acta 2002, 
1564, 31-37. 
 (30) Shi, G.; Guo, W.; Stephenson, S. M.; Lee, R. J. Efficient intracellular drug and 
gene delivery using folate receptor-targeted pH-sensitive liposomes composed 
of cationic/anionic lipid combinations. Journal of Controlled Release 2002, 80, 
309-319. 
 (31) Guo, W.; Gosselin, M. A.; Lee, R. J. Characterization of a novel diolein-based 
LPDII vector for gene delivery. Journal of Controlled Release 2002, 83, 121-
132. 
 (32) Anderson, V. C.; Thompson, D. H. Triggered Release of Hydrophilic Agents 
from Plasmalogen Liposomes Using Visible-Light Or Acid. Biochimica et 
Biophysica Acta 1992, 1109, 33-42. 
 (33) Hitzman, C. J.; Elmquist, W. F.; Wiedmann, T. S. Development of a respirable, 
sustained release microcarrier for 5-fluorouracil II: In vitro and in vivo 
optimization of lipid coated nanoparticles. Journal of pharmaceutical sciences 
2006, 95, 1127-1143. 
 (34) Hitzman, C. J.; Elmquist, W. F.; Wattenberg, L. W.; Wiedmann, T. S. 
Development of a respirable, sustained release microcarrier for 5-fluorouracil 
I: In vitro assessment of liposomes, microspheres, and lipid coated 
nanoparticles. Journal of pharmaceutical sciences 2006, 95, 1114-1126. 
 (35) Hitzman, C. J.; Wattenberg, L. W.; Wiedmann, T. S. Pharmacokinetics of 5-
fluorouracil in the hamster following inhalation delivery of lipid-coated 
nanoparticles. Journal of pharmaceutical sciences 2006, 95, 1196-1211. 
 (36) Umamaheshwari, R. B.; Jain, N. K. Receptor-mediated targeting of lipobeads 
bearing acetohydroxamic acid for eradication of Helicobacter pylori. Journal of 
Controlled Release 2004, 99, 27-40. 
102 
CHAPTER 4 
 (37) Demiguel, I.; Ioualalen, K.; Bonnefous, M.; Peyrot, M.; Nguyen, F.; Cervilla, 
M.; Soulet, N.; Dirson, R.; Rieumajou, V.; Imbertie, L.; Solers, C.; Cazes, S.; 
Favre, G.; Samain, D. Synthesis and Characterization of Supramolecular 
Biovector (Smbv) Specifically Designed for the Entrapment of Ionic Molecules. 
Biochimica et Biophysica Acta-Biomembranes 1995, 1237, 49-58. 
 (38) McNamara, K. P.; Nguyen, T.; Dumitrascu, G.; Ji, J.; Rosenzweig, N.; 
Rosenzweig, Z. Synthesis, characterization, and application of fluorescence 
sensing lipobeads for intracellular pH measurements. Analytical Chemistry 
2001, 73, 3240-3246. 
 (39) Ji, J.; Rosenzweig, N.; Jones, I.; Rosenzweig, Z. Molecular oxygen-sensitive 
fluorescent lipobeads for intracellular oxygen measurements in murine 
macrophages. Analytical Chemistry 2001, 73, 3521-3527. 
 (40) Ma, A. H.; Rosenzwieg, Z. Submicrometric lipobead-based fluorescence 
sensors for chloride ion measurements in aqueous solution. Analytical 
Chemistry 2004, 76, 569-575. 
 (41) Ma, A. H.; Rosenzweig, Z. Synthesis and analytical properties of micrometric 
biosensing lipobeads. Analytical and Bioanalytical Chemistry 2005, 382, 28-
36. 
 (42) Patton, J. N.; Palmer, A. F. Photopolymerization of bovine hemoglobin 
entrapped nanoscale hydrogel particles within liposomal reactors for use as an 
artificial blood substitute. Biomacromolecules 2005, 6, 414-424. 
 (43) Patton, J. N.; Palmer, A. F. Engineering temperature-sensitive hydrogel 
nanoparticles entrapping hemoglobin as a novel type of oxygen carrier. 
Biomacromolecules 2005, 6, 2204-2212. 
 (44) Rui, Y. J.; Wang, S.; Low, P. S.; Thompson, D. H. Diplasmenylcholine-folate 
liposomes: An efficient vehicle for intracellular drug delivery. Journal of the 
American Chemical Society 1998, 120, 11213-11218. 
 (45) Rui, Y. J.; Wang, S.; Low, P. S.; Thompson, D. H. Diplasmenylcholine-folate 
liposomes: An efficient vehicle for intracellular drug delivery. Journal of the 
American Chemical Society 1998, 120, 11213-11218. 
 (46) van Dijk-Wolthuis, W. N. E.; Tsang, S. K. Y.; Kettenes van den Bosch, J. J.; 
Hennink, W. E. A new class of polymerizable dextrans with hydrolyzable 
groups: hydroxyethyl methacrylated dextran with and without oligolactate 
spacer. Polymer 1997, 38, 6235-6242. 
 (47) Van den Bossche, J.; Shin, J.; Thompson, D. H. Improved Plasmalogen 
Synthesis using organobarium intermediates. in progress 2007,  
 (48) Davis, A. A.; Bernstein, P. S.; Bok, D.; Turner, J.; Nachtigal, M.; Hunt, R. C. A 
Human Retinal-Pigment Epithelial-Cell Line That Retains Epithelial 
Characteristics After Prolonged Culture. Investigative Ophthalmology & Visual 
Science 1995, 36, 955-964. 
103 
DEXTRAN NANOGELS WITH FUNCTIONAL COATINGS 
 (49) Ishiwata, H.; Vertutdoi, A.; Hirose, T.; Miyajima, K. Physical-Chemistry 
Characteristics and Biodistribution of Poly(Ethylene Glycol)-Coated Liposomes 
Using Poly(Oxyethylene) Cholesteryl Ether. Chemical & Pharmaceutical 
Bulletin 1995, 43, 1005-1011. 
 (50) Bochot, A.; Couvreur, P.; Fattal, E. Intravitreal administration of antisense 
oligonucleotides: Potential of liposomal delivery. Progress in Retinal and Eye 
Research 2000, 19, 131-147. 
 (51) Ribbeck, K.; Gorlich, D. The permeability barrier of nuclear pore complexes 
appears to operate via hydrophobic exclusion. Embo Journal 2002, 21, 2664-
2671. 
 (52) Vertut-Doi, A.; Ishiwata, H.; Miyajima, K. Binding and uptake of liposomes 
containing a poly(ethylene glycol) derivative of cholesterol (stealth liposomes) 
by the macrophage cell line J774: Influence of PEG content and its molecular 
weight. Biochimica et Biophysica Acta-Biomembranes 1996, 1278, 19-28. 
 (53) Illum, L.; Davis, S. S.; Wilson, C. G.; Thomas, N. W.; Frier, M.; Hardy, J. G. 
Blood Clearance and Organ Deposition of Intravenously Administered 
Colloidal Particles - the Effects of Particle-Size, Nature and Shape. 
International Journal of Pharmaceutics 1982, 12, 135-146. 
 (54) Illum, L.; Hunneyball, I. M.; Davis, S. S. The Effect of Hydrophilic Coatings on 
the Uptake of Colloidal Particles by the Liver and by Peritoneal-Macrophages. 
International Journal of Pharmaceutics 1986, 29, 53-65. 
 (55) Simoes, S.; Moreira, J. N.; Fonseca, C.; Duzgunes, N.; de Lima, M. C. On the 
formulation of pH-sensitive liposomes with long circulation times. Advanced 
Drug Delivery Reviews 2004, 56, 947-965. 
 (56) Delgado, C.; Francis, G. E.; Fisher, D. The uses and properties of PEG-linked 
proteins. Critical Reviews in Therapeutic Drug Carrier Systems 1992, 9, 249-
304. 
 
104 
5 
 
 
 
 
 
 
 
 
 
 
 
INFLUENCE OF FREE CHAINS ON THE 
SWELLING PRESSURE OF PEG-HEMA 
AND DEX-HEMA HYDROGELS  
 
 
 
 
 
 
 
 
 
 
 
 
Parts of this chapter were published in: 
 
T.G. Van Thienen, F. Horkay, K. Braeckmans, B.G. Stubbe, J. Demeester and S.C. 
De Smedt, International Journal of Pharmaceutics  2006, 337, 31-39 

CHAPTER 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
Self-exploding microgel particles show potential for advanced 
delivery of certain therapeutics.  In order to be able to develop drug 
delivery systems that release their content based on the increase of 
osmotic pressure, insight in the osmotic behavior of the composing 
degrading hydrogels is of great importance.  This study compares the 
degradation behavior of PEG-HEMA (hydroxyethyl methacrylated 
poly(ethylene glycol)) and dex-HEMA (hydroxyethyl methacrylated 
dextran) hydrogels. The degradation of PEG-HEMA gels takes several 
months to over a year, while that of dex-HEMA gels takes only days or 
weeks.  The faster degradation kinetics of dex-HEMA networks can be 
attributed to stabilization of the keto-enol form by hydroxyl groups.  
Upon degradation of PEG-HEMA and dex-HEMA hydrogels respectively 
free PEG and free dextran chains are produced.  We investigated the 
effect of unattached PEG and dextran chains on the swelling pressure 
of the degrading gels.  It is found that low molecular weight free chains 
significantly increase the swelling pressure.  However, the contribution 
of higher molecular weight free chains (MW > 10 kDa) is similar to that 
of the network chains.  
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INTRODUCTION 
 
Recently biodegradable hydrogels have gained much attention because of 
their useful properties in various applications, such as drug release1-8 and tissue 
engineering9-13.  Previously our research group reported results on the synthesis 
and characterization of “self-rupturing microcapsules”14-17 (Figure 1) consisting of a 
biodegradable dextran gel core surrounded by a (lipid or polymeric) membrane, 
which is permeable for small molecules (e.g., water and ions) but impermeable for 
the degradation products of the hydrogel (free polymer chains).  In the course of the 
degradation process the swelling pressure of the hydrogel (πsw) gradually 
increases18.  Provided that the increase in swelling pressure is sufficient to 
overcome the rupture strength of the surrounding membrane, the latter ruptures 
(Figure 1D).  The time of rupturing is primarily determined by the degradation 
kinetics of the gel core that governs the increase of πsw.  
 
 A B C D 
    
Figure 1. Schematic representation18 of a “self-rupturing” microcapsule14,15 based on a 
degradable microgel surrounded by a semipermeable membrane: (A) before degradation 
the polymer chains are connected into a three-dimensional network by chemical cross-
links. (B) The gels described in this paper degrade by hydrolysis of the cross-links 
connecting the polymer chains.  As degradation proceeds, the cross-link density decreases 
and free polymer chains are produced. (C) At the end of the degradation process the 
hydrogel becomes a polymer solution. (D) When the swelling pressure is sufficiently high 
the membrane will rupture. 
 
To design self-rupturing dextran based microcapsules our research group 
recently investigated the swelling pressure of degrading hydroxyethyl methacrylated 
dextran (dex-HEMA, Figure 2A) hydrogels18,19.  The polymer network in these 
hydrogels is formed by radical polymerization of a dex-HEMA solution.  The HEMA 
based cross-links, which connect the dextran chains, contain hydrolysable 
carbonate esters that make the dex-HEMA hydrogels (bio)degradable (Figure 2B).  
The completely degraded dex-HEMA hydrogel forms a solution consisting of 
dextran and poly(HEMA) chains16,17,20  
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Figure 2. (A) Chemical structure of the monomer in dex-HEMA, i.e. glucopyranose 
substituted with HEMA and (B) schematic representation of a dex-HEMA network before 
and after degradation. 
 
The swelling pressure of a neutral polymer gel is determined by two 
opposing effects21: the osmotic pressure (πosm) that expands the network and the 
elastic pressure (πel) that contracts the network: 
 
 elosmsw πππ +=  eq. 1 
 
where πel = –G’, G’ being the elastic (shear) modulus of the hydrogel.  
Equation 1 predicts that πsw of a completely degraded hydrogel (i.e. G’ = 0) is equal 
to the osmotic pressure of the solution of the degradation products.  Stubbe et al. 
found previously that eq. 1 satisfactorily describes the osmotic pressure of dex-
HEMA hydrogels in the course of degradation18. 
To break the membrane surrounding the microgel particles πosm should 
exceed the tensile strength of the membrane.  To satisfy this requirement polymers 
that exhibit high osmotic pressure in solution are ideal candidates.  
In chapter 5 we report on the swelling pressure measurements for degrading 
hydroxyethyl methacrylated poly(ethylene glycol)  (PEG-HEMA) gels (Figure 3A & 
B).   
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Figure 3. (A) Chemical structure of PEG-HEMA and (B) schematic representation of a 
PEG-HEMA network before and after degradation.  The HEMA cross-links degrade through 
hydrolysis of the carbonate esters, resulting in PEG chains and poly(HEMA).   
 
At identical cross-link density PEG-HEMA gels are expected to display 
higher πsw than dex-HEMA gels since the osmotic pressure of the PEG solution 
exceeds that of the dextran solution at the same  polymer concentration22.   PEG is 
biocompatible and PEG based gels are widely used in drug delivery9,23-27 and tissue 
engineering applications9.  Rathi et al. studied thermoreversible hydrogels made of 
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the triblock copolymer PLGA-PEG-PLGA (PLGA being poly-DL-lactide-co-
glycolide)28,29.  Dissolving PLGA-PEG-PLGA in water results in a solution at room 
temperature that becomes a hydrogel at body temperature.  Due to hydrolysis of 
the PLGA blocks, PLGA-PEG-PLGA hydrogels degrade slowly over a period of 4-6 
weeks28-30.  Other biodegradable PEG hydrogels have been made from PEG-
fumarate and N,N’-methylene-bisacrylamide31 or by conjugate addition of PEG 
multiacrylates (with a multi-armed structure) and dithiotreitol27.   
In this chapter we describe the synthesis of PEG-HEMA hydrogels and 
investigate their degradation behavior.  To the authors’ knowledge the osmotic 
properties of PEG-HEMA hydrogels have not been studied before.  Our further aim 
is to determine the swelling pressure of degrading PEG-HEMA hydrogels at 
different stages of degradation.  Particularly, we intend to quantify the effect of 
unattached PEG chains on the swelling pressure of degrading gels.  To this end we 
made osmotic swelling pressure measurements on PEG-HEMA hydrogels 
containing controlled amounts of PEG chains of known molecular weights.  We also 
compare the swelling and degradation behaviors of PEG-HEMA and dex-HEMA 
hydrogels.  
 
 
EXPERIMENTAL SECTION 
Materials 
Dextran (from Leuconostoc Mesenteroïdes, Mn = 19 kDa), HEMA, dimethyl 
sulfoxide (DMSO < 0.01% water), MgSO4, N,N,N’,N’-tetramethylenediamine 
(TEMED), PEG (Mn = 200 Da; 600 Da and 1.5 kDa) and hydroquinone monomethyl 
ether (HQM) were purchased from Fluka Chemie AG.  4-(N,N-
dimethylamino)pyridine (DMAP) and 1,1’-carbonyldiimidazole (CDI) were from 
Acros Chimica.  PEG (Mn = 4 kDa; 10 kDa and 20 kDa), potassium persulfate 
(KPS) and dichloromethane (DCM) were purchased from Merck.  Dextran (Mn = 
600 Da and 800 Da) was obtained from Dextran Products.  Dextran (Mn = 5 kDa 
and 77 kDa) were purchased from Sigma-Aldrich.  Dialysis tubes with different 
molecular weight cut offs (MWCO, regenerated cellulose) were obtained from 
Spectrum Labs (The Netherlands). 
 
Synthesis of PEG-HEMA and dex-HEMA 
The synthesis of PEG-HEMA comprised of two steps:  the first step being the 
activation of HEMA with CDI (resulting in HEMA-CI), the second step being the 
coupling of HEMA-CI to the terminal hydroxyl groups of PEG.   
The synthesis of HEMA-CI was performed as described by van Dijk-Wolthuis 
et al.17.  Briefly, 29 g (179 mmol) CDI was dissolved in 300 mL dichloromethane.  
11.6 g (89 mmol) HEMA was added and the mixture was stirred for 1 h under N2 at 
room temperature.  Then the solution was washed with water to remove imidazole, 
110 
CHAPTER 5 
unreacted HEMA and CDI.  The HEMA-CI solution in dichloromethane was dried 
over MgSO4.  Subsequently HQM was added to avoid the formation of poly(HEMA) 
and the solvent was evaporated resulting in a light yellow oil: HEMA-CI. 
PEG-HEMA was synthesized as follows.  50 g (12.5 mmol) PEG (Mn = 4 
kDa), dried in a vacuum oven for 24 h at room temperature, and 5 mg HQM were 
dissolved in 500 mL DMSO in a 1 L three-neck round bottomed flask under N2 
stream.  After dissolving 10 g DMAP in the PEG/DMSO solution 14 g HEMA-CI 
(62.5 mmol, 5 eq.) was added dropwise while stirring vigorously.  This mixture was 
allowed to react for 5 days under N2.  The reaction was terminated by decreasing 
the pH to 4.0 with HCl solution.  DMSO was removed by dialysis against deionized 
water for one week (MWCO of the dialysis tubes was 2 kDa), the water was 
refreshed twice a day.  Subsequently the solution was freeze dried and the fluffy 
white powder was stored at –20°C under N2.  Purity was determined by proton 
nuclear magnetic resonance spectroscopy (1H NMR) in D2O with a Gemini 300 
spectrometer (Varian).  The degree of methacrylation was determined by 1H NMR 
and found to be 96%, i.e., 96% of the terminal hydroxyl groups of PEG were 
substituted with HEMA.   
Importantly, in the storage of PEG and in the synthesis of PEG-HEMA the 
formation of PEG peroxides should be avoided32.  Such peroxides spontaneously 
initiate the polymerization of PEG-HEMA solutions.  To prevent peroxide formation 
we added HQM to the PEG-HEMA and stored the polymer at –20°C under N2. 
Dex-HEMA was prepared and characterized as described elsewhere17.  
Dextran (Mn = 19 kDa) was used in the synthesis of the dex-HEMA.  The degree of 
substitution (DS), defined as the number of HEMA groups per 100 glucose units, 
was determined by 1H NMR.  The DS of the two dex-HEMA samples used in this 
study were 2.5 and 5.4, respectively.   
 
Gelification procedure and swelling pressure measurements  
The swelling pressure of dex-HEMA and PEG-HEMA hydrogels was 
measured using a home-made apparatus described elsewhere18 and schematically 
represented.  The device consists of two stainless steel chambers: a “sample 
chamber”, containing the hydrogel and the calibrated pressure transducer, and a 
“buffer chamber”.  The chambers are separated by a semi-permeable membrane 
supported by a porous Bekipor frame, and further supported by a perforated Teflon 
cylinder.  The nominal MWCO of the membrane was respectively 100 Da (for πsw 
measurements on PEG-HEMA gels and on dex-HEMA gels containing 600 and 800 
Da dextran chains) and 2 kDa (for πsw measurements on dex-HEMA gels containing 
5, 10, 19 and 77 kDa dextran chains).   
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Figure 4. Schematic representation of the home-made osmometer. The hydrogel is 
moulded in the sample chamber resulting in perfect contact between pressure transducer 
and hydrogel and hydrogel and the semi-permeable membrane, which is supported on a 
porous wire frame. The water channels of the device are connected to a warm water bath 
allowing thermostatisation. The stainless steel pressure transducer is calibrated up to 690 
kPa.  
 
The buffer chamber was filled with phosphate buffer (PB, 10 mM, pH=7.5). 
The sample chamber was filled with dex-HEMA (or PEG-HEMA) hydrogels.  To 
generate a hydrogel out of the polymer (dex-HEMA, PEG-HEMA) solutions KPS 
and TEMED were used as initiator and catalyst respectively, following the method 
as described by van Dijk – Wolthuis et al.16.   
To a deoxygenated dex-HEMA (or PEG-HEMA) solution in PB were added 
KPS solution (90 µL KPS solution/g gel; 0.05 g KPS/mL PB) and TEMED solution 
(50 µL TEMED solution/g gel; 20% (v/v) TEMED in deoxygenated PB, pH was 
adjusted to 8.5 with HCl).  After homogenization one part of the solution was 
transferred into the sample chamber.  The other part of the solution was poured into 
a cylindrical stainless steal mould (diameter 2.3 cm, height 2 mm); the gel slabs 
thus made in the mould were used to measure G’.  The polymer volume fraction of 
the hydrogels was calculated using the relationship 
 
 1
1
v
w
vw
w
buffer
pol
pol
ρ
ϕ
+
=  eq. 2 
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where wpol and wbuffer are respectively the weight of the polymer and the 
buffer, ρ is the density of the buffer (1.07 g/mL) and v1 is the specific volume of the 
polymer (being 0.84 mL/g for PEG and 0.72 mL/g for dextran)33. 
As described above the PEG-HEMA solutions also contained KPS and 
TEMED.  As KPS and TEMED cannot diffuse through the MWCO 100 Da 
membrane, we added the same amount of TEMED and KPS to the PB in the buffer 
chamber.   
 
Rheological measurements   
Rheological measurements on hydrogel slabs, prepared in the mould as 
described above, were made using an AR1000-N controlled stress rheometer (TA-
instruments) according to a method described in detail by Meyvis et al.34.  The 
elastic moduli of the gels were obtained from oscillation measurements at 1 Hz 
applying a constant strain of 0.5%.  For G’ measurements on degrading hydrogels, 
the hydrogel slabs were submerged in PB at 37°C.  At regular time intervals, G’ of 
the hydrogel slabs was measured. 
 
Gel permeation chromatography 
The molecular weights of the dextran samples used in this study were 
determined by gel permeation chromatography (Table 1).  An aliquot (20 µl) of the 
samples (1% solution) was injected into a Waters GPC system (Waters 600 HPLC 
pump, Waters 2410 Refractive Index detector).  A Plgel 5µm Mixed-C column 
(Polymer Laboratories) was used.  The mobile phase was DMSO and the flow rate 
was 0.5 mL/min at 70°C.  Pullulans with varying molecular weight (Polymer 
Laboratories) were used as molecular weight standards. 
 
Determination of the critical overlap concentration  
The critical overlap concentration (c*) of the PEG and dextran solutions was 
estimated from eq. 335 
 [ ]η
1* =c  eq. 3 
 
where [η] is the intrinsic viscosity 
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c
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c
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In eq. 4 ηsp is the specific viscosity, ηrel is the relative viscosity and c is the 
polymer concentration in g/100 mL. The kinematic viscosities were measured by a 
Micro-Ubbelohde viscometer with Lauda S5 detector, which was connected to 
Lauda PVS1 Processor Viscosity System with a PVS 2.46 analysis program.  The 
measurements were performed at 4.0 ± 0.1°C.  The flow time of the PEG and 
dextran solutions was at most 10% - 20% over the solvent flow time.   
 
 
RESULTS AND DISCUSSION 
Comparison between the osmotic pressure of PEG and dextran 
solutions  
As outlined in the Introduction, the motivation of investigating the PEG-
HEMA system is that totally degraded PEG-HEMA hydrogels are expected to 
exhibit a higher osmotic pressure than dex-HEMA hydrogels.  Figure 2B and Figure 
3B show that degradation of dex-HEMA and PEG-HEMA hydrogels produces 
dextran and PEG molecules, respectively.  We made osmotic pressure 
measurements on solutions prepared from dextran and PEG samples of 
comparable molecular weights (approximately 20 kDa).  Figure 5 shows that the 
osmotic pressure of the PEG solution is significantly higher than that of the dextran 
solution at identical polymer concentration.  This result indicates that water is a 
thermodynamically better solvent for PEG than for dextran. Note that in the 
degradation process a small amount of poly(HEMA) chains is also produced (see 
Figure 2B and Figure 3B).  However, its contribution to the osmotic pressure is 
negligible18.  
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Figure 5. Osmotic pressure of dextran (Mn = 19 kDa ■) and PEG (Mn = 20 kDa ▲) 
solutions in water as measured in the swelling pressure device.   
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Degradation of PEG-HEMA hydrogels versus dex-HEMA 
hydrogels 
Addition of KPS and TEMED to the PEG-HEMA (or dex-HEMA) solution 
results in gelation.  In Figure 3B and Figure 2B are compared the structure of 
networks made from PEG-HEMA and dex-HEMA solutions: in PEG-HEMA the 
polymer molecules are end-linked, while in dex-HEMA the dextran side chains are 
cross-linked.   
Figure 6A shows that the elastic modulus G’ of PEG-HEMA hydrogels 
decreases in time when stored in buffer at 37°C.  As expected G’ also depends on 
the PEG-HEMA concentration, since with increasing PEG-HEMA concentration the 
cross-link density (which determines G’) increases.  The PEG-HEMA hydrogels 
degrade slowly.  In a previous study Stubbe et al. found that the degradation of dex-
HEMA hydrogels19 is roughly ten times faster than that of PEG-HEMA hydrogels 
(compare Figure 6A and B).  As illustrated in Figure 7, the faster degradation of 
dex-HEMA networks may be related to stabilization of the keto-enol form by 
hydroxyl groups16. 
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Figure 6. The elastic modulus of degrading PEG-HEMA.  The PEG-HEMA concentration in 
the gels are 15% (•); 20% (■) and 25% (▲).  (B) The elastic modulus of dex-HEMA 
hydrogels are as follows (Copyright ACS18): DS 7.5; 20% (▼);DS 5.0; 20% (▲); DS 2.5; 
30% (•) and DS 2.5; 25% (■).  The data are the average of three independent 
measurements.   
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Figure 7. Keto-enol tautomerism in dex-HEMA: adjacent hydroxyl groups on the glucose 
unit facilitate keto-enol tautomerism.  
Swelling pressure of PEG-HEMA hydrogels versus dex-HEMA 
hydrogels 
Figure 6A shows that the complete degradation of PEG-HEMA gels takes 
several months.  It is therefore difficult to measure the swelling pressure of 
degrading PEG-HEMA gels in real-time.  Previously Stubbe et al. showed that the 
swelling pressure of dex-HEMA gels at various degradation times can be 
“mimicked” by gels containing known amounts of uncross-linked dextran (dex-
HEMA/dextran gels)18.  In this experiment the dextran chains were introduced into 
dex-HEMA solutions prior to cross-linking.  Assuming that the osmotic behavior of 
degrading PEG-HEMA hydrogels can be mimicked by “PEG-HEMA/PEG” gels we 
determined the dependence of πsw and πel (= -G’) on the concentration of the 
uncross-linked PEG in the gel.  PEG-HEMA/PEG hydrogels were made by 
polymerization of PEG-HEMA solutions in the presence of known amounts of 
(vacuum dried) PEG.   
 
 A B 
0 0.02 0.032 0.038 0.045 0.067 0.121
0
50
100
150
200
250
300
350
400
π [
kP
a]
ϕ
0 0.00536 0.014 0.029 0.055 0.151
0
50
100
150
200
250
300
350
400
π [
kP
a]
ϕ
 
Figure 8. Swelling pressure (open), osmotic pressure (gray bars) and elastic pressure 
(black bars) of PEG-HEMA/PEG hydrogels (A) and dex-HEMA/dextran hydrogels (B; 
Copyright ACS19) containing increasing amounts of uncross-linked polymer chains 
(respectively dextran 19 kDa and PEG 4 kDa).  The values on the x-axis indicate the 
volume fraction of the uncross-linked polymer in the corresponding gel.  The total polymer 
volume fraction in the PEG-HEMA/PEG gels is 0.121.  The total polymer volume fraction in 
the dex-HEMA/dex gels is 0.151. 
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Figure 8A shows that πsw increases and πel decreases with increasing PEG 
concentration.  Remarkably, πosm (= πsw - πel) only weakly depends on the PEG 
content at constant overall (cross-linked + uncross-linked) polymer concentration.  
However, when the gel turns into a polymer solution πosm exhibits a jump-like 
increase.  These results are consistent with similar observations made on dex-
HEMA gels18,36 (see Figure 8B).  
 
The effect of uncross-linked chains on the osmotic properties of polymer gels 
has been studied on various systems.  In a recent study on cross-linked DNA gels 
Horkay et al.37 showed that πosm of the gel is significantly lower than πosm of the 
uncross-linked DNA solution.  The lower πosm of the gels was attributed to 
permanent elastic constrains generated by the cross-links.  The present results 
suggest that in PEG-HEMA/PEG and dex-HEMA/dextran hydrogels the “free 
chains” strongly interact with the cross-linked polymer and behave like “cross-linked 
chains”.  When the gel is completely degraded, i.e., the polymer chains are no 
longer connected, the osmotic pressure increases and approaches that of the 
corresponding uncross-linked polymer solution.  
 
Influence of the molecular weight of free chains in PEG-HEMA 
and dex-HEMA hydrogels on the osmotic pressure 
To gain a better understanding of the contribution of free chains to the 
osmotic pressure we measured πosm of PEG-HEMA/PEG and dex-HEMA/dextran 
hydrogels containing known amounts of uncross-linked polymer of different 
molecular weights.  (The molecular weight of the dextran samples measured by 
GPC are listed in Table 1)   
 
Table 1. Molecular weights of the dextran 
samples measured by GPC 
Supplier info 
[kDa] 
Mn  
[kDa] 
Mw  
[kDa] 
Pd 
0.60
0.80
10.00
19.00
77.00
0.86
1.82
10.80
17.28
28.69
1.24
3.40
18.47
28.26
45.30
1.44
1.87
1.71
1.63
1.58
 
Figure 9A shows πsw, πel and πosm of a dex-HEMA gel containing uncross-
linked dextran chains of various molecular weights.  For all the gels the volume 
fractions of cross-linked dex-HEMA and dextran were constant, ϕdex-HEMA = 0.151 
and ϕdextran = 0.045 respectively.  Clearly, πosm of dex-HEMA/dextran gels containing 
10, 19 and 77 kDa dextran chains is the same within the experimental error.  
Furthermore, πosm is close to that of the corresponding dex-HEMA hydrogel in the 
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absence of uncross-linked dextran (compare Figure 8B and Figure 9A).  However, 
the osmotic pressure of gels containing low molecular weight dextran oligomers 
(800 and 600 Da) is considerably higher.  Similar results are shown in Figure 9B for 
a more densely cross-linked dex-HEMA/dextran network (DS = 5.4 (Figure 9B) and 
DS = 2.5 (Figure 9A)).  
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Figure 9. Swelling pressure (open), osmotic pressure (grey bars) and elastic pressure 
(black bars) of dex-HEMA/dextran hydrogels (A & B) and PEG-HEMA/PEG hydrogels (C). 
The DS of the dex-HEMA used in A is 2.5 while it is 5.4 in B.  The x-axis indicates the 
molecular weight of the uncross-linked polymer.  In all dex-HEMA/dextran gels (A, B) the 
total polymer volume fraction is 0.151, while the volume fraction of uncross-linked dextran 
is 0.045.  In all PEG-HEMA/PEG gels (C) the total polymer volume fraction is 0.121, while 
the volume fraction of uncross-linked PEG chains is 0.036. 
 
Figure 9C shows πsw, πel and πosm of PEG-HEMA hydrogels containing free 
PEG chains of various molecular weights between 0.2 and 10 kDa.  The results 
indicate that the osmotic pressure of the gels containing low molecular weight 
chains (0.2 and 0.6 kDa) is higher than that of the gels containing higher molecular 
weight (1.5; 4 and 10 kDa) free chains.   
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Figure 10. Dependence of the osmotic pressure on the polymer concentration for aqueous 
PEG (A) and dextran (B) solutions of different molecular weights.  The data are obtained 
from Hansen et al.38 for PEG and from Smit et al.39 for dextran. 
 
In general, the osmotic pressure of polymer solutions increases with the 
number of mobile chains.  However, above the overlap concentration many polymer 
solutions exhibit universal behavior, i.e., the osmotic pressure is independent of the 
molecular weight of the polymer. This was indeed observed experimentally for 
PEG38 and dextran40 solutions (Figure 10A and B).  In samples containing low 
molecular weight oligomers chemical effects may also be important.  Different sites 
within a chain (chain ends and mid-chain segments) may interact differently with the 
cross-linked polymer.  It is known that many water soluble polymers (e.g., 
poly(ethylene oxide, poly(acrylic acid)) form clusters due to association of the 
hydrophobic end groups41-43.  The effect of end groups becomes less pronounced 
as the molecular weight of the polymer increases.  We also note that in the present 
gel systems the concentration of the low molecular weight polymers was below their 
overlap concentrations (Figure 11) 
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Figure 11: Overlap concentration c* as calculated from the intrinsic viscosity for dextran 
(A) and PEG (B) solutions as a function of the molecular weight.  The horizontal line 
denotes the concentration of the uncross-linked dextran in the dex-HEMA/dextran 
hydrogels shown in Figure 9A and B, and the concentration of the uncross-linked PEG in 
the PEG-HEMA/PEG hydrogels shown in Figure 9C. 
 
Clearly, low molecular weight free chains behave differently from the network 
chains. The difference between the osmotic contribution of the free chains and the 
network chains vanishes with increasing polymer molecular weight.  Beyond a 
threshold molecular weight (for the PEG-HEMA/PEG system above 10 kDa) the 
free chains are practically indistinguishable from the network chains. 
 
 
CONCLUSIONS  
 
We demonstrated that degradable PEG-HEMA hydrogels can be made by 
radical polymerization of aqueous PEG-HEMA solutions using a simple two step 
synthesis route by coupling the carbonylimidazole activated HEMA to PEG.  Total 
degradation of PEG-HEMA hydrogels (at pH 7.5) takes months to over a year, 
which is significantly longer than the degradation time (days to weeks) of dex-
HEMA gels. 
Upon degradation of PEG-HEMA and dex-HEMA hydrogels free PEG and 
dextran chains are produced.  It is found that the osmotic pressure of the fully 
degraded PEG-HEMA gels exceeds that of similar dex-HEMA hydrogels.  This 
observation is consistent with the results of osmotic pressure measurements made 
on solutions of the corresponding polymers.   
To mimic partially degraded hydrogels we used PEG-HEMA gels containing 
known amounts of uncross-linked PEG and dextran chains.  We studied the 
influence of the molecular weight of the uncross-linked polymers on πosm.  Different 
molecular weight dextran and PEG chains were incorporated into PEG-HEMA and 
dex-HEMA gels.  We found that the difference between the contributions of network 
chains and free chains to the osmotic pressure decreases with increasing molecular 
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weight.  Higher molecular weight free chains (MW > 10 kDa) behave like network 
chains.  
The knowledge of the osmotic properties of degradable dex-HEMA and 
PEG-HEMA gels is of great significance for the design and optimization of self-
rupturing microcapsules.  The major application of the self-rupturing microcapsules 
(illustrated in Figure 1) is pulsed drug delivery.  The ultimate goal is to insure that 
the drug molecules entrapped in the microcapsules are suddenly released when the 
surrounding membrane is ruptured.  Clearly, to realize a sudden release the drug 
molecules should not leak through the membrane before the membrane becomes 
disrupted by the swelling pressure of the microgel.  An increase in the swelling 
pressure due to degradation of the cross-linked polymer will exert a force on the 
membrane making it more permeable and leading to leakage of the drug.  It is 
therefore important to use degradable microgels whose πosm (and thus πsw) remains 
low during the degradation process and suddenly increases when the gel turns into 
a polymer solution.  Based on the results reported in the present chapter one may 
conclude that hydrogels made from high molecular weight polymers are favorable 
since the contribution of high molecular weight degradation products to the osmotic 
pressure is smaller.  
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Abstract  
In chapter 5 we showed that poly(ethylene glycol) (PEG) is an 
ideal polymer for the synthesis of biodegradable hydrogels.  This 
chapter investigates PEG based micro- and nanogels, with or without 
lipid coating, with the aim to slowly deliver encapsulated molecules.  
Hydroxyethyl methacrylated PEG (PEG-HEMA), PEG-HEMA with an 
oligo lactate spacer (PEG-lac-HEMA), and 8-armed PEG end capped 
with HEMA (Â-PEG-HEMA) were used. PEG-lac-HEMA matrices 
degraded very fast (in terms of days), while it took about one month for 
linear PEG-HEMA and several months for Â-PEG-HEMA hydrogels to 
become degraded. PEG based microgels were made by use of an all 
aqueous technique and could be lipid-coated by mixing the microgels 
(made positively or negatively charged through copolymerization with 
respectively methacrylic acid and dimethyl aminoethyl methacrylate) 
with a suspension of oppositely charged liposomes. The release of 
fluorescently labeled molecules incorporated in the PEG based 
microgels could be clearly governed by the type of molecules used 
(lasting from hours to months). PEG based nanogels could be made 
using liposomes as a nanoscopic mold, resulting in particles with a 
PEG gel core surrounded by a lipid coating. BSA could be easily 
encapsulated in the PEG nanogels which released the BSA over a 
period of about one week.  
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INTRODUCTION 
 
Micrometer and nanometer sized hydrogel particles show promise for the 
design of advanced drug delivery devices which may enhance the therapeutic index 
of many types of drugs.  We aim to design “simple”, tiny, biodegradable hydrogel 
particles which, after uptake by cells, slowly release their drug load in one or another 
cellular compartment or in the cytosol of the cells.  We search for hydrogel particles 
which deliver the encapsulated drugs not only over a couple of hours, but also over 
days, weeks and even over months.  Such slow delivering systems may be of interest 
for intracellular drug delivery in long living cells. 
Previous research from the Hennink group showed that dextran-hydroxyethyl 
methacrylate (dex-HEMA) has great potential for the synthesis of dex-HEMA 
microgels1-6.  In chapter 2 we showed that also dex-HEMA nanogels can be prepared 
using liposomes as a nanoscopic reactor.  Hereby liposomes are filled with a dex-
HEMA solution which is subsequently cross-linked with the formation of (lipid-coated) 
dex-HEMA nanogels7,8.  Dex-HEMA micro- and nanogels are biocompatible9 and 
degrade spontaneously under physiological conditions10.  The degradation rate of the 
dex-HEMA micro- and nanogels depends on their cross-link density which is 
determined by the number of HEMA groups substituted on the dextran backbone10.   
In this chapter the focus is on biodegradable poly(ethylene glycol) (PEG) 
micro- and nanogels.  PEG has been widely studied in pharmaceutical research for 
various purposes as (a) it is biocompatible11,12, (b) (low molecular weight) PEGs are 
excreted by the body13 and (c) PEG does not severely interact with blood- and 
cellular proteins14.  Biodegradable PEG/poly(lactic acid) (PLA) and PEG/poly(glycolic 
acid) (PGA) block co-polymers have been investigated.  When such co-polymers are  
end capped with acrylates they can be polymerized by UV or visible light.  These 
macromers were polymerized in direct contact with tissues for the delivery of pDNA15, 
growth factors16, and vaccines17.  For example, acrylate derivatized PLA-PEG-PLA is 
under investigation for the production of articular cartilage: after injecting acrylated 
PEG solutions together with chondrocytes or growth factors, transdermal 
photopolymerization leads to local formation of artificial cartilage18,19.  Also PEG-
diacrylates (without PLA or PGA blocks)20 and polycaprolactone-b-poly(ethylene 
glycol)-b-polycaprolactone (PEG-CAP)21 are developed for the in situ formation of 
articular cartilage.  PEG hydrogels can also be formed without photopolymerization: 
in combination with glycolide and/or lactide oligomers PEG forms a hydrogel upon 
injection in a 37°C environment. Such PEG hydrogels have been reported to be non-
cytotoxic22 and biodegradable under physiological conditions.  They are under 
investigation for the controlled delivery of insuline23,24, pDNA25 and other hydrophilic 
or lipophilic drugs (for example ketoprofen26, spironolactone26, misoprostol25, 5-
fluorouracil27, indomethacin27 and paclitaxel28). 
PEG based hydrogels which are responsive to various stimuli have been 
reported as well.  Andreopoulos et al. developed photoresponsive PEG based 
hydrogel membranes which can be cross-linked upon exposure to >300 nm light and 
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photodegrade when exposed to UV light (254 nm)29,30.  By the co-polymerization of 
poly(N-isopropylacrylamide), temperature responsive PEG based nanogels31, 
microgels32 and macroscopic matrices33 have been reported as well.  Very recently 
PEG based “cell receptor responsive hydrogels” were described.  Hydrogels were 
prepared by the interaction of multi-armed heparin modified PEG and the vascular 
endothelial growth factor (VEGF), a heparin binding growth factor34.  In the presence 
of VEGF receptors, on the surface of VEGF receptor expressing cells, VEGF is 
exchanged between the hydrogel and the VEGF receptor, resulting in the dissolution 
of the hydrogel and the release of VEGF to the cell. It was shown that such type of 
hydrogels increase proliferation of VEGF responsive cell lines.   
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The major part of previous research on PEG hydrogels concerned the 
synthesis, physicochemical and biological evaluation of macroscopic hydrogel slabs. 
The present study, in which PEG-HEMA (Figure 1A), star shaped PEG-HEMA 
(Figure 1B) and PEG-lactate-HEMA (Figure 1C) were used, deals with the following 
questions. (a)  Is it possible to make PEG based micron- and nanosized  hydrogel 
particles?  (b) Can we substantially vary the degradation time of PEG micro- and 
nanogels with the aim to tailor the release profiles of entrapped molecules? (c) How 
to surround PEG micro- and nanogels with a lipid coating as this may be of interest to 
modify their release characteristics and to optimize their cellular uptake and 
intracellular fate.   
 
 
EXPERIMENTAL SECTION  
Materials 
MgSO4, N,N,N’,N’-tetramethylenediamine (TEMED), dimethyl aminoethyl 
methacrylate (DMAEMA) and hydroquinone monomethyl ether (HQM) were 
purchased from Fluka Chemie AG (Switzerland).  4-(N,N-dimethylamino)pyridine 
(DMAP) and 1,1’-carbonyldiimidazole (CDI) were from Acros Chimica (Belgium).  
Bovine serum albumin was purchased from Sigma Aldrich (Germany).  Lactide was 
purchased from Purac Biochem (The Netherlands).  Poly(ethylene glycol) (PEG, Mn = 
4 kDa; 10 kDa and 20 kDa), potassium persulfate (KPS) and Triton X 100 (TX 100) 
were purchased from Merck (Germany).  Star shaped PEG (Â-PEG, 8 arms, 10 kDa) 
and fluorescein-isothiocyanate-PEG (FITC-PEG) were obtained from Nektar (Japan).  
Dextran with a molecular weight of 40 kDa (dexT40) was obtained from Amersham 
Bioscience (Sweden).  Dialysis tubes with different molecular weight cut offs (MWCO, 
regenerated cellulose) were obtained from Spectrum Labs (The Netherlands).  
Irgacure 2959 (I2959) was a free sample from Ciba Specialty Chemicals (Belgium).  
SOPC, DOTAP, CHOL, DPPC, DPPG and rho-DOPE (respectively being 1-stearoyl-
2-oleoyl-sn-glycero-3-phosphocholine;1,2-dioleoyl-3-trimethylammonium propane 
chloride; cholesterol, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-
Glycero-3-[phospho-rac-(1-glycerol)] (Sodium Salt) and rhodamine-dioleoyl-
phosphatidylethanolamine) were purchased from Avanti Polar Lipids (Alabaster, 
USA). 
 
Synthesis of PEG-HEMA and Â-PEG-HEMA 
For the synthesis of PEG-HEMA (Figure 1A) we refer to the previous 
chapter35.  The synthesis of Â-PEG-HEMA (Figure 1B) is very similar to the 
synthesis of PEG-HEMA.  In a first step HEMA-CI is synthesized as described 
before35.  The second step, being the coupling of HEMA-CI to the terminal hydroxyl 
groups of PEG, occurs as follows.  Â-PEG (Mn = 10 kDa), dried in a vacuum oven for 
24 h at room temperature, and 5 mg HQM are dissolved in 10 mL DMSO in a 25 mL 
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three-neck round bottomed flask under N2 stream.  After dissolving 0.2 g DMAP in 
the Â-PEG/DMSO solution, HEMA-CI is added drop wise while stirring vigorously.  
The amount of added HEMA-CI depends on how many arms of Â-PEG have to 
become substituted with HEMA and is calculated as follows (eq. 1): 
 
 5,1×××= −
−∗
−∗
− CIHEMA
PEG
PEG
CIHEMA MWMW
nm
m  eq. 1 
 
in which mHEMA-CI stands for the mass of HEMA-CI to be added, mÂ-PEG is the mass 
Â-PEG in the solution, n is the desired number of PEG-arms to be substituted by 
HEMA, MWÂ-PEG and MWHEMA-CI are the molecular weight of respectively Â-PEG (10 
kDa) and HEMA-CI (224 Da).  A factor 1,5 is taken into account as the incorporation 
efficiency of the acrylate groups on the terminal alcohol group on Â-PEG is not 
100%.   
This mixture was allowed to react for 5 days under N2.  The reaction was 
terminated by decreasing the pH to 4.0 with HCl.  DMSO was removed by dialysis 
against deionized water for one week (MWCO of the dialysis tubes was 2 kDa), the 
water was refreshed twice a day.  Subsequently the solution was freeze dried and 
the fluffy white powder was stored at –20°C under N2.  Purity was determined by 1H 
NMR in D2O with a Gemini 300 spectrometer (Varian).  The degree of substitution of 
the terminal alcohol groups on PEG with acrylate was determined using 1H NMR 
from the ratio of the integral value of the acrylate (~5.8 or 6.4 ppm) to the PEG star 
(~3.6 ppm).  The degree of substitution (DS; i.e. the extent of acrylation) was 
calculated by equation 2: 
 
 
EO
n
CH
CH
MW
M
I
IDS ××= 4
2
 eq. 2 
 
in which ICH and ICH2 are the vinylic integral and the oxyethylene integral, 
respectively.  MWEO is the molecular weight of the monomer in PEG (i.e. ethylene 
oxide), being 44 Da.  The factor 4 represents the number of protons in the ethylene 
oxide molecule.   
Importantly, in the storage of (Â-)PEG and in the synthesis of (Â-)PEG-HEMA 
the formation of PEG peroxides should be avoided36 as peroxides would 
spontaneously initiate the polymerization of (Â-)PEG-HEMA solutions.  To prevent 
peroxide formation we added HQM to the (Â-)PEG-HEMA and stored the polymer at 
–20°C under N2. 
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Synthesis of PEG-lac-HEMA 
The synthesis of PEG-lac-HEMA (Figure 1C) occurred in three steps.  First, L-
lactide was grafted onto HEMA in the presence of stannous octoate (SnOct2), 
yielding HEMA-lactate.  Second, HEMA-lactate was activated with CDI resulting in 
HEMA-lactate-CI.  Third, HEMA-lactate-CI was coupled to PEG, to yield PEG-lactate-
HEMA (PEG-lac-HEMA).   
The synthesis of HEMA-lactate and HEMA-lactate-CI has been described in 
detail by van Dijk-Wolthuis et al.37.  HEMA-lactate consisting of 2 lactyl residues was 
synthesized.  The grafting of HEMA-lactate-CI to PEG occurred as follows.  50 g 
(12.5 mmol) PEG (Mn = 4 kDa), dried in a vacuum oven for 24 h at room 
temperature, and a spatula tip of HQM were dissolved in 500 mL DMSO in a 1 L 
three-neck round bottomed flask under N2 stream.  After dissolving 10 g DMAP in the 
PEG/DMSO solution 23 g HEMA-lactate-CI (62.5 mmol, 5 eq.) was added drop wise 
while stirring vigorously.  This mixture was allowed to react for 4 days under N2.  The 
workup procedure was performed as described above for PEG-HEMA and Â-PEG-
HEMA.  
 
Rheological measurements on degrading PEG based hydrogel 
slabs 
PEG-HEMA, PEG-lac-HEMA and Â-PEG-HEMA solutions were polymerized 
by the use of KPS (0.05 g KPS/mL in PB solution) and TEMED (20% (v/v) TEMED 
solution in deoxygenated phosphate buffer (PB), pH was adjusted to 8.5 with HCl) 
following the method as described by  van Dijk-Wolthuis et al.38.  Briefly, 50 µL of 
TEMED solution was added to 1 g of polymer solution.  After homogenization, 90 µL 
of KPS solution was added to the system to initiate gelation. 
The PEG-HEMA, PEG-lac-HEMA and Â-PEG-HEMA hydrogel slabs, 
prepared in cylindrical moulds with a diameter of 2.3 cm and a height of 2 mm, were 
rheologically characterized using an AR1000- N controlled stress rheometer (TA-
instruments) according to a method described in detail by Meyvis et al.39.  For G’ 
measurements on degrading hydrogels, the hydrogel slabs were submerged in PB at 
37°C.  At regular time intervals, G’ of the hydrogel slabs was measured. 
 
Synthesis of PEG-HEMA, Â-PEG-HEMA and PEG-lac-HEMA 
microgels 
PEG-HEMA, Â-PEG-HEMA and PEG-lac-HEMA microgels were prepared as 
follows4:  Briefly, a deoxygenated aqueous solution of methacrylated PEG (0.25 g of 
a 30% (w/w) solution in PB) and a dextran solution (5 g of a 40% (w/w) solution 
dexT40 in PB) were mixed with each other.  The mixture was vigorously mixed with a 
vortex for 1 min under a N2 atmosphere to obtain a water-in-water emulsion.  The 
resulting emulsion was allowed to stabilize for 10 min.  Subsequently 100 µL TEMED 
solution and 180 µL KPS solution (composition as described above) were added to 
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the emulsion.  After gentle mixing the emulsion was incubated without stirring for 30 
min at 37°C to cross-link the methacrylate groups in the PEG chains.  The cross-
linked microgels were purified by 3 washing steps with 10 mL PB.  The microgels 
were collected by centrifugation and resuspended in 5 mL PB. 
To prepare negatively and positively charged dex-HEMA microgels 
respectively methacrylic acid (30 µL MAA, Figure 2A) or dimethyl aminoethyl 
methacrylate (30 µL DMAEMA, Figure 2B) were added to the starting methacrylated 
PEG solution.  To prepare fluorescently labeled methacrylated PEG microgels, 40 µL 
of a FITC-PEG solution (25 mg/mL in PB) was added to the methacrylated PEG 
solution. 
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Figure 2. Chemical structure of MAA (A) and DMAEMA (B). 
Lipid coating of (Â-)PEG-HEMA and PEG-lac-HEMA microgels 
The methacrylated PEG microgels were coated with a lipid membrane by the 
use of liposomes.  The liposomes were prepared by dissolving 5 mg of the desired 
lipids (respectively DOPC:DOTAP in a 9:1 molar ratio and DPPC:DPPG:CHOL in a 
4:1:5 molar ratio) in 200 µL chloroform.  0.05 mol% of rho-DOPE was added to make 
the lipid film fluorescent.  The chloroform was removed by use of N2 while gently 
spinning the test-tube, leaving a thin lipid film on the bottom of the tube.  The 
remaining chloroform was removed from the lipid film by vacuum drying during for at 
least 4h.  The liposome dispersion was obtained by hydrating the lipid film with 1 mL 
PB (at a temperature at least 10°C above the phase transition temperature during 30 
min and vortexing every 5 min).  For the DOPC:DOTAP liposomes this was at 25°C, 
for the DPPC:DPPG:CHOL liposomes this was 45°C. 
To coat the methacrylated PEG microgels, to a 1 mL (negatively or positively 
charged) liposome dispersion 2 mL of an (oppositely charged) microgel dispersion 
was added and incubated for 20 min at 25°C to allow sorption of the liposomes to the 
surface of the microgels.  The excess of lipid was removed by density gradient 
centrifugation.   
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Confocal laser scanning microscopy 
Confocal laser scanning images were recorded with a Bio-Rad MRC 1024 
microscope using a water immersion objective lens (Plan Apo 60X, NA 1.2, collar rim 
correction, Nikon) and a krypton/argon laser. 
 
Release of FITC-PEG from degrading (Â-)PEG-HEMA and PEG-lac-
HEMA microgels 
10 mL of a microgel dispersion was incubated at 37°C and mechanically 
agitated.  At regular time intervals the dispersion was centrifuged (3 min at 100¯g) 
and 2 mL of the supernatant was withdrawn and replaced by 2 mL of PB.  The 
supernatant samples were stored at 4°C until further analysis.   
The fluorescence intensity of the supernatant samples was measured with a 
Wallac Victor 2 (Perkin Elmer) plate reader.  The fluorescence values were 
normalized against the fluorescence values measured at the end of the release 
experiments.  It was verified that the measured fluorescence values belonged to the 
range in which a linear relation exists between the concentration of the FITC-PEG 
solutions and their fluorescence. 
 
Preparation of (protein loaded) PEG-HEMA nanogels 
PEG-HEMA nanogels were prepared using liposomes as a nanoscaled 
reactor, as described for dex-HEMA nanogels in chapter 27.  A conventional 
procedure to prepare the liposomes was used.  A 5 mg lipid film of SOPC was made 
as described above.  This dry lipid film was hydrated with 1 mL of a PEG-HEMA 
solution (i.e. 20% (w/w) PEG-HEMA in 50 mM PB at pH 7.0) which contained 0.05% 
I2959 as a photo initiator.  The resulting dispersion was placed at 25°C for 30 
minutes while vortexing every 5 minutes.  This dispersion of large vesicles was aged 
overnight.  Next, the dispersion was extruded with a LiposoFast Pneumatic-Actuator 
(Avestin) provided with a 400 nm polycarbonate membrane (Whatman International).  
After 11 back-and-forth passages of the dispersion through the extrusion membrane, 
the liposome dispersion was diluted 10 times with PB.  This dilution was necessary 
as not all the PEG-HEMA was entrapped in the liposomes.  If not diluted this “free” 
PEG-HEMA would form a gel in the polymerization step, thereby enclosing the 
liposomes in a polymer matrix.  The PEG-HEMA containing liposomes were 
subsequently exposed to UV light (365 nm from a Bluepoint 2.1 UV source, Honle 
UV Technology) at 25°C for 450 s which cross-linked the PEG-HEMA solution in the 
liposomes with the formation of “lipid-coated PEG-HEMA nanogels”.  To obtain 
“naked PEG-HEMA nanogels” the lipid layer was removed by adding 20.0 µL of a 
100 mM solution of TX 100 to 1 mL of the lipid-coated nanogel dispersion.   
To prepare bovine serum albumin (BSA) loaded PEG-HEMA nanogels, BSA 
(50 mg/mL) was added to the PEG-HEMA solution used to hydrate the dry lipid film.  
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Dynamic light scattering (DLS) analysis on degrading PEG-HEMA 
nanogels 
To study the degradation of the nanogels, a cuvette was filled with 1.2 mL of 
the nanogel dispersions and sealed with Parafilm™ to avoid contamination with dust 
particles.  The cuvette was placed at 37°C and the size distribution of the degrading 
particles was determined by dynamic light scattering (Autosizer 4700, Malvern 
Instruments) at regular times.   
 
Protein release from degrading PEG nanogels 
The amount of proteins released from the degrading PEG nanogels was 
measured as described in chapter 3.8.  A Vivaspin centrifugation filtration device 
(having a membrane with a 300 kDa MWCO, Vivascience) was filled with a known 
weight (at least 2,5 g) of a dispersion of BSA loaded PEG nanogels in PB.  
Respectively before the nanogels began to degrade and at different times during 
their degradation (which occurred at 37°C), the amount of released BSA was 
determined by centrifugation of the dispersion for 3 minutes (at 100×g).  The filtrate 
was stored (at 4°C) for BSA analysis and PB was added to the nanogel dispersion 
(remaining in the Vivaspin device) until the original weight of the dispersion.  The 
release of the BSA was measured until the nanogels were completely degraded, as 
could be detected by DLS measurements.   
The protein concentration in the samples was measured by Reversed Phase 
High Performance Liquid Chromatography (RP-HPLC, LaChrom Elite).  An aliquot (2 
µl) of the samples was automatically injected into a RP-HPLC system (Hitachi 
LaChrom Elite, L-2100 SMASH pump, L-2200 autosampler, L-2300 column oven and 
L-2450 Diode Array Detector).  A RP C4 column (Alltech, 300Å, 5 µm, 25 cm) was 
used.  A water/acetonitrile mixture (the solvent’s composition and the concentration 
gradient in function of time are given in chapter 3), adjusted to pH 2.0 with 
trifluoroacetic acid (TFA, Sigma) was used as the mobile phase at a constant flow 
rate of 0.75 mL/min.  A calibration curve was obtained by injecting various volumes of 
a 5 mg/mL protein solution in PB.  The protein concentration in the samples was 
calculated from the area under the BSA peak, using the calibration curve. 
 
 
RESULTS AND DISCUSSION  
Degradation behavior of PEG-HEMA, PEG-lac-HEMA en Â-PEG-
HEMA gels 
Figure 3A-C shows the elastic moduli of PEG-HEMA,  PEG-lac-HEMA and Â-
PEG-HEMA hydrogels degrading in phosphate buffer (pH 7.0) at 37°C.  Figure 3A 
shows that it takes approximately 6 months to degrade a PEG-HEMA (15% (w/w)) 
hydrogel while PEG-lac-HEMA hydrogels (even those which contain 65% (w/w) PEG-
lac-HEMA) are already degraded after some days (Figure 3B).  It suggests that the 
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lactate esters in PEG-lac-HEMA hydrolyze more rapidly than the carbonate esters in 
PEG-HEMA.  This is in agreement with observations by Van Dijk-Wolthuizen et al.10 
who showed that dex-HEMA degraded slower compared to dex-lac-HEMA. Figure 3C 
shows that the degradation of Â-PEG-HEMA hydrogels proceeds over several 
months.  As Â-PEG-HEMA molecules have multiple methacrylate groups per 
molecule (note that a linear PEG-HEMA chain only bears two methacrylate groups), 
the concentration of cross-links in Â-PEG-HEMA hydrogels is much higher than in 
linear PEG-HEMA hydrogels with the same PEG concentration.  Subsequently, to 
dissolve the network more cross-links have to be hydrolyzed which takes longer 
times.  
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Figure 3. Elastic moduli of degrading PEG based hydrogels. (A) PEG-HEMA hydrogels. (B) 
PEG-lac-HEMA hydrogels. (C) Â-PEG-HEMA hydrogels. The number of arms substituted 
with HEMA (per Â-PEG) is respectively 3.8, 6.7, 7.0 and 8.3.  G0 is the elastic modulus of 
the gel before degradation. 
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Obviously, as can be seen in Figure 3C, increasing the DS from 3.8 till 6.7 of 
Â-PEG-HEMA hydrogels (while keeping the Â-PEG-HEMA concentration constant) 
results in a network with a higher cross-link density and thus a higher G0 (i.e. the 
initial G’ value of the hydrogels before degradation).  However, a further increase in 
DS (to 7.0 and 8.3) results in softer gels which we attribute to higher degree of 
intramolecular cross-linking.  Intramolecular cross-links – in contrast to intermolecular 
cross-links- do not contribute to the network’s elasticity40. 
 
PEG based microgels 
Synthesis of PEG-HEMA, PEG-lac-HEMA and Â-PEG-HEMA  microgels. 
Since aqueous solutions of PEG-HEMA and dextran are immiscible, a PEG-
HEMA/dextran emulsion with dextran as continuous phase, can be made2.  When 
KPS and TEMED are added to PEG-HEMA/dextran emulsions, the methacrylated 
PEG droplets are expected to polymerize yielding PEG based microgels.  The CLSM 
images in Figure 4(A1, B1 and C1) show that polymerization of the emulsification 
indeed results in PEG-HEMA, PEG-lac-HEMA and Â-PEG-HEMA microgels.   
To make charged PEG-microgels we co-polymerized respectively MAA and 
DMAEMA with PEG-HEMA, as this results in negatively and positively charged 
particles respectively1.  Figure 4A2, B2 and C2 shows CLSM images of respectively 
PEG-HEMA-MAA, PEG-lac-HEMA-MAA and Â-PEG-HEMA-MAA microgels.  While 
also positively charged PEG-HEMA-DMAEMA and Â-PEG-HEMA-DMAEMA could 
be easily produced (Figure 4A3 and C3), it seemed hard to obtain PEG-lac-HEMA-
DMAEMA microspheres which might be attributed to the fact that PEG-lac-HEMA-
DMAEMA degrades too fast to make stable microgels.  
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Figure 4. CLSM images of naked (A) PEG-HEMA, (B) PEG-lac-HEMA and (C) Â-PEG-
HEMA microgels.  Subscript 1 refers to neutral gels, subscript 2 refers to negatively charged 
microgels (which contain MAA) and subscript 3 refers to positively charged microgels (which 
contain DMAEMA).  The microgel core was fluorescently labeled with FITC-PEG.  Scalebars 
represent 50 µm 
 
Lipid coating of PEG based microgels.  In a first approach we tried to coat 
the PEG microgels by a method previously reported by Kiser et al.41,42.  Therefore 
(neutral) PEG microgels were sedimented on a (neutral) lipid film, however, lipid-
coated PEG microgels could be hardly detected by CLSM.  Subsequently, following 
the strategy of Moya et al.43,44, positively and negatively charged PEG microgels 
were mixed with a suspension of oppositely charged liposomes.  CLSM clearly 
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revealed that all the PEG microgels became lipid-coated in this way (Figure 5A, B 
and C).  
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Figure 5. CLSM images of lipid-coated (A) PEG-HEMA, (B) PEG-lac-HEMA and (C) Â-PEG-
HEMA microgels.  Subscript 1 refers negatively charged microgels (which contain MAA) and 
subscript 2 refers to positively charged microgels (which contain DMAEMA).  Negative 
microgels were coated with DOPC:DOTAP (molar ratio 9:1) while positive microgels were 
coated with DPPC:DPPG:CHOL (molar ratio 4:1:5).  The lipid membrane and microgel core 
were fluorescently labeled with respectively 5 mol% rho-DOPE and FITC-PEG.  Scalebars 
represent 50 µm. 
 
Release from PEG based microgels. Figure 6 shows the release of FITC-
PEG from degrading PEG-HEMA, PEG-lac-HEMA and Â-PEG-HEMA microgels. 
The release from both lipid-coated as well as naked (i.e. without lipid coating) 
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microgels was investigated.  The inset tabulates the time it takes to release 
approximately 50% of the entrapped FITC-PEG (t1/2).     
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Figure 6. Release of FITC-PEG from degrading naked and lipid-coated PEG-HEMA (A), 
PEG-lac-HEMA (B) and Â-PEG-HEMA (C, DS 3.8) microgels with (S) neutral, (●) negative 
or () positive charge.  Negative microgels were coated with DOPC:DOTAP (molar ratio 9:1) 
while the positive ones were coated with DPPC:DPPG:CHOL (molar ratio 4:1:5).  100% 
release corresponds to the amount of FITC-PEG released at the end of the experiment, 
when the particles were completely degraded.   
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PEG-HEMA microgels deliver the encapsulated FITC-PEG over a period of 
approximately one month (Figure 6A1).  Generally speaking, as Figure 6A1 shows, 
the release of FITC-PEG from (neutral) PEG-HEMA, (negatively charged) PEG-
HEMA-MAA and (positively charged) PEG-HEMA-DMAEMA microgels occurs 
similarly.  Figure 6B1 shows that the release of FITC-PEG from neutral and charged 
PEG-lac-HEMA microgels is accomplished within hours, in agreement with the 
findings in Figure 3B which shows that PEG-lac-HEMA hydrogels degrade much 
faster than PEG-HEMA hydrogels.  Figure 6C1 shows the results of FITC-PEG 
release from Â-PEG-HEMA microgels.  The release from the positively charged Â-
PEG-HEMA microgels seems to occur much slower than from the corresponding 
neutral and negative Â-PEG-HEMA microgels.  
Figure 6A2, B2 and C2 shows the release of FITC-PEG from degrading lipid-
coated PEG-HEMA, PEG-lac-HEMA and Â-PEG-HEMA microgels.  The release of 
FITC-PEG from the lipid-coated PEG microgels seems similar to the release from the 
corresponding naked (i.e. non-coated) microgels (Figure 6A1, B1 and C1), indicating 
that the surrounding lipid membrane does not keep the FITC-PEG in the interior of 
the degrading PEG microgels. 
 
PEG based nanogels 
Synthesis of PEG-HEMA nanogels. As outlined in the introduction, as we 
are interested in degrading gel particles which can be taken up by cells for 
intracellular release of encapsulated drugs, we subsequently aimed to design PEG 
based nanogels, approximately one order of magnitude smaller than the PEG 
microgels described above.  In chapter 2 we reported on the synthesis of 
biodegradable dextran nanogels, of about 400 nm in size45.  We showed that lipid-
coated dextran nanogels can be prepared by UV polymerization of dex-HEMA 
containing liposomes which were obtained by hydrating a lipid film with a dex-HEMA 
solution.  “Naked” dextran nanogels (i.e. without lipid coating) were prepared by 
removing the lipid coating by TX 100. Using the liposome reactor technology, in this 
study we aimed to obtain PEG-HEMA nanogels.   
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Figure 7. Hydrodynamic diameter, as measured by DLS, of (A) SOPC coated PEG-HEMA 
nanogels and (B) naked PEG-HEMA nanogels stored in PB (pH 8.5) at 37°C.  To prepare the 
coated PEG-HEMA nanogels the SOPC lipid film was hydrated with a 20% (w/w) PEG-
HEMA solution.  To prepare the naked nanogels, the coated nanogels were exposed to TX 
100.  The shown data are the result of one set of experiments.  Repeated experiments 
revealed the same results.   
 
Figure 7A shows the outcome of DLS measurements on lipid-coated PEG-
HEMA nanogels stored in buffer (pH 8.5) at 37°C. The PEG-HEMA nanogels were 
obtained by hydrating a SOPC lipid film with a PEG-HEMA solution.  While the DLS 
measurements on the naked PEG-HEMA nanogels revealed that the naked nanogels 
get smaller in time (Figure 7B), clearly indicating degradation, we observed that the 
size of the lipid-coated nanogels (Figure 7A) did not decrease in time. One could 
wonder whether the PEG-HEMA gel in the lipid-coated particles did degrade. To 
examine this, we added TX 100 to the lipid-coated particles which were already in 
dispersion for 35 days. After removing the lipid coating, nanoparticles were no longer 
detected by DLS, proving that the nanogels in the interior of the liposomes were 
indeed degraded.  
 
BSA release from degrading PEG-HEMA nanogels.  We wondered whether 
(i) it is possible to load the PEG-HEMA nanogels with a model protein (BSA) and (ii) 
how the release of an encapsulated protein from PEG-HEMA nanogels looks like. 
Before measuring the release of BSA we characterized the BSA loaded PEG-HEMA 
nanogels by DLS.    
Figure 7A shows the outcome of DLS measurements on liposomes obtained 
by hydrating a SOPC lipid film with a PEG-HEMA solution containing BSA.  The 
PEG-HEMA filled liposomes are approximately 400 nm in size which is in accordance 
with the size of the pores of the used extrusion membrane, and show a rather narrow 
size distribution.  Also, polymerization of the PEG-HEMA/BSA solution to obtain lipid-
coated (BSA containing) PEG-HEMA nanogels did not alter the size and 
polydispersity of the particles (Figure 7B).  To obtain naked PEG-HEMA/BSA 
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nanogels the lipid coating was removed by adding TX 100.  Figure 7C shows the 
presence of about 400 nm sized naked PEG-HEMA/BSA nanogels, besides the 
presence of micelles (about 12 nm in size, as formed by TX 100 and SOPC lipids).   
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Figure 8. Size distribution, as measured by DLS, of SOPC coated PEG-HEMA nanogels 
loaded with BSA.  A 20% (w/w) PEG-HEMA solution was used to hydrate the SOPC lipid 
film.  (A) shows the SOPC liposomes before polymerization of the PEG-HEMA, (B) shows 
the SOPC coated PEG-HEMA nanogels after polymerization and (C) shows the particles 
after removal of the lipid coating. 
 
Figure 9 shows the release of BSA from degrading PEG-HEMA nanogels. The 
following observations are made.  First, the release of BSA starts immediately: after 
three days more than 50% of the BSA has been released.  Second, after 
approximately 7 days BSA release does no longer occur, although dex-HEMA 
nanogels could still be detected by DLS (even up to 35 days, see Figure 7B).  
Release from degrading hydrogel matrices may occur diffusion-controlled and/or 
degradation-controlled. Highly likely, the release of BSA from the PEG-HEMA 
nanogels is controlled by the degradation of the PEG-HEMA matrix. Cruise at al 
estimated the pore size of PEG-diacrylate hydrogels (4kDa, 20%, in which BSA could 
not permeate) to be 2.2 nm46. Subsequently we assume that the average pore size of 
the intact (i.e. not yet degraded) PEG-HEMA matrix in the nanogels is smaller than 
the size of BSA molecules (i.e. 7.2 nm5). When degradation proceeds, the average 
pore size increases resulting in release of BSA.  A third observation of Figure 9 is 
that the release of BSA from the lipid-coated and naked PEG-HEMA nanogels occurs 
similarly.  This is rather surprising since we observed in chapter 3 that BSA is not 
released from SOPC liposomes filled with a BSA solution8.  The following 
consideration may be important to explain our observations. First, degradation of a 
PEG-HEMA gel results in a PEG solution. As we showed in chapter 5, this raises the 
osmotic pressure35.  Subsequently, the increase in the osmotic pressure of the gel 
core in the lipid-coated PEG-HEMA nanogels may deform (and/or destroy) the lipid 
coating which allows the release of BSA into the medium.  
143 
SCREENING POLY(ETHYLENE GLYCOL) MICRO- AND NANOGELS FOR DRUG DELIVERY PURPOSES 
0 5 10 15 20 25 30 35 40
0
20
40
60
80
100
R
el
at
iv
e 
[%
]
Time [days]
 
Figure 9. Cumulative release of BSA from degrading PEG-HEMA nanogels with () or 
without (●) SOPC coating.  The lipid coating was hydrated with a 20% (w/w) PEG-HEMA 
solution.  100% release corresponds to the amount of BSA released when the nanogels were 
completely degraded (i.e. when nanogels could no longer be detected by DLS). 
 
CONCLUSIONS  
 
In this study PEG-HEMA, PEG-lac-HEMA and Â-PEG-HEMA hydrogels were 
investigated.  Rheological measurements on hydrogel slabs showed that PEG-lac-
HEMA matrices degrade very fast (in terms of days), while it takes about one month 
for linear PEG-HEMA and several months for Â-PEG-HEMA hydrogels to become 
degraded.  We showed that, under all aqueous conditions PEG-HEMA, PEG-lac-
HEMA and Â-PEG-HEMA microgels can be obtained by emulsion polymerization, 
making use of the principle of the immiscibility between dextran and PEG. Positively 
and negatively charged PEG microgels could be lipid-coated by mixing them with 
oppositely charged liposomes.  While the applied lipid coating did not influence the 
release of fluorescently labeled PEG from the microgels, the release was clearly 
influenced by the type of methacrylated PEG used (lasting from hours to months).  
Lipid-coated PEG-HEMA nanogels were obtained by UV polymerization of a PEG-
HEMA solution in the interior of liposomes.  While it took about 1 month for complete 
degradation of the PEG-HEMA nanogels, as measured by dynamic light scattering, 
encapsulated BSA was completely released after 7 days.   
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Background 
The last years the development of macromolecular drugs in the combat 
against hereditary sicknesses or cancer has gained much of attention.  Potential of 
these peptides, proteins or (oligo)nucleotides would be infinite, if it wasn’t for some 
major problems that showed up along the way.  
A first problem is the stability of these molecules once entered the body.  
Because of the presence of several enzymes and low pH (for example in the 
stomach), these therapeutic molecules are degraded and loose their therapeutic 
activity.   A second problem is that most of these medicines are aggressive and 
damage not only the target cells, but also the surrounding healthy cells causing 
severe side effects.  Last, the particles are removed too quick from the body: small 
particles are removed mostly by renal clearance, larger particles are taken up by 
phagocytosis.  As a results permanent administration or frequently repeated 
injections are necessary, causing patients incompliance. 
 
To cope with all these problems, several different carrier systems are under 
development last decade.  These drug delivery systems can bring the therapeutic 
molecules to a specific target during a sustained time interval.  Hydrogels are very 
suited for this purpose: they form a network from mutually cross-linked polymers and 
contain high amounts of water.  Especially biodegradable hydrogels are suited as a 
drug delivery system.  In the first place because no (surgical) intervention is needed 
to remove the system and in the second place because it is possible to govern the 
drug release from it by altering the cross-link density of the hydrogels.   
 
Many of the described molecules have intracellular targets, often in the 
nucleus.  To get there, the particles must meet some conditions. The most important 
criterium is that they must be small enough.  On the one hand the particles can be 
administered parenterally, they may not aggregate as this can block blood flow and 
they must be able to penetrate in cells.  Nanoscopic particles are most suited for this 
purpose.  On the other hand, particles can be administered locally, releasing the 
drugs over a sustained time interval without entering the bloodstream.  In this case, 
microscopic particles are most suited.   
Besides “being small enough” the particles must also fulfil some other criteria 
in order to be applicable: (i) they must encapsulate the therapeutic molecules in an 
efficient way without causing any damage during the production process, (ii) in the 
body, the encapsulated molecules must be protected against degradation and the 
particles may not aggregate, (iii) the therapeutic molecules must be released in an 
appropriate way, without burst release and of course (iv) the composing materials 
must be non-toxic and preferably biodegradable in the human body. 
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As mentioned earlier, many of these therapeutics are too toxic for “healthy” 
cells.  A possibility to save these cells is to encapsulate the active molecules in drug 
carrier systems and to target them directly to the target cells.  As a result, damage of 
healthy cells is avoided and less drugs have to be administered.  To types of 
targeting are known: active and passive targeting. 
As mentioned above, particles are removed from the bloodstream quickly by 
phagocytosis and the drugs will end up in the organs of the reticulo endothelial 
system (RES) like the liver, spleen and lymph.  When these organs were not the 
organs of interest, the drugs are lost and in addition liver, spleen and lymph can be 
severely damaged.   As a result, it would be appropriate to avoid phagocytic uptake.  
Phagocytes recognise foreign particles after binding of opsonines at the particles’ 
surface.  One of the most commonly used methods to avoid the binding of opsonines 
at the particles’ surface –and as a result camouflage the particles against 
phagocytosis- is by covering the particles’ surface with poly(ethylene glycol).  The 
particles can escape from the phagocytes and circulate longer in the bloodstream.  
Finally, they will escape from the bloodstream through leaky vasculature, which is 
typically for tumours, inflammation tissue or infarcted areas.  As a consequence, 
PEGylated particles will end up in this type of tissue.  This process is called passive 
targeting.  PEGylation has an additional advantage: the body hardly recognizes these 
foreign objects and almost no allergic or rejection reactions occur. 
A second way of targeting is the so-called active targeting.  The surface of the 
particles is provided with ligands that can only bind with receptors that reside on the 
surface of specific target cells.   
 
Particles that are large enough are taken up by endocytosis.  De content of the 
endosomes is degraded in the lysosomes.  It is well known however that PEGylated 
particles hardly escape from these endosomes and as a result they end up in 
lysosomes were they are degraded by enzymes before they have delivered their 
therapeutic content in the cytosol.  Hence it would be ideal if the nanogels could lose 
their PEGylated lipid coating after they are incorporated in the endosomes.  
Fortunately the endosomes show an intrinsic property which can help: the pH in the 
endosomes is much lower than in the rest of cell. 
 
In this thesis it was our intention to develop nanoscopic- and microscopic drug 
delivery systems composed of hydroxyethyl methacrylated dextran and poly 
(ethylene glycol) (respectively dex-HEMA and PEG-HEMA) in order to develop a 
sound formulation for long-term drug delivery.  Dex-HEMA and PEG-HEMA solutions 
form hydrogels upon radical polymerization: hydrolysable cross-links are formed.  
Hydrolysis of the formed hydrogel occurs under physiological conditions at the 
carbonate esters resulting in  dextran or PEG and some poly(HEMA) fragments.  The 
higher the amount of cross-links, the higher the cross-link density and the longer it 
takes to come to complete degradation of the hydrogels.  The cross-link density can 
be adapted simply by varying the number of HEMA groups on the dextran- or PEG 
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backbone.  This way hydrogels can be prepared, entrapping drug molecules in their 
polymer lattice, releasing the drugs rapidly or slowly- depending on the cross-link 
density. 
Moreover we wanted provide these nano- and microgels with a lipid coating.  
This can be a convenient tool to adapt the hydrogel surface.  First PEGylated lipids 
can be inserted to make particles which are possible to escape from phagocytes.  
Secondly, pH sensitive lipids can be inserted.  This way the (PEGylated) lipid coated 
particles can loose their coat after they arrive in the acidic environment of the 
endosomes and as a consequence it is easier to escape to the cytosol before they 
are degraded in the lysosome.  A last possibility, which was not carried out in this 
work, is inserting lipids conjugated with specific ligands that can only bind to specific 
target cells. 
In this work some physicochemical properties of PEG were studied too, since 
it proposes of some properties that are -to our opinion- ideal to make it as a 
nanoscopic or microscopic drug delivery system.  Some new polymerizable PEG 
molecules were prepare with this aim. 
 
Summary 
In the first chapter an overview is given of the published literature concerning 
sustained drug delivery from nanosized matter.  Both liposomes and nanoscopic 
hydrogel systems were discussed.  Liposomen are hollow lipid vesicles filled with 
water.  This unique structure offers the possibility to accommodate both hydrophilic 
and hydrophobic molecules, respectively in the aqueous core and in the lipid shell 
(see chapter 1 Figure 1).  Drug molecules escape generally from the liposomes by 
diffusion.  At present liposomal formulations for the sustained delivery of some 
chemotherapeutics are already FDA approved and several others are in the pipe line 
to commercial use.    
Nanogels on the other hand are no hollow structures, but are formed by a 
network of polymers filled with water in which drugs can be included.  (see chapter 1 
Figure 3).  Consequently they can hold more molecules and the release can be 
controlled more easily.  A wide range of different materials has been used to produce 
nanogels, ranging from synthetic polymers, among which poly(lactate-co-glycolide) is 
by far used, to some naturally occurring sugars like for example chitosan.   
Moreover, it is possible to provide nanogels with a coating which can do 
service as extra barrier against burst release or can help with active or passive 
targeting.  Some examples of coated nanogels were also discussed in the first 
chapter. 
 
In the second chapter we describe how nanoscopic particles can be 
produced which are mainly composed of dextran.  These nanogels are produced 
making use of liposomes as a nanoscopic mould: the liposomen are filled by 
hydrating a lipid film with a polymerizable dex-HEMA solution.  Afterwards dex-HEMA 
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is cross-linked by means of UV.  The result is a dextran nanogel surrounded by a 
double lipid layer, which was shown by dynamic light scattering, atomic force 
microscopy and electron microscopy.  Moreover the lipid layer can be removed from 
the nanogels by adding a detergent.  As discussed above, dex-HEMA hydrogels 
contain hydrolysable carbonate esters.  It was shown by means of dynamic light 
scattering that these nanogels degrade also under physiological circumstances and –
by increasing the cross-link density- the particles degraded during 5 up to 18 days.  
As our aim was to make a drug delivery systems which delivers its content 
intracellularly, it was also evaluated whether these particles can be taken up by cells.  
By means of confocale microscopy we could confirm that coated nanogels are 
indeed taken up VERO cells. 
 
In the third chapter it is described how model proteins, bovine serum albumin 
(BSA) and lysozyme, can be included in both the coated and naked nanogels.  This 
was done by administering them to the polymer solution that was used to hydrate the 
lipid film.  Afterwards the solution was polymerized in the cavity of the liposomes and 
as a result the proteins were included in the dex-HEMA nanogels.  When degradation 
occurs, the cross-links detach and the pores of the network enlarge. When the pores 
become larger than the dimensions of the included proteins, these proteins are 
released in the surrounding medium.  The release rate of the included molecules 
depends on the size of the molecule, on the cross-link density of the nanogel and on 
the presence of a lipid coating around the nanogels, provided that the incorporated 
molecules are sufficiently large.  A disadvantage of this system is that the proteins 
are already present during the polymerization process.  However we found out that 
lysozyme could preserve up to 75% of its original activity.  With a view to long-term 
storage we freeze-dried the nanogels and showed that this has no influence on the 
degradation profile of the particles.  It is also of vital importance that the nanogels do 
not aggregate in the body, as this can cause obstruction in the blood capillaries.  To 
examine this the behaviour of coated nanogels in human serum was examined.  
When the nanogels are sufficiently diluted, the particles did not aggregate. 
 
As already mentioned above, drug delivery systems for parenteral 
administration are often provided with a PEG coating, this to avoid rapid removal 
from the blood by phagocytosis.  In the fourth chapter PEGylated dex-HEMA 
nanogels were prepared by use of liposomes in which PEGylated lipids were 
incorporated (chapter 4 Figure 2).  The surface charge of these particles is lower 
than particles without a surrounding (neutral) PEG layer, which can be explained by 
the screening effect of the PEG molecules.  This reduced surface charge, however, 
caused a somewhat lower binding to the cell membrane, the first step in the process 
of endocytosis.  Fortunately, it was also shown that this reduced cell binding has 
hardly any influence on the cellular uptake of the particles: PEGylated nanogels are 
taken up as efficient as non-PEGylated particles by VERO and RPE cells.  Besides, 
the PEGylated particles do not show aggregation in human serum.  It was already 
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mentioned that PEGylated particles hardly escape from the endosomes, and as a 
result they often end up in the lysosomes were they are enzymatically degraded.  For 
this reason nanogels were developed with pH sensitive PEGylated lipid coating.  The 
pH sensitive lipid is a synthetic diplasmenylcholine that is hydrolysed at pH 4-5 
producing free fatty acids.  These fatty acids ensure that the lipid coating is 
destabilised and detaches from the nanogels (see chapter 4 Figure 4), which was 
shown visually as well as by dynamic light scattering. 
 
In the fifth chapter PEG was examined as a possible polymer to produce 
drug delivery systems.  The reason to examine PEG is that our research group 
developed earlier ‘exploding dex-HEMA microgels’ (see chapter 5 Figure 1).  These 
microgels exist of a dex-HEMA core surrounded by a lipid or polymeric shell.  During 
degradation of dex-HEMA the osmotic pressure is build up.  Initially this pressure 
remains fairly low, but at the end it shows a sudden increase.  When microgels 
composed of dex-HEMA and surrounded by a lipid or polymeric shell are produced, 
this remarkable pressure profile of dex-HEMA causes a sudden rupture of the 
surrounding coating and as a result the included drug molecules are released 
suddenly.  To avoid that the included molecules are released too rapidly (due to 
leaking for example), it is necessary to use strong membranes, but the pressure 
needed to rupture these membranes is often not reached by dex-HEMA.  It is well 
known that the osmotic pressure of PEG is higher than the osmotic pressure of 
dextran.  Hence ours interest in PEG: when higher osmotic pressure is reached, also 
stronger membranes can be disrupted.  In analogy with dex-HEMA also PEG was 
provided with a polymerizable group, resulting in hydroxyethyl methacrylated PEG 
(PEG-HEMA). 
To examine the pressure profile of PEG-HEMA, an earlier described method 
was used.  In this method, non degraded PEG-HEMA hydrogels containing free PEG 
(degradation product) were used to mimic degrading PEG-HEMA hydrogels.  This 
way it was shown that degrading PEG-HEMA hydrogels show similar osmotic 
behaviour as dex-HEMA, but much higher pressure peaks were recorded.   
To obtain a better insight in the contribution of free chains to the osmotic 
pressure we have examined the impact of the molecular weight of the free chains in 
dex-HEMA and PEG-HEMA hydrogels.  We revealed that the difference between the 
contributions of network chains and free chains to the osmotic pressure decreases 
with increasing molecular weight.  Higher molecular weight free chains behave as 
network chains. 
 
In chapter six both microscopic and nanoscopic hydrogel particles were made 
composed of PEG.  Two new polymerizable PEG polymers were produced: on the 
one hand PEG-lactate-HEMA, which degrades more rapidly than PEG-HEMA thanks 
to its lactate spacer and on the other side star-shaped PEG-HEMA (Â-PEG-HEMA).  
This eight armed molecule was provided with polymerizable hydroxyethyl 
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methacrylate.  This way Â-PEG-HEMA contains more polymerizable groups then 
PEG-HEMA and the corresponding hydrogels degrade significantly slower.   
By means of emulsion polymerization it is possible to produce PEG-HEMA, 
PEG-lac-HEMA and Â-PEG-HEMA microgels.   When they are co-polymerized with 
a positive or negative charged methacrylate we can provide them with a lipid coating.  
The coating process is based on electrostatic interactions between the charged 
microgels and the opposed charged lipid membrane.  The lipid coated microgels 
could be visualised by means of confocal microscopy.  To examine the ability of 
these (lipid coated) PEG microgels as a drug delivery system, the release profile of 
FITC-PEG was evaluated.  Encapsulated molecules are released fastest when the 
microgels were made of PEG-lac-HEMA: already after some hours the release has 
been completed.  Â-PEG-HEMA microgels on the other hand deliver their content 
slowest: the release of FITC-PEG lasts for a month.  PEG-HEMA microgels release 
their content during a almost three weeks.  Although the lipid coating has hardly any 
influence on the release profile, it might be convenient to provide the microgels with a 
coating as described in chapter 4. 
In analogy with dex-HEMA nanogels described in chapter 2-4, PEG-HEMA 
nanogels are also made based on the same method: a lipid film was hydrated with a 
PEG-HEMA a solution and afterwards polymerized by use of UV.  When compared to 
dex-HEMA nanogels, the degradation of PEG-HEMA nanogels is much slower, which 
was also seen on macroscopic scale in chapter 5: complete degradation of the 
nanogels takes 35 days.  Encapsulated BSA is more rapidly released than expected: 
after 7 days all included BSA has been released. 
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Achtergrond 
De laatste jaren is de ontwikkeling van macromoleculaire geneesmiddelen in 
de strijd tegen erfelijke ziekten, kanker of hart- en vaatziekten enorm toegenomen.  
Het potentieel van deze peptiden, eiwitten of (oligo)nucleotiden zou haast oneindig 
zijn, ware het niet dat er zich nog verschillende problemen voordoen.   
Een eerste probleem schuilt in de stabiliteit van het geneesmiddel wanneer 
het toegediend wordt in het lichaam.  Door de aanwezigheid van enzymen of door 
een verlaagde pH (bijvoorbeeld in de maag) worden deze therapeutische moleculen 
afgebroken en als gevolg onbruikbaar.  Een tweede probleem is dat bepaalde 
geneesmiddelen agressief zijn en niet alleen het doelweefsel beschadigen, maar ook 
alle andere cellen die ze op hun weg tegenkomen en daardoor voor ernstige 
neveneffecten kunnen zorgen.  Ten slotte worden deze geneesmiddelen zeer snel uit 
het lichaam verwijderd: wanneer ze voldoende klein zijn gebeurt dit voornamelijk 
door renale klaring, grotere moleculen worden vaak opgenomen door fagocyterende 
cellen.  Bijgevolg zijn continue toediening of toediening via herhaalde injecties 
noodzakelijk, en dit tot ongemak van de patiënt. 
 
Om al deze problemen het hoofd te kunnen bieden, zijn er de laatste decennia 
verschillende dragersystemen voor macromoleculaire farmaca ontwikkeld die in staat 
zijn het geneesmiddel doelgericht af te geven aan een bepaald celtype en dit 
bovendien doen over een bepaalde tijdspanne.  Voor de vervaardiging van deze 
dragersystemen zijn hydrogels zeer geschikt.  Hydrogels bestaan uit een netwerk 
gevormd door onderling verbonden polymeren die een grote hoeveelheid water 
vasthouden.  Vooral biodegradeerbare hydrogels zijn geschikt als afgiftesysteem.  
Ten eerste omdat ze, dankzij hun degradeerbaarheid, niet (chirurgisch) verwijderd 
moeten worden, en ten tweede omdat het mogelijk is om de vrijstelling van de 
ingesloten geneesmiddelen te sturen, onder andere via het aanpassen van de 
vernettingsdichtheid.   
 
Veel van de beschreven macromoleculaire geneesmiddelen moeten in de cel 
terechtkomen, heel vaak zelfs in de celkern.  Om hier te geraken moeten de 
afgiftesystemen aan verschillende voorwaarden voldoen.  De voornaamste 
voorwaarde is dat ze klein genoeg moeten zijn.  Enerzijds kunnen de partikels 
parenteraal toegediend worden en dan moeten ze in de bloedbaan kunnen circuleren 
zonder verstoppingen te veroorzaken en kunnen binnendringen in de cellen.  
Hiervoor zijn nanoscopisch kleine deeltjes het meest geschikt.  Anderzijds kunnen de 
partikels lokaal worden toegediend, daar blijven zonder in de bloedbaan terecht te 
komen en het geneesmiddel gedurende lange tijd vrijgeven.  Microscopisch kleine 
deeltjes zijn hiervoor meer geschikt.   
Naast “voldoende klein zijn” moeten deze afgiftesystemen nog aan enkele 
andere criteria voldoen om toepasbaar te zijn: (i) ze moeten de geneesmiddelen 
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efficiënt insluiten zonder ze te beschadigen tijdens het productieproces, (ii) in het 
lichaam moeten de ingesloten geneesmiddelen beschermd worden tegen afbraak en 
de partikels mogen niet aggregeren, (iii) de geneesmiddelen moeten op een 
geschikte manier vrijgesteld worden, zonder initieel een verhoogde vrijstelling te 
vertonen en uiteraard (iv) mag het materiaal waaruit de drager gemaakt is niet 
toxisch zijn en bij voorkeur afbreekbaar in het lichaam.   
 
Zoals reeds eerder gesteld zijn vele geneesmiddelen te toxisch voor 
“gezonde” cellen en het is bijgevolg van groot belang om deze zoveel mogelijk te 
sparen.  Een mogelijkheid is om de actieve stof te encapsuleren en ze specifiek naar 
de doelcellen te richten.  Op deze manier worden niet alleen nefaste gevolgen 
vermeden voor gezonde cellen, maar moet ook minder geneesmiddel worden 
toegediend.  Dit zogenaamde targetten kan op verschillende manieren gebeuren: 
passief of actief.   
Zoals reeds beschreven zullen partikels die zich in de bloedbaan bevinden 
snel uit het lichaam verwijderd worden door fagocytose en zullen de ingesloten 
geneesmiddelen bijgevolg in de organen van het reticulo endotheliaal stelsels (RES) 
zoals de lever, de milt of het lymfesysteem terechtkomen.  Wanneer dit niet de 
doelcellen waren, is het geneesmiddel onherroepelijk verloren en kunnen deze 
organen bovendien schade oplopen.  Het zou dus ideaal zijn, mocht het mogelijk zijn 
om het proces van fagocytose te vermijden.  Fagocyterende cellen herkennen 
lichaamsvreemde objecten doordat zogenaamde opsonines binden aan het 
oppervlak van deze partikels.  Eén van de meeste gebruikte manier om het binden 
van deze opsonines te verhinderen -en aldus de partikels te camoufleren voor 
fagocyten- is het oppervlak van de partikels bedekken met poly(ethyleen glycol) 
(PEG).  Zodoende krijgen de partikels de kans om te ontsnappen aan fagocyten en 
kunnen ze langer in de bloedbaan circuleren.  Daarna kunnen ze eruit ontsnappen 
via fenestrae (“gaatjes”) in de vasculatuur, hetgeen typisch voorkomt bij tumoren of 
beschadigd weefsel.  Bijgevolg zullen gePEGyleerde partikels uiteindelijk 
terechtkomen in het doelweefsel.  Dit noemt men passief targetten.  PEGyleren van 
partikels heeft een bijkomend voordeel: het lichaam herkent deze vreemde objecten 
nagenoeg niet en bijgevolg treden er weinig allergische reacties of 
afstotingsverschijnselen op.   
Een tweede manier om enkel doelcellen te bereiken is via het zogenaamde 
actief targetten.  Het oppervlak van de partikels wordt voorzien met bepaalde 
liganden die binden met receptormoleculen die specifiek voorkomen op het 
oppervlak van doelcellen.   
 
Partikels die voldoende groot zijn, worden door de cel opgenomen via 
endosomen.  De inhoud van de endosomen wordt afgebroken in de lysozomen.  Nu 
is het al een tijdje bekend dat gePEGyleerde partikels moeilijk ontsnappen uit 
endosomen, waardoor ze vaak eindigen in lysozomen en bijgevolg de bio-actieve 
moleculen  afgebroken zijn nog voor hun vrijgave in de cel.  Vandaar dat het ideaal 
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zou zijn, mochten de nanogels hun gePEGyleerde lipid coating verliezen nadat ze 
opgenomen zijn in de endosomen.  Gelukkig vertonen de endosomen een intrinsieke 
eigenschappen die hierbij kan helpen: de pH in het endosoom is veel lager dan in de 
rest van de cel.     
 
In deze thesis was het de bedoeling om nanoscopische en microscopische 
dragersystemen van hydroxyethyl gemethacryleerd dextraan en poly(ethyleen 
glycol), respectievelijk dex-HEMA en PEG-HEMA genoemd, te bestuderen met het 
oog op de ontwikkeling van een degelijke formulatie voor vertraagde 
geneesmiddelen vrijgave.  Dex-HEMA en PEG-HEMA oplossingen kunnen 
gepolymerizeerd worden onder invloed van radicalen.  Ze vormen hydrogels die 
afbreken onder fysiologische omstandigheden: ter hoogte van de carbonaatesters 
komen de knooppunten los en wordt dextraan en kleine fragmenten poly(HEMA) 
vrijgesteld.  Hoe sterker de hydrogels vernet zijn, hoe te langer het duurt om de gels 
volledig af te breken.  De vernettingsgraad kan eenvoudig worden aangepast door 
het aantal HEMA groepen op het polymeer te laten variëren.  Op die manier kunnen 
hydrogels ontwikkeld worden waarin geneesmiddelen ingesloten zitten die –
afhankelijk van de vernettingsgraad- traag of snel worden afgegeven. 
We wilden bovendien deze nano- en microgels van een lipid coating voorzien.  
Dit kan een handig hulpmiddel zijn om het oppervlak van de gels naar wens aan te 
passen.  Ten eerste kunnen er gePEGyleerde lipiden ingevoegd worden om 
gePEGyleerde partikels te maken, die kunnen ontsnappen een de fagocyterende 
cellen.  Ten tweede kunnen pH gevoelige lipiden ingevoegd worden.  Op deze 
manier kan de (gePEGyleerde) lipid coating loskomen van de partikels wanneer ze in 
het endosoom terecht komen en kunnen de deeltjes hierdoor gemakkelijker 
onsnappen zonder afgebroken te worden in het lysozoom.  Een laatste mogelijkheid, 
die hier niet uitgevoerd werd, is het invoegen van lipiden waarop liganden gebonden 
zijn die binden aan specifieke receptoren die enkel op de doelcellen voorkomen. 
In dit werk werden ook enkele fysicochemische eigenschappen van PEG 
bestudeerd, aangezien het  naar onze mening enkele eigenschappen vertoont die 
het tot een ideaal materiaal maken voor gebruik als afgiftesysteem.  Met dit doel  
werden enkele nieuwe polymerizeerbare PEG moleculen aangemaakt.  
 
Samenvatting 
In het eerste hoofdstuk wordt een overzicht gegeven van de reeds 
verschenen literatuur over vertraagde vrijstelling van geneesmiddelen uit 
nanoscopische systemen.  Zowel liposomen als nanoscopische hydrogel systemen 
werden besproken.  Liposomen zijn holle vesikels gevuld met water met een wand 
die bestaat uit een dubbele lipidenlaag.  Deze unieke structuur biedt de mogelijkheid 
om zowel hydrofiele als hydrofobe moleculen te herbergen, respectievelijk in de 
waterige kern en in de wand (zie hoofdstuk 1 Figuur 1).  De geneesmiddelen 
ontsnappen doorgaans uit de liposomen door diffusie.  Momenteel zijn er reeds 
157 
ACHTERGROND & SAMENVATTING 
liposoom formulaties in gebruik voor de toediening van chemotherapeutica en 
verschillende andere geneesmiddelen zitten in de pijplijn naar commercieel gebruik.    
Nanogels daarentegen zijn geen holle structuren, maar bestaan uit een 
netwerk van polymeren gevuld met water waarin geneesmiddelen kunnen worden 
ingesloten.  Bijgevolg kunnen ze veel méér moleculen vasthouden en de vrijgave 
ervan kan gemakkelijker gestuurd worden.  Er is een waaier van verschillende 
materialen gebruikt om nanogels te produceren, gaande van synthetische 
polymeren, waaronder poly(lactaat-co-glycolide) veruit het meest gebruikt wordt, tot 
natuurlijk voorkomende suikers zoals chitosan.   
Nanogels kunnen bovendien voorzien worden van een coating die dienst kan 
doen als extra barrière tegen vervroegde vrijstelling of die kan helpen bij actieve of 
passieve targetting.  Ook hiervan werden enkele voorbeelden besproken in het 
eerste hoofdstuk.   
 
In het tweede hoofdstuk wordt beschreven hoe nanoscopische partikels 
kunnen aangemaakt worden die voornamelijk bestaan uit dextraan.  Deze nanogels 
worden gemaakt gebruik makende van liposomen als gietvorm: de liposomen 
worden gevuld door een lipide film te hydrateren met een polymerizeerbare dex-
HEMA oplossing.  Nadien worden ze vernet met behulp van UV bestraling.  Als 
resultaat worden dextraan nanogels bekomen, omgeven door een dubbele lipid laag, 
hetgeen werd aangetoond door dynamische lichtverstrooiing, atomic force 
microscopy en elektronen microscopie.  De lipid laag kan bovendien van de nanogels 
verwijderd worden door het toevoegen van een detergent.  Zoals hierboven 
besproken bevatten dex-HEMA hydrogels hydrolyse gevoelige carbonaat esters.  Via 
dynamische lichtverstrooiing werd nagegaan of deze nanogels ook afbreken onder 
fysiologische omstandigheden.  Dit was inderdaad het geval en door verhoging van 
de vernettingsgraad kon de degradatieperiode waarover de partikels afbraken 
verlengd worden van 5 tot 18 dagen.  Aangezien het de bedoeling is om 
afgiftesystemen te maken die het geneesmiddel uiteindelijk in de cel afgeven, werd 
ook geëvalueerd of deze partikels werden opgenomen door cellen.  Via confocale 
microscopie werd bevestigd dat gecoate nanogels inderdaad worden opgenomen 
door VERO cellen.   
 
In het derde hoofdstuk wordt beschreven hoe modeleiwitten, BSA en 
lysozyme, kunnen worden ingesloten in zowel de gecoate als in de niet gecoate 
nanogels.  Dit lukt door ze toe te dienen aan de polymeeroplossing waarmee de lipid 
film gehydrateerd wordt.  Daarna wordt de oplossing gepolymerizeerd binnenin het 
liposoom en zitten de eiwitten ingesloten in het dex-HEMA netwerk.  Wanneer 
degradatie optreedt van dit netwerk en de mazen groter worden dan de afmetingen 
van de ingesloten eiwitten, komen deze eiwitten vrij.  De vrijstelling van de ingesloten 
moleculen is afhankelijk van de grootte van het molecule, van de vernettingsgraad 
van de nanogel en van de aanwezigheid van een lipid coating rond de nanogels, op 
voorwaarde dat de ingesloten moleculen voldoende groot zijn.  Een nadeel van deze 
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manier van insluiten is dat de eiwitten reeds aanwezig zijn tijdens het 
polymerizatieproces.  Nochtans konden we aantonen dat lysozyme tot 75% van zijn 
originele activiteit kan behouden.  Met het oog op langdurige opslag konden we ook 
aantonen dat vriesdrogen een optie is.  De degradatie-eigenschappen van de 
nanogels veranderen hierdoor niet.  Het is ook van cruciaal belang dat de nanogels 
niet gaan aggregeren eens ze in het lichaam zitten, dit zou immers verstopping van 
bloedvaten kunnen veroorzaken.  Om dit na te gaan werd het gedrag van gecoate 
nanogels in humaan serum nagegaan.  Wanneer de nanogels voldoende verdund 
zijn, treedt geen aggregatie op.   
 
Zoals hierboven beschreven worden parenteraal toegediende dragersystemen 
vaak voorzien van een PEG coating, dit om te vermijden dat ze te snel uit de 
bloedbaan verwijderd zouden worden.  In het vierde hoofdstuk worden dex-HEMA 
nanogels aangemaakt die voorzien zijn van een PEG coating.  Dit gebeurt door in de 
gebruikte liposomen lipiden in te sluiten waaraan een PEG staart gekoppeld is.  De 
oppervlaktelading van deze partikels is lager dan van partikels waar geen PEG 
coating rond zit, wat verklaard wordt door het afschermend effect van de neutrale 
PEG laag.  Deze verminderde oppervlakte lading zorgt er wel voor dat de partikels 
minder goed binden aan het oppervlak van cellen, de eerste stap in het proces van 
endocytose.  Gelukkig kon ook worden aangetoond dat deze verminderde binding 
nauwelijks invloed heeft op de opname van de partikels: gePEGyleerde nanogels 
worden net zo efficiënt opgenomen door VERO en RPE cellen als niet 
gePEGyleerde nanogels.  Ze vertonen ook geen aggregatie in serum.  Er werd 
eerder al vermeld dat gePEGyleerde partikels moeilijk ontsnappen uit het endosoom, 
waardoor ze uiteindelijk in de lysozomen belanden en afgebroken worden.  Daarom 
werden nanogels ontwikkeld met een pH gevoelige gePEGyleerde lipid coating.  Bij 
zure pH (zoals in het endosoom) komt de lipid coating los en zijn de partikels 
bijgevolg ge-dePEGyleerd.  Hiertoe werden synthetisch aangemaakte 
diplasmenylcholines ingesloten.  Deze pH gevoelige lipiden breken af bij pH 4-5 en 
stellen vetzuren vrij.  Deze vetzuren zorgen ervoor dat de lipid coating 
gedestabiliseerd wordt en loskomt, wat zowel door dynamische lichtverstrooiing als 
visueel kon worden aangetoond. 
 
In het vijfde hoofdstuk werd PEG onderzocht als mogelijk polymeer om 
geneesmiddelenafgiftesystemen te maken.  De reden dat PEG onderzocht wordt is 
omdat door onze onderzoeksgroep reeds eerder exploderende dex-HEMA microgel 
partikels werden onderzocht.  Deze micropartikels bestaan uit een dex-HEMA kern 
en zijn omgeven door een lipid of polymeer membraan (zie hoofdstuk 6 Figuur 1).  
Tijdens degradatie van dex-HEMA wordt een osmotische druk opgebouwd.  Initieel 
blijft deze druk tamelijk laag, maar op het einde vertoont deze een plotse stijging.  
Van dit merkwaardig drukprofiel van dex-HEMA wordt gebruik gemaakt om de lipid 
coating plots te doen barsten, waardoor ingesloten geneesmiddelen in één keer 
worden vrijgesteld.  Om te vermijden dat ingesloten moleculen te snel vrijgesteld 
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worden door defecten in het membraan, is het nodig om voldoende stevige 
membranen te gebruiken.  Vaak is de druk die bereikt wordt door degraderende dex-
HEMA hydrogels onvoldoende.  Het is bekend dat PEG hogere osmotische drukken 
vertoont in oplossing dan dextraan.  Vandaar onze interesse in PEG: wanneer 
hogere osmotische drukken bereikt worden, kunnen ook sterkere membranen 
gebroken worden.  Naar analogie met dex-HEMA wordt ook PEG voorzien van een 
polymerizeerbare groep wat resulteert in hydroxyethyl methacrylaat PEG (PEG-
HEMA).   
Om het zweldruk profiel op te stellen van PEG-HEMA werd een reeds eerder 
gepubliceerde manier gebruikt om degraderende gels na te bootsen met behulp van 
niet gedegradeerde PEG-HEMA gels die verschillende hoeveelheden vrij PEG 
(afbraakproduct) bevatten.    Op deze manier werd aangetoond dat PEG-HEMA een 
gelijkaardig osmotisch drukprofiel vertoont als dex-HEMA, maar veel hogere 
“drukpieken” vertoont dan dextraan.   
Om een beter inzicht te krijgen in de bijdrage van vrije ketens aan de 
osmotische druk zijn we nagegaan wat is van het effect van het moleculair gewicht 
van de vrije ketens in dex-HEMA en PEG-HEMA hydrogels.   We ontdekten dat het 
verschil tussen de bijdrage van netwerk ketens en vrije ketens tot de osmotische 
druk afneemt als het moleculair gewicht van de vrije ketens afneemt.  Of eenvoudiger 
gezegd: vrije ketens met een hoog moleculair gewicht gedragen zich als netwerk 
ketens. 
 
In hoofdstuk zes worden zowel microscopische als nanoscopische hydrogel 
partikels gemaakt uitgaande van PEG.  Er werden twee nieuwe polymerizeerbare 
PEG moleculen aangemaakt: enerzijds PEG-lactaat-HEMA, dat dankzij zijn lactaat 
spacer sneller afbreekt dan PEG en anderzijds stervormige PEG-HEMA (Â-PEG-
HEMA).  Deze “ster” heeft 8 armen en aan het uiteinde van elke arm wordt een 
hydroxyethyl methacrylaat groep gekoppeld.  Op deze manier bevat Â-PEG-HEMA 
meer polymerizeerbare groepen en breken de overeenkomstige hydrogels 
beduidend trager af in vergelijking met PEG-HEMA.   
Via emulsiepolymerizatie is het mogelijk om microgels te maken van zowel 
PEG-HEMA, PEG-lac-HEMA en Â-PEG-HEMA. Wanneer we ze co-polymerizeren 
met een positief of negatief geladen methacrylaat kunnen we ze bovendien voorzien 
van een lipid coating.  De lipid coating is gebaseerd op elektrostatische interactie 
tussen de geladen microgels en het tegenovergesteld geladen lipid membraan.  De 
lipid gecoate microgels konden gevisualiseerd worden via confocale microscopie.  
Om de mogelijkheid na te gaan om deze (lipid gecoate) PEG microgels te gebruiken 
als afgiftesysteem voor geneesmiddelen, werd het vrijstellingsprofiel van FITC-PEG 
geëvalueerd.  Ingesloten moleculen worden het snelst vrijgesteld door microgels 
gemaakt uit PEG-lac-HEMA: reeds na enkele uren is de vrijstelling voltooid.  Â-PEG-
HEMA microgels daarentegen geven hun inhoud het traagste af: de vrijstelling van 
FITC-PEG duurt een maand.  PEG-HEMA stelt zijn inhoud vrij gedurende een drietal 
weken.  Hoewel de lipidcoating blijkbaar nauwelijks invloed heeft op het 
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vrijstellingsprofiel, zou het gebruik ervan wel handig kunnen zijn om de microgels te 
voorzien van een functionele coating zoals beschreven in hoofdstuk 4. 
Naar analogie met dex-HEMA nanogels beschreven in hoofdstukken 2 tot 4, 
worden ook PEG-HEMA nanogels gemaakt op dezelfde methode: een lipid film wordt 
gehydrateerd met een PEG-HEMA oplossing en daarna gepolymerizeerd met UV.  
De degradatie van PEG-HEMA nanogels verloopt veel trager, wat we ook reeds 
vaststelden op macroscopische schaal in hoofdstuk 5: volledige degradatie duurt 35 
dagen.  Ingesloten BSA wordt sneller vrijgesteld dan verwacht: na 7 dagen is alle 
ingesloten BSA vrijgesteld.   
161 
 
CURRICULUM VITAE 
CURRICULUM VITAE 
 
Personalia 
 
ir. Tinneke Van Thienen 
geboren te Dendermonde op 07/02/1979  
1 zoontje Toon, geboren op 10/09/2006 
gehuwd met Bert Noseda op 24/03/2007 
 
Studies 
 
SECUNDAIR ONDERWIJS 
1997:  Latijn-Wetenschappen aan de Heilige Familie te Sint Niklaas. 
 
UNIVERSITAIRE OPLEIDINGEN 
1999:  kandidaat-Bio-ingenieur, behaald met onderscheiding (Ugent) 
2002:  Bio-ingenieur in de scheikunde, behaald met onderscheiding (Ugent) 
  Thesis: Ringtransformaties van gesubstituteerde cyclobutanonen  
  (promotor: Prof. dr. ir. N. De Kimpe, vakgroep Organische Chemie) 
 
2006: Geaggregeerde voor het secundair onderwijs in de toegepaste biologische 
wetenschappen (Ugent), behaald met onderscheiding 
 
Loopbaan 
 
2003-2007:  Doctoraatsstudent, IWT-mandaat (1 september 2003 tot 13 mei 2007) 
 Laboratorium Algemene Biochemie en Fysische Farmacie 
 Faculteit Farmaceutische Wetenschappen 
 Universiteit Gent 
 Promotoren: Prof. J. Demeester en Prof. S.C. De Smedt   
2007-... R&D specialist bij Vyncolit, Gent 
163 
CURRICULUM VITAE 
Studieverblijven in het buitenland 
 
Synthese van dex-HEMA, PEG-HEMA en PEG-lac-HEMA (Prof. W.E. Hennink, RUU, 
Utrecht, Nederland) 
 
Aanmaak pH gevoelige lipiden (Prof. D. Thompson, Purdue University, West Lafayette, 
USA). (14-29 januari 2006) 
 
Deelname aan congressen 
 
Niet actieve deelname: 
13 december 2002: Belgian-Dutch Biofarmacy Day in Leuven 
19-23 Juli 2003: 30th Annual Meeting of the Controlled Release Society in 
Glasgow, Scotland 
 
Actieve deelname: 
6-9 Maart 2004: “Lipid coating of degrading hydrogel microparticles for drug delivery” 
(poster) 
 Particles 2004 in Orlando, Florida, USA 
3 december 2004: “Synthesis and characterization of biodegradable nanogels” (poster) 
 Belgian-Dutch Biofarmacy Day in Oss, Nederland 
20 mei 2005: “Polysaccharide Nanogels with tunable Degradation properties” 
(lezing) 
 Belgian-Dutch Biofarmacy Day in Gent 
7 maart 2006:  “New Drug Delivery Opportunities for Micro- and Nanogels?” (lezing) 
 Cell culture and in vitro models for drug absorption and delivery 
in Saarbrucken, Duitsland 
5-7 april 2006:  “On the synthesis and characterization of biodegradable dextran 
nanogels with tunable degradation properties” (poster)  
 9th European Symposium on Controlled Drug Delivery in 
Noordwijk Aan Zee, Nederland  
13-16 mei 2006:  “On the synthesis and characterization of biodegradable dextran 
nanogels with tunable degradation properties” (lezing) 
 Particles 2006 in Orlando, Florida, USA 
164 
LIST OF PUBLICATIONS 
LIST OF PUBLICATIONS 
 
 (1) Van Thienen, T. G.; Raemdonck, K.; Demeester, J.; De Smedt, S. C. Protein 
release from biodegradable dextran nanogels. Langmuir 2007, 23, 9794-
9891.  
 (2) Van Thienen, T. G.; Vercauteren, D.; Van den Bossche, J.; Thompson, D. 
H.; Demeester, J.; De Smedt, S. C. Dextran nanogels with functional 
coatings: PEG-lipid-coated and pH sensitive lipid-coated nanogels. 
Pharmaceutical Research 2007, submitted.  
 (3) Van Thienen, T. G.; Demeester, J.; De Smedt, S. C. Screening 
poly(ethyleneglycol) micro- and nanogels for drug delivery purposes. 
International Journal of Pharmaceutics 2007, accepted for publication. 
 (4) Van Thienen, T. G.; Horkay, F.; Braeckmans, K.; Stubbe, B. G.; Demeester, 
J.; De Smedt, S. C. Influence of free chains on the swelling pressure of PEG-
HEMA and dex-HEMA hydrogels. International Journal of Pharmaceutics 
2007, 337, 31-39. 
 (5) Van Thienen, T. G.; Lucas, B.; Flesch, F. M.; Van Nostrum, C. F.; 
Demeester, J.; De Smedt, S. C. On the synthesis and characterization of 
biodegradable dextran nanogels with tunable degradation properties. 
Macromolecules 2005, 38, 8503-8511. 
 (6) Raemdonck, K.; Van Thienen, T. G.; Sanders, N. N.; Demeester, J.; De 
Smedt, S. C. Dextran micro-and nanogels for time-controlled release of 
siRNA. Langmuir 2007, in progress. 
(7)  De Geest, B. G.; Stubbe, B. G.; Jonas, A. M.; Van Thienen, T.; Hinrichs, W. 
L. J.; Demeester, J.; De Smedt, S. C. Self-exploding lipid-coated microgels. 
Biomacromolecules 2006, 7, 373-379. 
(8)  Verniest, G.; Claessens, S.; Bombeke, F.; Van Thienen, T.; De Kimpe, N. 
Synthesis of 2-aryl-4-chloropyrroles via ring expansion of 2-aryl-1-
chlorocyclopropanecarbaldehydes. Tetrahedron 2005, 61, 2879-2887. 
 (9) Verniest, G.; Boterberg, S.; Colpaert, J.; Van Thienen, T.; Stevens, C. V.; De 
Kimpe, N. Synthesis of 2-substituted cyclobutanones as gamma-irradiation 
marker products of lipid-containing foods. Synletters 2004, 1273-1275. 
 
 
165 
  
  
 
 
